Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers

ABSTRACT

The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Patent ApplicationNo. PCT/US15/52676, filed on Sep. 28, 2015, which claims priority toU.S. Provisional Patent Application No. 62/057,047 filed Sep. 29, 2014and to U.S. Provisional Patent Application No. 62/212,232 filed Aug. 31,2015, the entire contents all of which are incorporated by referenceherein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant DK038432awarded by the National Institutes of Health. The government has certainrights in the invention.

FIELD OF THE DISCLOSURE

The present disclosure provides compositions, kits, and methods toprotect organs by inducing acquired cytoresistance without causinginjury to the organ. The compositions, kits, and methods can utilizeheme proteins and, optionally, agents that impact heme proteinmetabolism. Other compounds that up-regulate stress proteins (e.g., ironand vitamin B12) may also be used.

BACKGROUND OF THE DISCLOSURE

Injury to a bodily organ can elicit protective responses by the organsuch that it is able to better protect itself should injurious events(i.e., insults) continue or re-occur. For example, a bout of kidneyinjury can evoke protective responses that, after an 18 hour lag time,protect the kidney against subsequent, more severe forms of kidneydamage. This protection can last for an extended period of time (days toweeks). This protective phenomenon is known in the art as “ischemicpreconditioning” or “acquired cytoresistance.”

One thought has been to use the phenomenon of acquired cytoresistance topreemptively protect organs, especially when a known insult is imminent.For example, the phenomenon could be induced to protect organs before aninsult, such as exposure to surgery, cardiopulmonary bypass, orradiocontrast toxicity administrations. This approach has not beendeployed into clinical use, however, because there has not been amechanism to induce acquired cytoresistance in a controlled mannerwithout causing an unacceptable injury to the organ that is to beprotected.

SUMMARY OF THE DISCLOSURE

The current disclosure provides compositions, kits, and methods thatallow the induction of acquired cytoresistance without causing injury tothe organ. Because acquired cytoresistance can be induced withoutcausing injury to the organ, the phenomenon can be used in a clinicalsetting to preemptively protect organs, especially when a known insultis approaching.

Without being bound by theory, the compositions, kits, and methodsinduce acquired cytoresistance by up-regulating expression of protectivestress proteins. Particular embodiments induce acquired cytoresistancethrough administration of heme proteins at a level, or with an approach,such that the heme proteins do not cause injury to the organ that is tobe protected. Induction of acquired cytoresistance can also be achievedby administering other compounds, such as iron and/or vitamin B12.

Approaches that induce acquired cytoresistance without causing injuryinclude administering a therapeutically effective amount of a hemeprotein, iron and/or vitamin B12 (B12); increasing the biologicalhalf-life of the heme protein, iron and/or B12; potentiating the actionof the heme protein, iron and/or B12; and reducing toxicity associatedwith heme protein, iron and/or B12 administration. Each of theseapproaches can be practiced alone or in combination.

The described approaches can be accomplished by one or more of:administering a therapeutically effective amount of a heme protein, ironand/or B12; administering the heme protein, iron and/or B12 incombination with a heme protein degradation inhibitor; administering amodified heme protein, iron and/or B12; and/or choosing an appropriatecomposition and delivery route.

Exemplary heme proteins include low molecular weight heme proteins,rapidly-cleared heme proteins, and myoglobin. An exemplary form of ironincludes iron sucrose. Exemplary heme protein degradation inhibitorsinclude protoporphyrins, metal protoporphyrins, and hematin. Exemplarymodified heme proteins and heme protein degradation inhibitors includePEGylated heme proteins and heme protein degradation inhibitors andnitrited heme proteins and heme protein degradation inhibitors.Exemplary compositions include slow-release depots. Exemplary deliveryroutes include intravenous, subcutaneous, or intramuscular injection.Exemplary methods to reduce toxicity include administration withmannitol, glycine, and saline. Additional examples, embodiments, andcombinations are provided in the Detailed Description.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B show heme oxygenase mRNA expression (FIG. 1A) andprotein expression (FIG. 1B) following vehicle (control), myoglobin(Mgb) or myoglobin in combination with Sn-protoporphyrin (SnPP;Mgb+SnPP) administration 18 hours before glycerol insult. This FIG.demonstrates that the administration of myoglobin alone induces therepresentative cytoprotective molecule heme oxygenase 1 (HO-1), and thatthe combination of HO-1 plus a transient heme oxygenase inhibitor (SnPP)dramatically increases the myoglobin induced HO-1 mRNA and proteinincreases.

FIG. 2 left panels show cellular kidney damage following glycerolinduced acute renal failure. Whereas severe injury is seen in theabsence of preconditioning (extensive necrosis, top left; severe castformation, bottom left), pre-treatment with myoglobin+SnPP 18 hrs beforeglycerol injection resulted in essentially normal renal histology (rightpanels top and bottom).

FIG. 3 shows that N-Mgb+SnPP elevates mRNA for the protective stressprotein, interleukin-10 (IL-10).

FIG. 4 shows that N-Mgb+SnPP elevates the hatpoglobin mRNA (left) andprotein levels (right).

FIG. 5 shows assessment of the impact of equimolar nitrite binding tomyoglobin Fe on the expression of myoglobin toxicity. HK-2 cells (aproximal tubule cell line derived from normal human kidney) wereincubated in keratinocyte serum free medium either under normal(control) conditions or in the presence of 10 mg/mL horse skeletalmuscle myoglobin or nitrited myoglobin (produced by equimolar Na nitriteaddition to 10 mg/ml myoglobin). After 18 hr incubations, the severityof cell injury (% cell death) was assessed by MTT assay. Myoglobininduced 40% cell death (40% decrease in MTT cell uptake), compared tocontrol incubated cells. Nitrite binding to myoglobin reduced cell deathby 75%. Thus, nitrite binding is able to reduce myoglobin's cytotoxiceffects.

FIG. 6 shows the dose-response relationship between plasma hemeoxygenase 1 (HO-1) and administered N-myoglobin dose. Normal mice wereinjected intramuscularly (IM) with either 0, 1, 2, or 5 mg/Kg nitritedmyoglobin+SnPP (constant dose of 1 μmole). Eighteeen hrs later, plasmaHO-1 levels were assessed by ELISA. A steep dose-response relationshipbetween the administered N-myoglobin dose and plasma HO-1 levels wasobserved. Thus, HO-1 assay has potential biomarker utility forN-Mgb/SnPP induced HO-1 induction.

FIG. 7 shows maintenance of normal serum creatinine levels over a 25fold variation in N-myoglobin dose. Mice were subjected to a 2 hrsubcutaneous infusion of 1, 3, 6, 12, or 25 mg/Kg of nitrited myoglobin(holding SnPP at a constant dose of 1 μmole). Eighteen hrs later,potential renal injury was assessed by measuring serum creatinineconcentrations. No significant increase was observed at any of the N-Mgbdoses, indicating a lack of over toxicity (n, 2-4 mice/group).

FIG. 8 shows renal histology 18 hours after N-Mgb−SnPP administration.The top 2 panels are PAS-stained kidney sections from a control mouse(C) and a mouse 18 hour after N-Mgb−SnPP treatment (Rx). The tubularepithelium from treated mice maintains a normal histologic appearancewith a completely intact brush border (dark staining of luminalmembrane). The bottom 2 panels depict hematoxylin and eosin-stainedsections. No histologic injury is apparent with N-Mgb−SnPP pretreatment.

FIG. 9 shows synergistic induction of HO-1 with N-Mgb−SnPP treatment ofnormal mice. The left panel depicts HO-1 mRNA levels 4 hours aftertreatment. Whereas N-Mgb alone and SnPP alone induced modest mRNAincreases, a 20-fold HO-1 mRNA increase is seen with combined agentadministration. At 18 hours after administration, a synergistic HO-1protein increase was observed (P values vs controls). GAPDH,glyceraldehyde-3-phosphate dehydrogenase; HO-1, heme oxygenase 1; mRNA,messenger RNA; N-Mgb, nitrited myoglobin; SnPP, tin protoporphyrin.

FIG. 10 shows synergistic induction of IL-10 with N-Mgb−SnPP treatmentof normal mice. The left panel depicts IL-10 mRNA levels at 4 hoursafter treatment. N-Mgb alone and SnPP alone evoked either minimal or noIL-10 mRNA increases. However, with combined administration, a 10-foldIL-10 mRNA increase was observed. As shown in the right panel, only thecombined treatment induced IL-10 protein increases as assessed at the18-hour time point (P values vs controls).

FIG. 11 shows haptoglobin mRNA and protein expression after N-Mgb−SnPPadministration to normal mice. Combined N-Mgb 1 SnPP evoked far greaterhaptoglobin mRNA increases at 4 hours after injection than did eitheragent alone. However, by 18 hours after agent administration, N-Mgbalone and N-Mgb+SnPP induced comparable haptoglobin protein increases.This suggests that N-Mgb accounted for the haptoglobin increases thatwere produced by combined N-Mgb+SnPP administration. (P values vscontrols).

FIG. 12 shows degrees of protection induced by test agents in theglycerol model of rhabdomyolysis-induced AKI. Control mice (C) developedmarked AKI as denoted by BUN and creatinine concentrations. SnPPconferred no significant protection, whereas N-Mgb induced a modestprotective effect. Conversely, combined N-Mgb−SnPP administrationconferred complete functional protection as gauged by normal BUN andcreatinine levels at 18 hours after glycerol administration (normallevels are depicted by the solid horizontal line).

FIG. 13 shows combined N-Mgb 1 SnPP (Rx) treatment confers markedprotection against the maleate model of AKI. Maleate injection causedmarked BUN and creatinine increases. Treatment (Rx) conferred a nearcomplete protective effect (horizontal lines represent normal BUN andcreatinine concentrations). P value vs no treatment (no Rx).

FIG. 14 shows maleate-induced cardiotoxicity is reduced by pretreatmentwith N-Mgb+SnPP. Mice were treated with 1 mg/Kg N-myoglobin+1 μmole SnPPor IV vehicle injection). Eighteen hrs later, 800 mg/Kg maleate wasadministered IP. The extent of myocardial injury was determined 18 hrspost maleate injection by measuring plasma troponin I concentrations (byELISA). Maleate injection caused a 10 fold increase in plasma troponinlevels. Pre-treatment with N-Mgb+SnPP reduced the maleate inducedtroponin increase by 75%.

FIG. 15 shows N-Mgb+SnPP (Rx) treatment confers protection againstunilateral ischemia-reperfusion (I/R)-induced progressive kidneydisease. Mice were subjected to 30 minutes of left renal ischemia withor without N-Mgb−SnPP pretreatment 18 hours earlier. At 2 weekspostischemia, I/R led to a 38% reduction in renal mass (gauged by kidneyweight). Pretreatment (Rx) conferred significant protection as gauged byonly a 12% reduction in renal mass. Protection was also implied bymarked reductions in NGAL mRNA and protein levels in the 2-weekpost-ischemic left kidneys.

FIG. 16 shows a dose-response relationship between increasing doses ofN-Mgb (with a fixed dose of SnPP, 1 umol) and HO-1/haptoglobin proteinlevels in renal cortex and plasma. Increasing doses of N-Mgb,administered intraperitoneally, led to increasing levels of each proteinin plasma and renal cortex. The correlation coefficients for plasma vsrenal concentrations were 0.57 and 0.82 for HO-1 and haptoglobin,respectively. The correlations between the dose administered and plasmaprotein levels were r=0.85 and r=0.75 for HO-1 and haptoglobin,respectively.

FIG. 17 shows a dose-response relationship between administered IP doseof N-Mgb vs BUN/creatinine concentrations at 18 hours after glyceroladministration. Increasing doses of N-Mgb (with a fixed dose of SnPP; 1umol) led to increasing degrees of protection against glycerol-inducedAKI. When analyzed with the results given in FIG. 16, strong directrelationships between plasma and renal cortical HO-1/haptoglobinconcentrations and degrees of protection against glycerol-induced AKIare apparent. The horizontal lines indicate normal BUN and creatinineconcentrations. As shown in the right panel, the administered doses werewell tolerated by the kidney as evidenced by maintenance of normal18-hour plasma creatinine concentrations across the tested dosage range.

FIG. 18 shows upregulation of HO-1, haptoglobin (hapto), and IL-10 geneexpression in liver and heart with combined N-Mgb/SnPP treatment. Thedegrees of increase with treatment, expressed as a fold increase overcontrol values are presented. Each was increased in both liver (top 2panels) and heart (bottom 2 panels). Individual values are given inTables 9 and 10.

FIG. 19 shows preconditioning with N-Mgb—SnPP mitigates postischemicliver injury and hepatotoxic injury. Degrees of hepaticischemic-reperfusion (I/R) injury were judged by plasma lactatedehydrogenase (LDH) and alanine aminotransferase (ALT) levels.Pretreatment with N-Mgb−SnPP significantly decreased both LDH and ALTconcentrations (left and middle panels). It also decreased the extent ofhepatotoxic injury induced by intraperitoneal glycerol injection (rightpanel).

FIG. 20 shows gross appearance of liver sections obtained at 18-hourpostischemia without (top) and with (bottom) N-Mgb−SnPP pretreatment.Liver ischemia evoked extensive gross necrosis as evidenced by whitish-gray liver appearance (top). However, with N-Mgb−SnPP pretreatment, theliver retained a near normal appearance (bottom).

FIG. 21 shows vitamin B12 and Fe sucrose each induces marked HO-1protein increases within 4 hrs and persists for 18 hrs of their IVinjection.

FIG. 22 shows maleate injection caused severe AKI as denoted by markedBUN and PCr increases over maleate injected controls (C). Neither SnPPalone nor FeS alone significantly altered the severity of renal injury.However, combined FeS+SnPP conferred marked protection, as denoted by75% reductions in BUN/PCr concentrations (the horizontal lines representthe means of BUN/PCr levels in normal mice).

FIG. 23 shows that within 18 hrs of inducing IRI, 4 fold elevations inBUN and PCr concentrations resulted. Pre-treatment with FeS+SNPPconferred significant protection, lowering the BUN and PCr levels by50%. The horizontal lines represent mean BUN/PCr levels in normal mice.

FIG. 24 shows that maleate injection induced severe AKI. Pre-treatmentwith FeS+B12 markedly mitigated this injury, as denoted by BUN/PCrreductions. The horizontal lines represent mean BUN/PCr levels in normalmice.

FIG. 25 shows severe renal failure resulted within 18 hrs of glycerolinjection. Pre-treatment with FeS+B12 conferred substantial functionalprotection, as denoted by marked reductions in both 18 hr BUN and PCrconcentrations. The horizontal lines represent mean BUN/PCr levels fornormal mice.

FIG. 26 shows marked and significant increases in HO-1 mRNA, as assessed4 hr post injection. By 18 hrs, HO-1 mRNA levels returned to normalvalues.

FIG. 27 shows the 4 hr mRNA increases are correlated with a significantincrease in HO-1 protein levels. These levels remained elevated at the18 hr time point, particularly in the case of FeS administration.

DETAILED DESCRIPTION

Injury to a bodily organ can elicit protective responses by the organsuch that it is able to better protect itself should injurious events(i.e., insults) continue or re-occur. This protective phenomenon isknown in the art as “ischemic preconditioning” or “acquiredcytoresistance.”

One thought has been to use the phenomenon of acquired cytoresistance topreemptively protect organs, especially when a known insult is imminent.For example, the phenomenon could be induced to protect organs before aninsult, such as exposure to surgery, ballon angioplasty, induced cardiacor cerebral ischemic-reperfusion injury, or radiocontrast toxicity.Alternatively or additionally, the phenomenon could be induced in organdonors (e.g., kidney, liver) to prevent or reduce cold storage injuryand/or reimplantation ischemic-reperfusion injury. These approaches havenot been deployed into clinical use, however, because, until the currentdisclosure, there had not been a mechanism to successfully induceacquired cytoresistance in a controlled manner without causing an injuryto the organ that is to be protected itself.

The current disclosure provides compositions, kits, and methods thatallow the induction of acquired cytoresistance without injury to theorgan that is to be protected. Because acquired cytoresistance can beinduced without causing injury to the organ, the phenomenon can be usedin a clinical setting to preemptively protect organs, especially when aknown insult is approaching.

Without being bound by theory, the compositions, kits, and methodsinduce acquired cytoresistance by up-regulating expression of protectivestress proteins. Acquired cytoresistance can be induced throughadministration of heme proteins at a level, or with an approach, suchthat the heme proteins do not cause an injury to the organ that is to beprotected. In particular embodiments, induction of acquiredcytoresistance can also be achieved by administering compounds thatup-regulate stress proteins through the same or similar biologicalpathways utilized by heme proteins. Such compounds include, for example,iron and vitamin B12 and associated metabolites.

An “insult” is an occurrence that is likely to cause injury to an organ.Exemplary insults include shock (low blood pressure), kidneyhypoperfusion, surgery, induced cardiac or cerebralischemic-reperfusion, cardiopulmonary bypass, balloon angioplasty,radiocontrast toxicity administrations, chemotherapy, drugadministration, nephrotoxic drug administration, blunt force trauma,puncture, poison, smoking, etc.

An “injury” is a detrimental effect on an organ evidenced by cell deathwithin the organ, cell damage within the organ, damaged structure withinthe organ and/or decreased function of the organ as compared to one ormore relevant control groups, conditions or reference levels.

“Absence of injury” to an organ, “without causing an injury” to anorgan, “does not injure the organ” and similar phrases mean that anyeffect on an organ is, within the scope of sound medical judgment,commensurate with a reasonable benefit/risk ratio of administration. Inparticular embodiments, absence of an injury can be demonstrated byshowing that the function of an organ is not statistically significantlydifferent from a relevant control group, condition, or reference levelaccording to a known test of organ function at the time usingappropriate statistical comparisons. Exemplary assays of organ functioninclude measuring markers associated with organ function; measuring theoutput of an organ; and measuring a performance metric of the organ ascompared to one or more relevant control groups, conditions or referencelevels.

By inducing acquired cytoresistance, the compositions, kits, and methodsdisclosed herein protect organs from injury, such as insult-inducedinjury. “Protecting an organ from injury” and similar phrases includeone or more of: up-regulating the expression of protective stressproteins; preserving organ function in whole or in part (e.g., measuringthe output of an organ; measuring a performance metric of the organ);reducing organ cell injury (in particular embodiments, as manifested bydecreased leakage of intracellular proteins into the circulation), andreducing cell death within the organ as compared to one or more relevantcontrol groups, conditions, or reference levels.

Numerous assays that can be used to assess presence or absence of aninjury and associated protection are disclosed herein and can be used inanimal and human models of organ function. Lack of injury and/orprotection of an organ can be confirmed by comparing a relevant measurefrom a subject with a reference level. Reference levels can include“normal” or “control” levels or values, defined according to, e.g.,discrimination limits or risk defining thresholds, in order to definecut-off points and/or abnormal values for organ function. The referencelevel can be a level of an indicia typically found in a subject who isnot suffering from organ injury. Other terms for “reference levels”include “index,” “baseline,” “standard,” “healthy,” “pre-injury,” etc.Such normal levels can vary, based on whether an indicia is used aloneor in a formula combined with other indicia to output a score.Alternatively, the reference level can be derived from a database ofscores from previously tested subjects who did not develop organ injuryover a clinically relevant time period. Reference levels can also bederived from, e.g., a control subject or population whose organ injurystatus is known. In some embodiments, the reference level can be derivedfrom one or more subjects who have been exposed to treatment for anorgan injury, or from subjects who have shown improvements in organfunction following injury as a result of exposure to treatment. In someembodiments the reference level can be derived from one or more subjectswith organ injury who have not been exposed to treatment. A referencelevel can also be derived from injury severity algorithms or computedindices from population studies.

In particular embodiments, a “reference level” can refer to astandardized value for organ function which represents a level notassociated with any injury; a level associated with a particular type ofinjury; a level associated with a severity of injury; or a levelassociated with a particular subject at the time of a diagnosis, at thebeginning of a treatment, or at a time point during a treatment. Thereference level can be a universal reference level which is usefulacross a variety of testing locations or can be a reference levelspecific for a testing location and specific assay used to measure theorgan function. In certain embodiments, the reference level, is derivedfrom (i) an individual who does not have organ injury or organ injury ofa particular type; or (ii) a group of individuals who do not have organinjury or organ injury of a particular type. Reference levels for asubject can also be related to time points of the subject undergoingtreatments to monitor the natural progression or regression of organinjury in the subject.

In particular embodiments, reference levels can be derived from a“dataset”. A dataset represents a set of numerical values resulting fromevaluation of a sample (or population of samples) under a desiredcondition. The values of the dataset can be obtained, for example, byexperimentally obtaining measures from a sample and constructing adataset from these measurements; or alternatively, by obtaining adataset from a service provider such as a laboratory, or from a databaseor a server on which the dataset has been stored.

Up-Regulation of Protective Stress Proteins. Without being bound bytheory, the up-regulation of a number of stress proteins leads to theinduction of acquired cytoresistance. “Up-regulation” includes anincrease in expression of a gene or nucleic acid molecule of interest orthe activity of a protein, e.g., an increase in gene expression orprotein activity as compared to the expression or activity in anotherwise identical or comparable gene or protein that has not beenup-regulated.

Up-regulation of the following exemplary stress proteins can lead to theinduction of acquired cytoresistance: heme oxygenase (HO), haptoglobin,hemopexin, hepcidin, alpha-1 antitrypsin (AAT), interleukin-10 (IL-10),heat-shock proteins, neutrophil gelatinase-associated lipocalin (NGAL),and HMG CoA reductase.

Heme oxygenase (HO) is the rate-limiting enzyme in heme catabolism.There are three distinct HO isozymes: HO-1 (e.g., SEQ ID NO:1), HO-2(isoform A; e.g., SEQ ID NO:2; isoform B; e.g., SEQ ID NO. 3; isoform C;e.g., SEQ ID NO: 4), and HO-3 (e.g., SEQ ID NO:5). HO-1 is an isozymewhose expression is up-regulated following diverse forms of tissuestress, such as induced by heme proteins, heavy metals, hypoxia, andvarious redox sensitive pathways. In contrast, HO-2 is an isozymeexpressed constitutively. HO-3 is a recently identified isozyme whosefunctions are currently unknown.

Haptoglobin (e.g., SEQ ID NO:6) is a blood plasma protein having amolecular weight of 86,000 to 400,000 and plays an important role in themetabolism of hemoglobin liberated into the blood stream. When liberatedexcessively in the blood the hemoglobin is excreted into the urinethrough the renal tubules, resulting in not only an iron loss but alsodisorders of the renal tubules. Because haptoglobin binds selectivelyand firmly to hemoglobin in vivo and thereby forms ahemoglobin-haptoglobin complex, it has important functions in therecovery of iron and in the prevention of renal disorders.

Hemopexin (Hpx; e.g., SEQ ID NO:7) is a 60 kDa protein which is presentin the plasma in high amounts being second to only albumin,immuglobulins, and the plasma proteases. Hemopexin is often alsoreferred to as beta-1 B-glycoprotein. Hemopexin has a high affinity toheme (K_(D) <10⁻¹²M), and it is believed that the biological role of Hpxis related to the transportation of heme thus preventing heme inducedoxidative damages and heme bound iron loss. Hemopexin sequesters freeheme from the plasma which induces a structural change whereby theheme-Hpx complex gains increased affinity to receptors in the liver,where it is engulfed by receptor-mediated endocytosis and heme isreleased at the low pH in the endosomes. After that, Hpx is returned tothe circulation and can undergo further rounds of transportation.

Hemopexin is folded in two homologous domains, each of 200 amino acids,joined by a 20 amino acid residue linker. There is 25% sequence identitybetween the two domains. Two histidines coordinate the heme iron, namelyHis213 from the linker peptide and His270 from a loop of the C-terminaldomain, giving a stable bis-histidyl Fe(III) complex. The numbering iswith respect to the mature protein. Clin. Chim. Acta, 312, 2001, 13-23and DNA Cell Biol., 21, 2002, 297-304 provide reviews of Hpx chemistry.

Hepcidin (prepropeptide; e.g., SEQ ID NO:8) is the key signal regulatingiron homeostasis (Philpott, Hepatology 35:993 (2002); Nicolas et al.,Proc. Natl. Acad. Sci. USA 99:4396 (2002)). High levels of humanhepcidin result in reduced iron levels, and vice versa. Mutations in thehepcidin gene which result in lack of hepcidin activity are associatedwith juvenile hemochromatosis, a severe iron overload disease (Roetto etal., Nat. Genet., 33:21-22, 2003). Studies in mice have demonstrated arole of hepcidin in control of normal iron homeostasis (Nicolas et al.,Nat. Genet., 34:97-101, 2003; Nicolas et al., Proc. Natl. Acad. Sci.USA, 99:4596-4601, 2002; Nicolas et al., Proc. Natl. Acad. Sci. USA,98:8780-8785, 2001).

In addition, data is accumulating implicating hepcidin in ironsequestration during inflammation (See, e.g., Weinstein et al., Blood,100:3776-36781, 2002; Kemna et al., Blood, 106:1864-1866, 2005; Nicolaset al., J. Clin. Invest., 110:1037-1044, 2002; Nemeth et al., J. Clin.Invest., 113:1271-1276, 2004; Nemeth et al., Blood, 101:2461-2463, 2003and Rivera et al., Blood, 105:1797-1802, 2005). Hepcidin gene expressionhas been observed to be robustly up-regulated after inflammatorystimuli, such as infections, which induce the acute phase response ofthe innate immune systems of vertebrates. In mice, hepcidin geneexpression was shown to be up-regulated by lipopolysaccharide (LPS),turpentine, Freund's complete adjuvant, and adenoviral infections.Hepcidin expression is induced by the inflammatory cytokine IL-6. Astrong correlation between hepcidin expression and anemia ofinflammation was also found in patients with chronic inflammatorydiseases, including bacterial, fungal, and viral infections.

Human hepcidin, a 25 amino acid peptide (e.g., SEQ ID NO:9) withanti-microbial and iron-regulating activity, was discoveredindependently by two groups investigating novel anti-microbial peptides.(Krause et al., FEBS Lett. 480:147 (2000); Park et al., J. Biol. Chem.276:7806 (2001)). It has also been referred to as LEAP-1(liver-expressed antimicrobial peptide). A hepcidin cDNA encoding an 83amino acid pre-propeptide in mice and an 84 amino acid pre-propeptide inrat and human were subsequently identified in a search for liverspecific genes that were regulated by iron (Pigeon et al., J. Biol.Chem. 276:7811 (2001)). The 24 residue N-terminal signal peptide isfirst cleaved to produce pro-hepcidin, which is then further processedto produce mature hepcidin, found in both blood and urine. In humanurine, the predominant form contains 25 amino acids, although shorter 22and 20 amino acid peptides are also present.

The mature peptide is notable for containing eight cysteine residueslinked as four disulfide bridges. The structure of hepcidin was studiedby Hunter et al., J. Biol. Chem., 277:37597-37603 (2002), by NMR usingchemically synthesized hepcidin with an identical HPLC retention time tothat of native hepcidin purified from urine. Hunter et al. reportedtheir determination that hepcidin folded into a hairpin loop structurecontaining a vicinal disulfide bond (C1-C8, C2-C7, C3-C6, C4-C5).

Alpha-1 antitrypsin (AAT; e.g., SEQ ID NO:10) is a glycoprotein secretedby hepatocytes and normally present in the serum and in the majority oftissues in high concentrations, where it acts as an inhibitor of serineproteases. Protease inhibition by AAT is an essential component of theregulation of tissue proteolysis, and AAT deficiency is implicated inthe pathology of several diseases. Apart from its activity as anantiprotease, AAT could have an important anti-inflammatory biologicalfunction because it has an outstanding inhibitory capacity in respect ofmany inflammation mediators and in respect of oxidant radicals (BrantlyM. Am J Respir Cell Mol. Biol., 2002; 27: 652-654).

Interleukin-10 (IL-10; e.g., SEQ ID NO. 11) is a pleiotropic cytokineproduced by several cell types such as macrophages, monocytes, Th2 typeand regulatory T-cells and B-cells. IL-10 is a cytokine withimmunosuppressive and anti-inflammatory properties; it regulates anumber of cellular myeloid and lymphoid activities and directly inhibitsthe production of several inflammatory cytokines by T-cells and NaturalKiller (NK) cells. IL-10 is known as a B-cell proliferation factor andis active in autoimmunity, antibody production, tumorigenesis andtransplant tolerance. Eur. J. Immunogenet. 1997 24 (I): 1-8. IL-10 alsoalters macrophage response to infection yet stimulates Fc receptors onthe same cells. Annals Allergy Asthma lmmunol. 1997 79:469-483; J.Immunol. 1993 151: 1224-1234; and J. lmmunol. 1992 149:4048-4052.

Heat shock proteins were originally observed to be expressed inincreased amounts in mammalian cells which were exposed to suddenelevations of temperature, while the expression of most cellularproteins is significantly reduced. It has since been determined thatsuch proteins are produced in response to various types of stress,including glucose deprivation.

Heat shock proteins have the ability to bind other proteins in theirnon-native states, and in particular to bind nascent peptides emergingfrom ribosomes or extruded into the endoplasmic reticulum. Hendrick andHartl., Ann. Rev. Biochem. 62:349-384 (1993); Hartl., Nature 381:571-580(1996). Further, heat shock proteins have been shown to play animportant role in the proper folding and assembly of proteins in thecytosol, endoplasmic reticulum, and mitochondria; in view of thisfunction, they are referred to as “molecular chaperones”. Frydman etal., Nature 370: 111-117 (1994); Hendrick and Hartl., Ann. Rev. Biochem.62:349-384 (1993); Hartl, Nature 381:571-580 (1996).

Examples of heat shock proteins include BiP (also referred to as grp78(e.g., SEQ ID NO:12)), hsp/hsc70 (e.g., SEQ ID NO:13), gp96 (grp94)(e.g., SEQ ID NO:14), hsp60 (e.g., SEQ ID NO:15), hsp40 (e.g., SEQ IDNO:16), hsp70/72 (e.g., SEQ ID NO:17), and hsp90 (isoform 1; e.g., SEQID NO:18; isoform 2; e.g., SEQ ID NO. 19).

Lipocalins are a family of extracellular ligand-binding proteins thatare found in a variety of organisms from bacteria to humans. Lipocalinspossess many different functions, such as the binding and transport ofsmall hydrophobic molecules, nutrient transport, cell growth regulation,modulation of the immune response, inflammation, and prostaglandinsynthesis.

Neutrophil gelatinase-associated lipocalin (NGAL; e.g., SEQ ID NO: 20),which is also known as human neutrophil lipocalin (HNL), N-formylpeptide binding protein, and 25 kDa α2-microglobulin-related protein, isa 24 kDa protein, which can exist as a monomer, a homodimer, or aheterodimer with proteins, such as gelatinase B or matrixmetalloproteinase-9 (MMP-9). A trimeric form of NGAL also has beenidentified. NGAL is secreted from specific granules of activated humanneutrophils. Homologous proteins have been identified in mouse(24p3/uterocalin) and rat (α2-microglobulin-related protein/neu-relatedlipocalin). Structural data have confirmed NGAL has an eight-strandedβ-barrel structure, which is characteristic of lipocalins; however, NGALhas an unusually large cavity lined with more polar and positivelycharged amino acid residues than normally seen in lipocalins. NGAL isbelieved to bind small lipophilic substances, such as bacteria-derivedlipopolysaccharides and formyl peptides, and may function as a modulatorof inflammation.

NGAL is an early marker for acute renal injury or disease. In additionto being secreted by specific granules of activated human neutrophils,NGAL is also produced by nephrons in response to tubular epithelialdamage and is a marker of tubulointerstitial (TI) injury. NGAL levelsrise in acute tubular necrosis (ATN) from ischemia or nephrotoxicity,even after mild “subclinical” renal ischemia. Moreover, NGAL is known tobe expressed by the kidney in cases of chronic kidney disease (CKD) andacute kidney injury ((AKI); see, e.g., Devarajan et al., Amer. J. KidneyDiseases 52 (3); 395-399 (September 2008); and Bolignano et al., Amer.J. Kidney Diseases 52 (3): 595-605 (September 2008)). Elevated urinaryNGAL levels have been suggested as predictive of progressive kidneyfailure. It has been previously demonstrated that NGAL is markedlyexpressed by kidney tubules very early after ischemic or nephrotoxicinjury in both animal and human models. NGAL is rapidly secreted intothe urine, where it can be easily detected and measured. NGAL isresistant to proteases, suggesting that it can be recovered in the urineas a faithful marker of NGAL expression in kidney tubules.

The HMG-CoA reductase enzyme plays a central role in the production ofcholesterol and other isoprenoids in the liver and other tissues via themevalonate pathway. The conversion of3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate iscatalyzed by HMG-CoA reductase, and is an early and rate-limiting stepin the cholesterol biosynthetic pathway in the liver and other tissues.Stress-induced increases in HMG CoA reductase mediate cholesterolsynthesis leading to increased plasma membrane cholesterol.

Expression of protective stress proteins is up-regulated byadministration of heme proteins. Heme proteins are metalloproteins thatcontain a heme prosthetic group (a protoporphyrin ring with a centralFe; a protoporphyrin ring includes four pyrole rings linked by methinebridges. Four methyl, two vinyl, and two propionate side chains can alsobe attached). In particular embodiments, the heme proteins are lowmolecular weight heme proteins. “Low molecular weight heme proteins”include those with a molecular weight of 25 kDa or less; 24 KDa or less;23 kDa or less; 22 kDa or less; 21 kDa or less; 20 kDa or less; 19 kDaor less; 18 kDa or less; 17 kDa or less; 16 kDa or less; 15 kDa or less;14 kDa or less; 13 kDa or less; 12 kDa or less; 11 kDa or less; or 10kDa or less. In another embodiment, heme proteins are rapidly clearedwhen administered intravenously. “Rapidly cleared” means a urinaryexcretion rate that has a urinary clearance rate of >50% of serumcreatinine or urea. In another embodiment the heme proteins are lowmolecular weight heme proteins that are rapidly cleared whenadministered intravenously. Myoglobin (e.g., SEQ ID NO:21) is one hemeprotein that can be used with the compositions, kits, and methodsdisclosed herein. References to heme proteins include modified hemeproteins, variant heme proteins and D-substituted analog heme proteins.References to myoglobin include modified myoglobin, variant myoglobinand D-substituted analog myoglobin as described elsewhere herein.

Myoglobin is present in striated muscle tissue and functions to storeand deliver oxygen by reversibly binding O₂ at myoglobin's open bindingsite. Through this reversible binding, myoglobin creates anintracellular source of oxygen for cellular mitochondria. Unlikehemoglobin, another heme protein, myoglobin naturally exists only as amonomer.

When muscle tissue is damaged, myoglobin is released into thebloodstream. Large amounts of myoglobin in the blood can cause renalinjury by provoking constriction of renal vessels, forming obstructingcasts in the lumina of renal tubules, and initiating interstitialinflammation, as described in Zager, R. A., Ren. Fail., 14, 341-344(1992). Moreover, Nath et al. state that heme proteins, such ashemoglobin, when released into the extracellular space, can instigatetissue toxicity and that myoglobin is directly implicated in thepathogenesis of renal failure in rhabdomyolysis. J. Clin. Invest., 1992July (90) 1: 267-70. Accordingly, heme proteins and myoglobin inparticular can damage the renal system.

Based on these known detrimental effects of heme proteins, includingmyoglobin, it was not expected that heme proteins such as myoglobincould play a role in inducing acquired cytoresistance without causing anorgan injury. Thus, one aspect of the current disclosure includesidentifying compositions, kits, and methods to administer myoglobin in amanner that induces acquired cytoresistance without causing an injury tothe organ that it is administered to protect.

Approaches that allow heme protein administration to induce acquiredcytoresistance without causing an organ injury include selecting atherapeutically effective amount of the heme protein; increasing thebiological half-life of the heme protein; potentiating the action of theheme protein; and reducing toxicity associated with heme proteinadministration.

One embodiment disclosed herein includes selecting a therapeuticallyeffective amount of a heme protein, such as myoglobin. Therapeuticallyeffective amounts, methods to identify therapeutically effective amountsand exemplary therapeutically effective amounts are described more fullybelow.

The biological half-life of a heme protein can be extended byadministering the heme protein in combination with a heme proteindegradation inhibitor. In particular embodiments, heme proteindegradation inhibitors can reduce or eliminate the cleavage of the hemeprotein's porphoryin ring by HO, reducing or eliminating release of theheme protein's toxic Fe content. In particular embodiments,administration of a heme protein degradation inhibitor in combinationwith a heme protein can allow for administration of lower doses of theheme protein.

In particular embodiments, any compound that blocks binding of heme toHO can function as a heme protein degradation inhibitor. For example, anumber of synthetic analogs of iron protoporphyrin IX are known. Thesecompounds are commercially available and/or can be readily synthesizedby known methods. They include, for example, platinum, zinc, nickel,cobalt, copper, silver, manganese, chromium, and tin protoporphyrin IX.For convenience, these compounds can be referred to generically asMe-protoporphyrin or MePP, were Me stands for metal, and specifically byutilizing the chemical symbol for the metal such as Cr-protoporphyrin(CrPP), Sn-protoporphyrin (SnPP), Zn-protoporphyrin (ZnPP) for thechromium, tin, and zinc protoporphyrin compounds respectively.

Hemin and/or hematin can also be used as competitive HO-1 inhibitors. Insome instances, hemin and hematin are used interchangeably and refer toprotoporphyrin IX containing a ferric iron ion attached to a chlorideligand. Others distinguish hemin and hematin, referring to the Cl ligandform as hemin and referring to hematin as the same compound withhydroxide attached to the iron ion rather than chloride. Both can beused as competitive HO-1 inhibitors within the teachings of the currentdisclosure. Indeed, and as stated, any compound that blocks binding ofheme to HO can function as a heme protein degradation inhibitor.

That blocking the action of HO could beneficially assist in theinduction of acquired cytoresistance without causing an injury wasunexpected. For example, Nath et al., showed that knocking out the HO-1gene in mice worsened renal injury in the glycerol model of heme proteintoxicity. The authors stated that HO-1 is a critical protectant againstacute heme protein-induced toxicity in vivo. Am. J. of Path., 2000 May156 (5): 1527-1535.

Moreover, that Me-protoporphyrins could be used in combination with aheme protein to induce acquired cytoresistance without causing an injurywas unexpected. This is because Me-protoporphyrins are generally thoughtto adversely affect organs in various models of organ injury.

For example, Agarwal et al. found that pretreatment withSn-protoporphyrin exacerbated renal injury in a HO-based in vivo modelof heme protein mediated renal injury. Particularly, pretreatment withSn-protoporphyrin led to higher serum creatinine values on days 3through 5 and lower inulin clearances on day 5. Renal hemodynamicsstudied at day 2 after cisplatin demonstrated reduced renal blood flowrates, increased renal vascular resistance and increased fractionalexcretion of sodium in rats treated with Sn-protoporphyrin. Kidney Int.October 1995 48 (4): 1298-307. In the glycerol model rhabdomyolysis,Nath et al., found that the kidney responds to high amounts of hemeproteins by inducing HO and that blocking the action of HO with acompetitive inhibitor (here, Sn-protoporphyrin) exacerbated kidneydysfunction. J. Clin. Invest. 1992 July: 90 (1): 267-70. Ferenbach etal., and Goodman et al., have similarly shown that inhibition of HOusing Me-protoporphyrins worsens renal damage. See Nephron. Exp.Nephrol. 2010 April 115 (3): e33-7 and Kidney Int. October 2007 72 (8):945-53 respectively. Based on these teachings of the art, one ofordinary skill in the art would not have expected the beneficial effectsof HO-1 inhibition currently disclosed.

Without being bound by theory, heme proteins activate redox sensitivetranscription factors, leading to the up-regulation of redox sensitivecytoprotective proteins. This pathway is initiated by Mgb's ironcontent. Thus, as demonstrated herein alternative approaches forinducing iron-mediated renal tubular cytoprotective gene signaling arealso effective. These alternative approaches include administration ofiron and/or vitamin B12. The rationale for B12 is that both cobalt andcyanide can independently induce HO-1. Thus, B12 represents a safemethod to administer both cyanide and cobalt as a single agent, as bothare integral parts of the B12 molecule.

Modified heme proteins and heme protein degradation inhibitors (e.g.,protoporphyrins, hemin, hematin) can include those with (a) increasedprotein serum half-life and/or functional in vivo half-life, (b) reducedprotein antigenicity, (c) increased protein storage stability, (d)increased protein solubility, (e) prolonged circulating time, and/or (f)increased bioavailability, e.g. increased area under the curve (AUC).

In particular embodiments, modified heme proteins and heme proteindegradation inhibitors (“modifications”) include those wherein one ormore amino acids have been replaced with a non-amino acid component, orwhere the amino acid has been conjugated to a functional group or afunctional group has been otherwise associated with an amino acid. Themodified amino acid may be, e.g., a glycosylated amino acid, a PEGylatedamino acid, a farnesylated amino acid, an acetylated amino acid, abiotinylated amino acid, an amino acid conjugated to a lipid moiety, oran amino acid conjugated to an organic derivatizing agent. Amino acid(s)can be modified, for example, co-translationally or post-translationallyduring recombinant production (e.g., N-linked glycosylation at N-X-S/Tmotifs during expression in mammalian cells) or modified by syntheticmeans. The modified amino acid can be within the sequence or at theterminal end of a sequence. Modifications also include nitrited hemeproteins, such as nitrited myoglobin.

In its native state, myoglobin is 17 kDa and thus is rapidly filteredand excreted by the kidney. By increasing myoglobin's size, itsexcretion can be slowed, thus, allowing for a more prolonged and durableprotective effect. In one embodiment, the modified protein is aPEGylated heme protein or heme protein degradation inhibitor.

PEGylation is one method that can be used to increase the size ofmyoglobin and other low molecular weight proteins. PEGylation is aprocess by which polyethylene glycol (PEG) polymer chains are covalentlyconjugated to other molecules such as drugs or proteins. Several methodsof PEGylating proteins have been reported in the literature. Forexample, N-hydroxy succinimide (NHS)-PEG was used to PEGylate the freeamine groups of lysine residues and N-terminus of proteins; PEGs bearingaldehyde groups have been used to PEGylate the amino-termini of proteinsin the presence of a reducing reagent; PEGs with maleimide functionalgroups have been used for selectively PEGylating the free thiol groupsof cysteine residues in proteins; and site-specific PEGylation ofacetyl-phenylalanine residues can be performed.

Covalent attachment of proteins or peptides to PEG has proven to be auseful method to increase the circulating half-lives of proteins andpeptides in the body (Abuchowski, A. et al., Cancer Biochem. Biophys.,1984, 7:175-186; Hershfield, M. S. et al., N. Engl. J. Medicine, 1987,316:589-596; and Meyers, F. J. et al., Clin. Pharmacol. Ther., 1991,49:307-313). The attachment of PEG to proteins and peptides not onlyprotects the molecules against enzymatic degradation, but also reducestheir clearance rate from the body. The size of PEG attached to aprotein has significant impact on the circulating half-life of theprotein. The ability of PEGylation to decrease clearance is generallynot a function of how many PEG groups are attached to the protein, butthe overall molecular weight of the altered protein. PEGylationdecreases the rate of clearance from the bloodstream by increasing theapparent molecular weight of the molecule. Up to a certain size, therate of glomerular filtration of proteins is inversely proportional tothe size of the protein. Usually the larger the PEG is, the longer thein vivo half-life of the attached protein is. In addition, PEGylationcan also decrease protein aggregation (Suzuki et al., Biochem. Bioph.Acta vol. 788, pg. 248 (1984)), alter protein immunogenicity (Abuchowskiet al.; J. Biol. Chem. vol. 252 pg. 3582 (1977)), and increase proteinsolubility as described, for example, in PCT Publication No. WO92/16221).

Several sizes of PEGs are commercially available (Nektar AdvancedPEGylation Catalog 2005-2006; and NOF DDS Catalogue Ver 7.1), which aresuitable for producing proteins with targeted circulating half-lives. Avariety of active PEGs have been used including mPEG succinimidylsuccinate, mPEG succinimidyl carbonate, and PEG aldehydes, such asmPEG-propionaldehyde.

In another embodiment, the modified protein is a nitrited heme proteinor nitrited heme protein degradation inhibitor. Nitrite is involved inregulating production of nitric oxide (NO) from nitric oxide synthase(NOS) independent pathways. Inorganic nitrite can undergo a one electronreduction back to NO through various mechanisms with oxygen-binding hemeproteins (hemoglobin and myoglobin), deoxyhemoglobin, deoxymyoglobin,xanthine oxidoreductase, endothelial NOS, acidic disproportionation, andmembers of the mitochondrial electron transport chain, e.g.,mitochondrial heme proteins all being potential electron donors.

Nitrite binding to heme iron, such as in myoglobin, can increase theheme protein's ability to up-regulate expression of stress proteins,such as, heat shock proteins (e.g., HSP 72); HO-1; haptoglobin;hemopexin, hepcidin, IL-10, AAT, NGAL and/or HMG CoA reductase.Nitrite-Fe binding disclosed herein can also decrease toxicityassociated with heme protein administration. Without being bound bytheory, up-regulated expression of stress proteins serves to promoteacquired cytoresistance.

Nitrited forms of active ingredients are used in particular embodimentsbecause, without being bound by theory, the current disclosure suggeststhat following glomerular filtration, N-Mgb and SnPP undergo proximaltubule uptake where they activate redox sensitive transcription factors,leading to the up-regulation of redox sensitive cytoprotective proteins.Again without being bound by theory, this pathway is initiated by Mgb'siron (Fe) content. Nitrite binding to Mgb Fe facilitates Fe signalingwhile reducing potential Fe toxicity. Concomitant administration of SnPPalso facilitates Fe signaling. These same pathways can be activated inextra-renal organs via SnPP tissue binding sites/signaling and Mgbuptake via scavenger receptors.

Reference to proteins including heme proteins, heme protein degradationinhibitors, and protective stress proteins described herein also includevariants and D-substituted analogs thereof.

“Variants” of proteins disclosed herein include proteins having one ormore amino acid additions, deletions, stop positions, or substitutions,as compared to a protein disclosed herein.

An amino acid substitution can be a conservative or a non-conservativesubstitution. Variants of proteins disclosed herein can include thosehaving one or more conservative amino acid substitutions. A“conservative substitution” involves a substitution found in one of thefollowing conservative substitutions groups: Group 1: alanine (Ala orA), glycine (Gly or G), Ser, Thr; Group 2: aspartic acid (Asp or D),Glu; Group 3: asparagine (Asn or N), glutamine (Gln or Q); Group 4: Arg,lysine (Lys or K), histidine (His or H); Group 5: Ile, leucine (Leu orL), methionine (Met or M), valine (Val or V); and Group 6: Phe, Tyr,Trp.

Additionally, amino acids can be grouped into conservative substitutiongroups by similar function, chemical structure, or composition (e.g.,acidic, basic, aliphatic, aromatic, sulfur-containing). For example, analiphatic grouping may include, for purposes of substitution, Gly, Ala,Val, Leu, and Ile. Other groups containing amino acids that areconsidered conservative substitutions for one another include:sulfur-containing: Met and Cys; acidic: Asp, Glu, Asn, and Gln; smallaliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, andGly; polar, negatively charged residues and their amides: Asp, Asn, Glu,and Gln; polar, positively charged residues: His, Arg, and Lys; largealiphatic, nonpolar residues: Met, Leu, Ile, Val, and Cys; and largearomatic residues: Phe, Tyr, and Trp. Additional information is found inCreighton (1984) Proteins, W.H. Freeman and Company.

Variants of proteins disclosed herein also include sequences with atleast 70% sequence identity, at least 80% sequence identity, at least85% sequence, at least 90% sequence identity, at least 95% sequenceidentity, at least 96% sequence identity, at least 97% sequenceidentity, at least 98% sequence identity, or at least 99% sequenceidentity to a protein disclosed herein. More particularly, variants ofthe proteins disclosed herein include proteins that share: 70% sequenceidentity with any of e.g., SEQ ID NO:1-29; 80% sequence identity withany of e.g., SEQ ID NO:1-29; 81% sequence identity with any of e.g., SEQID NO:1-29; 82% sequence identity with any of e.g., SEQ ID NO:1-29; 83%sequence identity with any of e.g., SEQ ID NO:1-29; 84% sequenceidentity with any of e.g., SEQ ID NO:1-29; 85% sequence identity withany of e.g., SEQ ID NO:1-29; 86% sequence identity with any of e.g., SEQID NO:1-29; 87% sequence identity with any of e.g., SEQ ID NO:1-29; 88%sequence identity with any of e.g., SEQ ID NO:1-29; 89% sequenceidentity with any of e.g., SEQ ID NO:1-29; 90% sequence identity withany of e.g., SEQ ID NO:1-29; 91% sequence identity with any of e.g., SEQID NO:1-29; 92% sequence identity with any of e.g., SEQ ID NO:1-29; 93%sequence identity with any of e.g., SEQ ID NO:1-29; 94% sequenceidentity with any of e.g., SEQ ID NO:1-29; 95% sequence identity withany of e.g., SEQ ID NO:1-29; 96% sequence identity with any of e.g., SEQID NO:1-29; 97% sequence identity with any of e.g., SEQ ID NO:1-29; 98%sequence identity with any of e.g., SEQ ID NO:1-29; or 99% sequenceidentity with any of e.g., SEQ ID NO:1-29.

Variants of myoglobin can include myoglobin proteins that share: 70%sequence identity with e.g., SEQ ID NO:21; 80% sequence identity withe.g., SEQ ID NO:21; 81% sequence identity with e.g., SEQ ID NO:21; 82%sequence identity with e.g., SEQ ID NO:21; 83% sequence identity withe.g., SEQ ID NO:21; 84% sequence identity with e.g., SEQ ID NO:21; 85%sequence identity with e.g., SEQ ID NO:21; 86% sequence identity withe.g., SEQ ID NO:21; 87% sequence identity with e.g., SEQ ID NO:21; 88%sequence identity with e.g., SEQ ID NO:21; 89% sequence identity withe.g., SEQ ID NO:21; 90% sequence identity with e.g., SEQ ID NO:21; 91%sequence identity with e.g., SEQ ID NO:21; 92% sequence identity withe.g., SEQ ID NO:21; 93% sequence identity with e.g., SEQ ID NO:21; 94%sequence identity with e.g., SEQ ID NO:1; 95% sequence identity withe.g., SEQ ID NO:21; 96% sequence identity with e.g., SEQ ID NO:21; 97%sequence identity with e.g., SEQ ID NO:21; 98% sequence identity withe.g., SEQ ID NO:21; or 99% sequence identity with e.g., SEQ ID NO:21.

“% sequence identity” refers to a relationship between two or moresequences, as determined by comparing the sequences. In the art,“identity” also means the degree of sequence relatedness between proteinsequences as determined by the match between strings of such sequences.“Identity” (often referred to as “similarity”) can be readily calculatedby known methods, including those described in: Computational MolecularBiology (Lesk, A. M., ed.) Oxford University Press, NY (1988);Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.)Academic Press, NY (1994); Computer Analysis of Sequence Data, Part I(Griffin, A. M., and Griffin, H. G., eds.) Humana Press, NJ (1994);Sequence Analysis in Molecular Biology (Von Heijne, G., ed.) AcademicPress (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux,J., eds.) Oxford University Press, NY (1992). Preferred methods todetermine sequence identity are designed to give the best match betweenthe sequences tested. Methods to determine sequence identity andsimilarity are codified in publicly available computer programs.Sequence alignments and percent identity calculations may be performedusing the Megalign program of the LASERGENE bioinformatics computingsuite (DNASTAR, Inc., Madison, Wis.). Multiple alignment of thesequences can also be performed using the Clustal method of alignment(Higgins and Sharp CABIOS, 5, 151-153 (1989) with default parameters(GAP PENALTY=10, GAP LENGTH PENALTY=10). Relevant programs also includethe GCG suite of programs (Wisconsin. Package Version 9.0, GeneticsComputer Group (GCG), Madison, Wis.); BLASTP, BLASTN, BLASTX (Altschul,et al., J. Mol. Biol. 215:403-410 (1990); DNASTAR (DNASTAR, Inc.,Madison, Wis.); and the FASTA program incorporating the Smith-Watermanalgorithm (Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.](1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher:Plenum, New York, N.Y. Within the context of this disclosure it will beunderstood that where sequence analysis software is used for analysis,the results of the analysis are based on the “default values” of theprogram referenced. “Default values” mean any set of values orparameters which originally load with the software when firstinitialized.

“D-substituted analogs” include protein disclosed herein having one moreL-amino acids substituted with one or more D-amino acids. The D-aminoacid can be the same amino acid type as that found in the referencesequence or can be a different amino acid. Accordingly, D-analogs canalso be variants.

While exemplary sequences are provided herein, sequence informationprovided by public databases can be used to identify additional relatedand relevant protein sequences and associated nucleic acid sequencesencoding such proteins.

Iron. Reference to iron can include iron molecules or iron in aniron-containing complex. “Iron-containing complexes” or “iron complexes”are compounds that contain iron in the (II) or (III) oxidation state,complexed with an organic compound. Iron complexes include iron polymercomplexes, iron carbohydrate complexes, and iron aminoglycosancomplexes. These complexes are commercially available and/or can besynthesized by methods known in the art.

Examples of iron carbohydrate complexes include iron simple saccharidecomplexes, iron oligosaccharide complexes, and iron polysaccharidecomplexes, such as: iron carboxymaltose, iron sucrose, ironpolyisomaltose (iron dextran), iron polymaltose (iron dextrin), irongluconate, iron sorbital, iron hydrogenated dextran, which may befurther complexed with other compounds, such as sorbital, citric acidand gluconic acid (for example iron dextrin-sorbitol-citric acid complexand iron sucrose-gluconic acid complex), and mixtures thereof.

Examples of iron aminoglycosan complexes include iron chondroitinsulfate, iron dermatin sulfate, iron keratan sulfate, which may befurther complexed with other compounds and mixtures thereof.

Examples of iron polymer complexes include iron hyaluronic acid complex,iron protein complexes, and mixtures thereof. Iron protein complexesinclude ferritin, transferritin, as well as ferritin or transferritinwith amino acid substitutions, and mixtures thereof.

Particular embodiments utilize low molecular weight iron complexes(e.g., low molecular weight iron sucrose complexes). The molecularweight of the complex can be less than 25,000 and non-polymeric. Inadditional embodiments, the molecular weight of the complex can be lessthan 12,000 or less than 5000 or less than 2500. It is to be understoodthat the lower the molecular weight of the iron complex and,correspondingly, the smaller the iron complex, the faster the ironcomplex may be incorporated into a patient's blood.

In particular embodiments, iron within the claims and exemplaryembodiments refers to iron sucrose.

Vitamin B12 & Metabolites. Vitamin B12 is unique among vitamins in thatit contains a metal ion, cobalt. Particular embodiments include thewater soluble cyanocobalamin which is an organometallic compound with atrivalent cobalt ion bound inside a corrin ring. Methylcobalamin and5-deoxyadenosyl cobalamin are forms of vitamin B12 primarily used by thehuman body. Additional forms include adenosyl cobalamin and hydroxylcobalamin. Vitamin B12 may be obtained from any appropriate synthetic ornatural source, and all analogues, derivatives, salts, and prodrugs, aswell as mixtures thereof.

In embodiments, a derivative of vitamin B12 that can be utilized isproduced by cleaving at least a portion of the PO⁴− group of vitaminB12. For example, the PO₄ group of vitamin B12 can be cleaved using anuclease, or removed with a nuclease in combination with a phosphatase.A derivative of vitamin B12 can have a structure

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; R₂ can be OH or H; andR₃ can be OH or H.

In embodiments, vitamin B12 can be coupled with a saccharide-metalcomplex. Additionally, a derivative of vitamin B12 can be coupled with asaccharide-metal complex. In some embodiments, a saccharide-metalcomplex can be derived from a disaccharide. For example asaccharide-metal complex can be derived from sucrose. In other examples,a saccharide-metal complex can be derived from lactose. In illustrativeexamples, the saccharide-metal complex can be iron sucrose. By couplingvitamin B12 with iron sucrose, iron and vitamin B12 can be delivered toan organ using a single structure.

The linkage between a saccharide-metal complex and vitamin B12 or aderivative of vitamin B12 can be formed using an acid-labile hydrazinelinker. Additionally, the linkage between a saccharide-metal complex andvitamin B12 or a derivative of vitamin B12 can be formed using an acidlabile hydrazone linker. Examples of a hydrazone linker used inconjunction with vitamin B12 is discussed in Bagnato J D, Eilers A L,Horton R A, Grisson C B: Synthesis and characterization of acobalamin-colchicine conjugate as a novel tumor-targeted cytotoxid. J.Org. Chem. 2004: 69, 8987-8996. In other embodiments, the linkagebetween a saccharide-metal complex and vitamin B12 or a derivative ofvitamin B12 can be formed using a polyether. To illustrate, polyethyleneglycol can be used to link a saccharide-metal complex to vitamin B12 ora derivative of vitamin B12. In additional embodiments, the linkagebetween a saccharide-metal complex and vitamin B12 or a derivative ofvitamin B12 can be formed using a peptide linker. In illustrativeexamples, a poly-glycine-serine linker can be used to couple asaccharide-metal complex to vitamin B12 or a derivative of vitamin B12.In further embodiments, the linkage between a saccharide-metal complexand vitamin B12 or a derivative of vitamin B12 can be formed using oneor more peptides. In other illustrative examples, a polyamide can beused to link a saccharide-metal complex with vitamin B12 or a derivativeof vitamin B12. In particular illustrative examples, a proteaseresistant polyamide can be used to link a saccharide-metal complex withvitamin B12 or a derivative of vitamin B12.

In some cases, the linkage between a saccharide-metal complex andvitamin B12 or a derivative of vitamin B12 can be formed at multiplesites of the saccharide-metal complex. For example, the linkage betweena saccharide-metal complex and vitamin B12 or a derivative of vitaminB12 can be at multiple hydroxyl sites of the saccharide-metal complex.In other embodiments, the linkage between a saccharide-metal complex andvitamin B12 or a derivative of vitamin B12 can be at a single site ofthe saccharide-metal complex. To illustrate, the linkage between asaccharide-metal complex and vitamin B12 or a derivative of vitamin B12can be at a single hydroxyl site of the saccharide-metal complex.Additionally, the linkage between a saccharide-metal complex and vitaminB12 can be with the phosphate group of vitamin B12 and a hydroxyl groupof the saccharide-metal complex. Further, the linkage between asaccharide-metal complex and a derivative of vitamin B12 can be betweena hydroxyl group of the saccharide-metal complex and a site resultingfrom cleaving the phosphate group from vitamin B12.

Example structures having a linkage between a saccharide-metal complexand vitamin B12 can have the following form:

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; A is a phosphategroup, L is a linker, B is a saccharide-based structure, and M is ametal complexed with the saccharide-based structure. In illustrativeembodiments, A can be PO₄, L can be a hydrazone linker, B can be asaccharide-based structure, and M can be Fe. In embodiments, B caninclude 10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen atoms.In particular embodiments, B can be derived from sucrose.

Example structures having a linkage between a saccharide-metal complexand a derivative of vitamin B12 can have the following form:

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; R₂ can be OH or H; Lis a linker, B is a saccharide-based structure, and M is a metalcomplexed with the saccharide-based structure. In illustrativeembodiments, L can be a hydrazone linker and M can be Fe. Inembodiments, B can include 10-16 carbon atoms, 9-15 oxygen atoms, and16-28 hydrogen atoms. In particular embodiments, B can be derived fromsucrose.

Additional example structures having a linkage between asaccharide-metal complex and a derivative of vitamin B12 can have thefollowing form:

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; R₃ can be OH or H; Lis a linker, B is a saccharide-based structure, and M is a metalcomplexed with the saccharide-based structure. In an illustrativeembodiment, L can be a hydrazone linker and M can be Fe. In embodiments,B can include 10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogenatoms. In particular embodiments, B can be derived from sucrose.

Other example structures having a linkage between a saccharide-metalcomplex and a derivative of vitamin B12 can have the following form:

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; L is a linker, B is asaccharide-based structure, and M is a metal complexed with thesaccharide-based structure. In illustrative embodiments, L can be ahydrazone linker and M can be Fe. In embodiments, B can include 10-16carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen atoms. In particularembodiments, B can be derived from sucrose.

Example structures having a linkage between multiple saccharide-metalcomplexes and a derivative of vitamin B12 can have the following form:

where R₁ can be 5′-deoxyadenosyl, CH₃, OH, or CN; L₁ is a first linker,L₂ is a second linker, B₁ is a first saccharide-based structure, B₂ is asecond saccharide-based structure, M₁ is a first metal, and M₂ is asecond metal complexed with the saccharide-based structure. Inillustrative embodiments, L₁ and L₂ can be hydrazone linkers and M₁ andM₂ can be Fe. In embodiments, B₁ and B₂ can include 10-16 carbon atoms,9-15 oxygen atoms, and 16-28 hydrogen atoms. In particular embodiments,B₁ and B₂ can be derived from sucrose.

In embodiments, a saccharide-metal complex can be derived from adisaccharide. For example a saccharide-metal complex can be derived fromsucrose. In other examples, a saccharide-metal complex can be derivedfrom lactose. Example structures of a saccharide-metal complex can havethe following form:

It is to be understood that although the above structure indicates asingle Fe atom complexed with a sucrose derived compound, one or more Featoms can be complexed with one or more repeating units of the sucrosederived compound to balance the charges of the groups as needed.

Compositions. Heme proteins (including modifications, variants andD-substituted analogs thereof), heme protein degradation inhibitors(e.g., HO-1 inhibitors, protoporphyrins, hemin and/or hematin), iron andvitamin B12 (individually and collectively, “active ingredients”) can beprovided alone or in combination within a composition. In particularembodiments, composition includes at least one heme protein and/or atleast one heme protein degradation inhibitor and at least onepharmaceutically acceptable carrier. Salts and/or pro-drugs of activeingredients can also be used.

A pharmaceutically acceptable salt includes any salt that retains theactivity of the active ingredient and is acceptable for pharmaceuticaluse. A pharmaceutically acceptable salt also refers to any salt whichmay form in vivo as a result of administration of an acid, another salt,or a prodrug which is converted into an acid or salt.

Suitable pharmaceutically acceptable acid addition salts can be preparedfrom an inorganic acid or an organic acid. Examples of such inorganicacids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic,sulfuric and phosphoric acid. Appropriate organic acids can be selectedfrom aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic,carboxylic and sulfonic classes of organic acids.

Suitable pharmaceutically acceptable base addition salts includemetallic salts made from aluminum, calcium, lithium, magnesium,potassium, sodium and zinc or organic salts made fromN,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine,ethylenediamine, N-methylglucamine, lysine, arginine and procaine.

A prodrug includes an active ingredient which is converted to atherapeutically active compound after administration, such as bycleavage of a protein or by hydrolysis of a biologically labile group.

In some embodiments, the compositions include active ingredients of atleast 0.1% w/v of the composition; at least 1% w/v of composition; atleast 10% w/v of composition; at least 20% w/v of composition; at least30% w/v of composition; at least 40% w/v of composition; at least 50%w/v of composition; at least 60% w/v of composition; at least 70% w/v ofcomposition; at least 80% w/v of composition; at least 90% w/v ofcomposition; at least 95% w/v of composition; or at least 99% w/v ofcomposition.

In other embodiments, active ingredients can be provided as part of acomposition that can include, for example, at least 0.1% w/w ofcomposition; at least 1% w/w of composition; at least 10% w/w ofcomposition; at least 20% w/w of composition; at least 30% w/w ofcomposition; at least 40% w/w of composition; at least 50% w/w ofcomposition; at least 60% w/w of composition; at least 70% w/w ofcomposition; at least 80% w/w of composition; at least 90% w/w ofcomposition; at least 95% w/w of composition; or at least 99% w/w ofcomposition.

Particular embodiments include a nitrited heme protein degradationinhibitor with a nitrited heme protein. Particular embodiments include anitrited protoporphyrin with a nitrited heme protein. Particularembodiments include a nitrited metal protoporphyrin with a nitrited hemeprotein. Particular embodiments include a nitrited SnPP with a nitriatedheme protein. Particular embodiments include a nitrited hemin with anitrited heme protein. Particular embodiments include a nitrited hematinwith a nitrited heme protein. In particular forms of these exemplaryembodiments, the nitrited heme protein is myoglobin. Particularembodiments also include more than one nitrited heme protein degradationinhibitor (e.g. a nitrited protoporphyrin, nitrited hemin and/ornitrited hematin) with a heme protein (e.g., myoglobin or nitritedmyoglobin). In further particular embodiments, a combination of hemeprotein degradation inhibitor is provided wherein not all constituentsof the combination are nitrited.

Particular embodiments include iron, optionally in combination with ametal protoporphyrin, SnPP and/or vitamin B12. The iron can be ironsucrose. These embodiments can additionally include heme proteins (e.g.,myoglobin or nitrited myoglobin) and/or heme protein degradationinhibitor (e.g., protoporphyrins, hemin and/or hematin and/or theirnitrated forms). When embodiments utilize iron in combination withvitamin B12, the iron and B12 can be complexed or cross-linked into asingle unit.

Exemplary generally used pharmaceutically acceptable carriers includeany and all absorption delaying agents, antioxidants, binders, bufferingagents, bulking agents or fillers, chelating agents, coatings,disintegration agents, dispersion media, gels, isotonic agents,lubricants, preservatives, salts, solvents or co-solvents, stabilizers,surfactants, and/or delivery vehicles.

Exemplary antioxidants include ascorbic acid, methionine, and vitamin E.

Exemplary buffering agents include citrate buffers, succinate buffers,tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers,lactate buffers, acetate buffers, phosphate buffers, histidine buffers,and/or trimethylamine salts.

An exemplary chelating agent is EDTA.

Exemplary isotonic agents include polyhydric sugar alcohols includingtrihydric or higher sugar alcohols, such as glycerin, erythritol,arabitol, xylitol, sorbitol, or mannitol.

Exemplary preservatives include phenol, benzyl alcohol, meta-cresol,methyl paraben, propyl paraben, octadecyldimethylbenzyl ammoniumchloride, benzalkonium halides, hexamethonium chloride, alkyl parabenssuch as methyl or propyl paraben, catechol, resorcinol, cyclohexanol,and 3-pentanol.

Stabilizers refer to a broad category of excipients which can range infunction from a bulking agent to an additive which solubilizes theactive ingredient or helps to prevent denaturation or adherence to thecontainer wall. Typical stabilizers can include polyhydric sugaralcohols; amino acids, such as arginine, lysine, glycine, glutamine,asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine,glutamic acid, and threonine; organic sugars or sugar alcohols, such aslactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol,myoinisitol, galactitol, glycerol, and cyclitols, such as inositol; PEG;amino acid polymers; sulfur-containing reducing agents, such as urea,glutathione, thioctic acid, sodium thioglycolate, thioglycerol,alpha-monothioglycerol, and sodium thiosulfate; low molecular weightpolypeptides (i.e., <10 residues); proteins such as human serum albumin,bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymerssuch as polyvinylpyrrolidone; monosaccharides such as xylose, mannose,fructose and glucose; disaccharides such as lactose, maltose andsucrose; trisaccharides such as raffinose, and polysaccharides such asdextran. Stabilizers are typically present in the range of from 0.1 to10,000 parts by weight based on active ingredient weight.

The compositions disclosed herein can be formulated for administrationby, for example, injection, inhalation, infusion, perfusion, lavage, oringestion. The compositions disclosed herein can further be formulatedfor intravenous, intradermal, intraarterial, intranodal, intralymphatic,intraperitoneal, intralesional, intraprostatic, intravaginal,intrarectal, topical, intrathecal, intratumoral, intramuscular,intravesicular, oral and/or subcutaneous administration and moreparticularly by intravenous, intradermal, intraarterial, intranodal,intralymphatic, intraperitoneal, intralesional, intraprostatic,intravaginal, intrarectal, intrathecal, intratumoral, intramuscular,intravesicular, and/or subcutaneous injection.

For injection, compositions can be formulated as aqueous solutions, suchas in buffers including Hanks' solution, Ringer's solution, orphysiological saline. The aqueous solutions can contain formulatoryagents such as suspending, stabilizing, and/or dispersing agents.Alternatively, the formulation can be in lyophilized and/or powder formfor constitution with a suitable vehicle, e.g., sterile pyrogen-freewater, before use. Particular embodiments are formulated for intravenousadministration.

For oral administration, the compositions can be formulated as tablets,pills, dragees, capsules, liquids, gels, syrups, slurries, suspensionsand the like. For oral solid formulations such as, for example, powders,capsules and tablets, suitable excipients include binders (gumtragacanth, acacia, cornstarch, gelatin), fillers such as sugars, e.g.lactose, sucrose, mannitol and sorbitol; dicalcium phosphate, starch,magnesium stearate, sodium saccharine, cellulose, magnesium carbonate;cellulose preparations such as maize starch, wheat starch, rice starch,potato starch, gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxy- methylcellulose, and/orpolyvinylpyrrolidone (PVP); granulating agents; and binding agents. Ifdesired, disintegrating agents can be added, such as corn starch, potatostarch, alginic acid, cross-linked polyvinylpyrrolidone, agar, oralginic acid or a salt thereof such as sodium alginate. If desired,solid dosage forms can be sugar-coated or enteric-coated using standardtechniques. Flavoring agents, such as peppermint, oil of wintergreen,cherry flavoring, orange flavoring, etc. can also be used.

Compositions can be formulated as an aerosol. In one embodiment, theaerosol is provided as part of an anhydrous, liquid or dry powderinhaler. Aerosol sprays from pressurized packs or nebulizers can also beused with a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol, a dosage unitmay be determined by providing a valve to deliver a metered amount.Capsules and cartridges of gelatin for use in an inhaler or insufflatormay also be formulated containing a powder mix of heme protein and asuitable powder base such as lactose or starch.

Compositions can also be formulated as depot preparations. Depotpreparations can be formulated with suitable polymeric or hydrophobicmaterials (for example as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salts.

Additionally, compositions can be formulated as sustained-releasesystems utilizing semipermeable matrices of solid polymers containing atleast one active ingredient. Various sustained-release materials havebeen established and are well known by those of ordinary skill in theart. Sustained-release systems may, depending on their chemical nature,release active ingredients following administration for a few weeks upto over 100 days. Depot preparations can be administered by injection;parenteral injection; instillation; or implantation into soft tissues, abody cavity, or occasionally into a blood vessel with injection throughfine needles.

Depot formulations can include a variety of bioerodible polymersincluding poly(lactide), poly(glycolide), poly(caprolactone) andpoly(lactide)-co(glycolide) (PLG) of desirable lactide:glycolide ratios,average molecular weights, polydispersities, and terminal groupchemistries. Blending different polymer types in different ratios usingvarious grades can result in characteristics that borrow from each ofthe contributing polymers.

The use of different solvents (for example, dichloromethane, chloroform,ethyl acetate, triacetin, N-methyl pyrrolidone, tetrahydrofuran, phenol,or combinations thereof) can alter microparticle size and structure inorder to modulate release characteristics. Other useful solvents includewater, ethanol, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP),acetone, methanol, isopropyl alcohol (IPA), ethyl benzoate, and benzylbenzoate.

Exemplary release modifiers can include surfactants, detergents,internal phase viscosity enhancers, complexing agents, surface activemolecules, co-solvents, chelators, stabilizers, derivatives ofcellulose, (hydroxypropyl)methyl cellulose (HPMC), HPMC acetate,cellulose acetate, pluronics (e.g., F68/F127), polysorbates, Span®(Croda Americas, Wilmington, Del.), poly(vinyl alcohol) (PVA), Brij®(Croda Americas, Wilmington, Del.), sucrose acetate isobutyrate (SAIB),salts, and buffers.

Excipients that partition into the external phase boundary ofmicroparticles such as surfactants including polysorbates,dioctylsulfosuccinates, poloxamers, PVA, can also alter propertiesincluding particle stability and erosion rates, hydration and channelstructure, interfacial transport, and kinetics in a favorable manner.

Additional processing of the disclosed sustained release depotformulations can utilize stabilizing excipients including mannitol,sucrose, trehalose, and glycine with other components such aspolysorbates, PVAs, and dioctylsulfosuccinates in buffers such as Tris,citrate, or histidine. A freeze-dry cycle can also be used to producevery low moisture powders that reconstitute to similar size andperformance characteristics of the original suspension.

Any composition disclosed herein can advantageously include any otherpharmaceutically acceptable carriers which include those that do notproduce significantly adverse, allergic, or other untoward reactionsthat outweigh the benefit of administration. Exemplary pharmaceuticallyacceptable carriers and formulations are disclosed in Remington'sPharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. Moreover,formulations can be prepared to meet sterility, pyrogenicity, generalsafety, and purity standards as required by U.S. FDA Office ofBiological Standards and/or other relevant foreign regulatory agencies.

Kits. Also disclosed herein are kits including one or more containersincluding one or more of the active ingredients and/or compositionsdescribed herein. In various embodiments, the kits may include one ormore containers containing one or more active ingredients and/orcompositions to be used in combination with the active ingredientsand/or compositions described herein. Associated with such container(s)can be a notice in the form prescribed by a governmental agencyregulating the manufacture, use, or sale of pharmaceuticals orbiological products, which notice reflects approval by the agency ofmanufacture, use, or sale for human administration.

Optionally, the kits described herein further include instructions forusing the kit in the methods disclosed herein. In various embodiments,the kit may include instructions regarding preparation of the activeingredients and/or compositions for administration; administration ofthe active ingredients and/or compositions; appropriate reference levelsto interpret results associated with using the kit; proper disposal ofthe related waste; and the like. The instructions can be in the form ofprinted instructions provided within the kit or the instructions can beprinted on a portion of the kit itself. Instructions may be in the formof a sheet, pamphlet, brochure, CD-Rom, or computer-readable device, orcan provide directions to instructions at a remote location, such as awebsite. The instructions may be in English and/or in any national orregional language. In various embodiments, possible side effects andcontraindications to further use of components of the kit based on asubject's symptoms can be included. The kits and instructions can alsobe tailored according to the type of organ to be protected and the typeof insult the organ may encounter.

In various embodiments, the packaging, active ingredients and/orcompositions, and instructions are combined into a small, compact kitwith printed instructions for use of each of the active ingredientsand/or compositions. In various embodiments in which more than oneactive ingredient and/or composition is provided, the sequencing of useof the active ingredients and/or compositions can be labeled in the kit.

In various embodiments, the kits described herein include some or all ofthe necessary medical supplies needed to use the kit effectively,thereby eliminating the need to locate and gather such medical supplies.Such medical supplies can include syringes, ampules, tubing, facemask, aneedleless fluid transfer device, an injection cap, sponges, sterileadhesive strips, Chloraprep, gloves, and the like. Variations incontents of any of the kits described herein can be made. Particularkits provide materials to administer compositions through intravenousadministration.

Methods of Use. As stated, the compositions, kits, and methods disclosedherein can be used to protect organs from injury by inducing acquiredcytoresistance in the absence of an injury. There are numerous potentialuses for the compositions, kits, and methods, some of which aredescribed herein.

Methods disclosed herein include treating organs with active ingredientsdisclosed herein including salts and prodrugs thereof. Treating organsincludes delivering therapeutically effective amounts. Therapeuticallyeffective amounts include those that provide effective amounts,prophylactic treatments, and/or therapeutic treatments.

An organ is a part of a subject that is typically self-contained and hasa specific vital function. Examples of organs include the heart, liver,kidneys, spleen, pancreas, brain, lungs, intestines, stomach, etc. Inparticular embodiments, therapeutically effective amounts can beadministered directly to organs.

Therapeutically effective amounts can also be administered to organs byadministering the therapeutically effective amount to the subject inwhich the organ resides. Subjects include humans, veterinary animals(dogs, cats, reptiles, birds, etc.), livestock (horses, cattle, goats,pigs, chickens, etc.), and research animals (monkeys, rats, mice, fish,etc.). Treating subjects includes delivering therapeutically effectiveamounts. Thus, unless stated otherwise, administration to an organ canbe by administration to a subject, resulting in physiological deliveryto the organ or can be by administration directly to the organ.

An “effective amount” is the amount of an active ingredient orcomposition necessary to result in a desired physiological change in anorgan or subject. Effective amounts are often administered for researchpurposes. Effective amounts disclosed herein protect organs from injuryby inducing acquired cytoresistance in the absence of an injury.

A “prophylactic treatment” includes a treatment administered to an organthat does not display signs or symptoms of organ injury or displays onlyearly signs or symptoms of organ injury such that treatment isadministered for the purpose of diminishing, preventing, or decreasingthe risk of developing further organ injury. Thus, a prophylactictreatment functions as a preventative treatment against organ injury.

A “therapeutic treatment” includes a treatment administered to an organthat displays symptoms or signs of organ injury and is administered tothe organ for the purpose of reducing the worsening of organ injury.

The actual dose amount administered to a particular organ (or subject)can be determined by a physician, veterinarian, or researcher takinginto account parameters such as physical and physiological factorsincluding target; body weight; severity of condition; upcoming insult,when known; type of organ requiring protection; previous or concurrenttherapeutic interventions; idiopathy of the subject; and route ofadministration.

The amount and concentration of active ingredient in a composition, aswell as the quantity of the composition administered, can be selectedbased on clinically relevant factors, the solubility of the activeingredient in the composition, the potency and activity of the activeingredient, and the manner of administration of the composition, as wellas whether the active ingredient is modified (e.g., nitrited, PEGylated)or administered in combination with a heme protein degradation inhibitor(e.g., an HO-1 inhibitor) among other considerations.

A composition including a therapeutically effective amount of an activeingredient(s) disclosed herein can be administered intravenously to asubject for protection of organs in a clinically safe and effectivemanner, including one or more separate administrations of thecomposition. For example, 0.05 mg/kg to 5.0 mg/kg can be administered toa subject per day in one or more doses (e.g., doses of 0.05 mg/kg QD,0.10 mg/kg QD, 0.50 mg/kg QD, 1.0 mg/kg QD, 1.5 mg/kg QD, 2.0 mg/kg QD,2.5 mg/kg QD, 3.0 mg/kg QD, 0.75 mg/kg BID, 1.5 mg/kg BID, or 2.0 mg/kgBID). For certain organs and indications, the total daily dose of anactive ingredient can be 0.05 mg/kg to 3.0 mg/kg administeredintravenously to a subject one to three times a day, includingadministration of total daily doses of 0.05-3.0, 0.1-3.0, 0.5-3.0,1.0-3.0, 1.5-3.0, 2.0-3.0, 2.5-3.0, and 0.5-3.0 mg/kg/day of compositionusing 60-minute QD, BID, or TID intravenous infusion dosing. In oneparticular example, compositions can be intravenously administered QD orBID to a subject with, e.g., total daily doses of 1.5 mg/kg, 3.0 mg/kg,4.0 mg/kg of a composition with up to 92-98% wt/wt of a heme protein.

Additional useful doses can often range from 0.1 to 5 μg/kg or from 0.5to 1 μg/kg. In other examples, a dose can include 1 μg/kg, 5 μg/kg, 10μg/kg, 15 μg/kg, 20 μg/kg, 25 μg/kg, 30 μg/kg, 35 μg/kg, 40 μg/kg, 45μg/kg, 50 μg/kg, 55 μg/kg, 60 μg/kg, 65 μg/kg, 70 μg/kg, 75 μg/kg, 80μg/kg, 85 μg/kg, 90 μg/kg, 95 μg/kg, 100 μg/kg, 150 μg/kg, 200 μg/kg,250 μg/kg, 350 μg/kg, 400 μg/kg, 450 μg/kg, 500 μg/kg, 550 μg/kg, 600μg/kg, 650 μg/kg, 700 μg/kg, 750 μg/kg, 800 μg/kg, 850 μg/kg, 900 μg/kg,950 μg/kg, 1000 μg/kg, 0.1 to 5 mg/kg, or from 0.5 to 1 mg/kg. In otherexamples, a dose can include 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55mg/kg, 60 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90mg/kg, 95 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 350 mg/kg,400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, 1000mg/kg, or more.

Each of the described doses of active ingredients can be a heme proteinalone, heme proteins in combination, a heme protein degradationinhibitor alone, heme protein degradation inhibitors in combination or acombination of one or more heme proteins and one or more heme proteindegradation inhibitors, iron, and/or vitamin B12. In particularembodiments, when included in combinations to producue a dose, such as adose stated herein, the substituents in the combination can be providedin exemplary ratios such as: 1:1; 1:1.25; 1:1.5; 1:1.75; 1:8; 1:1.2;1:1.25; 1:1.3; 1:1.35; 1:1.4; 1:1.5; 1: 1.75; 1:2; 1:3; 1:4; 1:5; 1:6:1:7; 1:8; 1:9; 1:10; 1:15; 1:20; 1:30; 1:40; 1:50; 1:60; 1:70; 1:80;1:90; 1:100; 1:200; 1:300; 1:400; 1:500; 1:600; 1:700; 1:800; 1:900;1:1000; 1:1:1; 1:2:1; 1:3:1; 1:4:1; 1:5;1; 1:10:1; 1:2:2; 1:2:3; 1:3:4;1:4:2; 1:5;3; 1:10:20; 1:2:1:2; 1:4:1:3; 1:100:1:1000; 1:25:30:10;1:4:16:3; 1:1000:5:15; 1:2:3:10; 1:5:15:45; 1:50:90:135; 1:1.5:1.8:2.3;1:10:100:1000 or additional beneficial ratios depending on the numberand identity of substituents in a combination to reach the stateddosage. The substituents in a combination can be provided within thesame composition or within different compositions.

Therapeutically effective amounts can be achieved by administeringsingle or multiple doses during the course of a treatment regimen (e.g.,QID, TID, BID, daily, every other day, every 3 days, every 4 days, every5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly,every 2 months, every 3 months, every 4 months, every 5 months, every 6months, every 7 months, every 8 months, every 9 months, every 10 months,every 11 months, or yearly).

In particular embodiments, compositions are administered within 48 hoursof an upcoming insult, within 46 hours of an upcoming insult, within 44hours of an upcoming insult, within 42 hours of an upcoming insult,within 40 hours of an upcoming insult, within 38 hours of an upcominginsult, within 36 hours of an upcoming insult, within 34 hours of anupcoming insult, within 32 hours of an upcoming insult, within 30 hoursof an upcoming insult, within 28 hours of an upcoming insult, within 26hours of an upcoming insult, within 24 hours of an upcoming insult,within 22 hours of an upcoming insult, within 20 hours of an upcominginsult, within 18 hours of an upcoming insult, within 16 hours of anupcoming insult, within 14 hours of an upcoming insult, within 12 hoursof an upcoming insult, within 10 hours of an upcoming insult, within 8hours of an upcoming insult, within 6 hours of an upcoming insult,within 4 hours of an upcoming insult, or within 2 hours of an upcominginsult. In one particular embodiment, compositions are administeredwithin 18 hours of an upcoming insult.

In additional particular embodiments, compositions are administered atleast 48 hours before an upcoming insult, at least 46 hours before anupcoming insult, at least 44 hours before an upcoming insult, at least42 hours before an upcoming insult, at least 40 hours before an upcominginsult, at least 38 hours before an upcoming insult, at least 36 hoursbefore an upcoming insult, at least 34 hours before an upcoming insult,at least 32 hours before an upcoming insult, at least 30 hours before anupcoming insult, at least 28 hours before an upcoming insult, at least26 hours before an upcoming insult, at least 24 hours before an upcominginsult, at least 22 hours before an upcoming insult, at least 20 hoursbefore an upcoming insult, at least 18 hours before an upcoming insult,at least 16 hours before an upcoming insult, at least 14 hours before anupcoming insult, at least 12 hours before an upcoming insult, at least10 hours before an upcoming insult, at least 8 hours before an upcominginsult, at least 6 hours before an upcoming insult, at least 4 hoursbefore an upcoming insult, or at least 2 hours before an upcominginsult. In one particular embodiment, compositions are administered atleast 18 hours before an upcoming insult.

Transplant Protection. In particular embodiments, organs are protectedfrom injury during transplant. The compositions can be administered (i)to an organ donor before organ isolation from the donor; (ii) to theisolated organ before transplantation, and/or (iii) to the organtransplant recipient. This method of use can apply to any organ capableof transplant from one individual subject to a second individualsubject. In particular embodiments, therapeutically effective amountscan be delivered directly to an organ following removal from a subjector prior to implantation in a second subject.

Renal System Protection. Until the current disclosure, there were noagents able to prevent or mitigate the occurrence of AKI in patients athigh risk, such as individuals undergoing surgery, cardiopulmonarybypass, or radiocontrast toxicity. It is noteworthy that acute kidneyfailure is a major risk factor for both morbidity and mortality as wellas the need for long term kidney dialysis. The latter costs the FederalGovernment billions of dollars in its end stage kidney disease/Medicareprogram. Thus, prevention of AKI/acute kidney failure presented acritical and completely unmet clinical need.

“Acute kidney injury”, (AKI) also known as “acute renal failure” (ARF)or “acute kidney failure”, refers to a disease or condition where arapid loss of renal function occurs due to damage to the kidneys,resulting in retention of nitrogenous (urea and creatinine) andnon-nitrogenous waste products that are normally excreted by the kidney.Depending on the severity and duration of the renal dysfunction, thisaccumulation is accompanied by metabolic disturbances, such as metabolicacidosis (acidification of the blood) and hyperkalaemia (elevatedpotassium levels), changes in body fluid balance, effects on many otherorgan systems/organ system failure, intravascular volume overload, comaand death. It can be characterized by oliguria or anuria (decrease orcessation of urine production), although nonoliguric ARF may occur. AKIis a serious complication in hospitals, resulting in a prolongedhospital stay and high mortality. Cardiac disease and cardiac surgeryare both common causes of AKI. Once patients have AKI, the mortalitythereof is high.

AKI may be a consequence of various causes including a) pre-renal(causes in the blood supply), which includes, hypovolemia or decreasedblood volume, usually from shock or dehydration and fluid loss orexcessive diuretics use; hepatorenal syndrome, in which renal perfusionis compromised due to liver failure; vascular problems, such asatheroembolic disease and renal vein thrombosis, which can occur as acomplication of nephrotic syndrome; infection, usually sepsis, andsystemic inflammation due to infection; severe burns; sequestration dueto pericarditis and pancreatitis; and hypotension due toantihypertensives and vasodilators; b) intrinsic renal damage, whichincludes renal ischemia (transient blood flow reductions orinterruption) toxins or medication (e.g. some NSAIDs, aminoglycosideantibiotics, iodinated contrast, lithium, phosphate nephropathy due tobowel preparation for colonoscopy with sodium phosphates);rhabdomyolysis or breakdown of muscle tissue, where the resultantrelease of myoglobin in the blood affects the kidney, which can also becaused by injury (especially crush injury or extensive blunt trauma),statins, stimulants and some other drugs; hemolysis or breakdown of redblood cells, which can be caused by various conditions such assickle-cell disease, and lupus erythematosus; multiple myeloma, eitherdue to hypercalcemia or “cast nephropathy”; acute glomerulonephritiswhich may be due to a variety of causes, such as anti-glomerularbasement membrane disease/Goodpasture's syndrome, Wegener'sgranulomatosis, or acute lupus nephritis with systemic lupuserythematosus; and c) post-renal causes (obstructive causes in theurinary tract) which include, medication interfering with normal bladderemptying (e.g. anticholinergics); benign prostatic hypertrophy orprostate cancer; kidney stones; abdominal malignancy (e.g. ovariancancer, colorectal cancer); obstructed urinary catheter; or drugs thatcan cause crystalluria and drugs that can lead to myoglobinuria &cystitis.

Methods of the current disclosure include protecting the kidney byinducing acquired cytoresistance. As stated, appropriate therapeuticallyeffective amounts can initially be determined using animal models toidentify dose ranges. Particular exemplary therapeutically effectiveamounts of active ingredient include 10 mg/kg; 20 mg/kg; 30 mg/kg; 40mg/kg; 50 mg/kg; 60 mg/kg; 70 mg/kg; 80 mg/kg; 90 mg/kg, and 100 mg/kg.

Exemplary animal models of kidney injury include: glycerol-induced renalfailure (mimics rhabdomyolysis); ischemia-reperfusion-induced ARF(simulates the changes induced by reduced kidney blood flow, resultingin tissue ischemia and cell tubule cell death); drug-induced models suchas gentamicin, cisplatin, NSAID, ifosfamide-induced ARF (mimics therenal failure due to clinical administration of respective drugs);uranium, potassium dichromate-induced ARF (mimics the occupationalhazard); S-(1,2-dichlorovinyl)-L-cysteine-induced ARF (simulatescontaminated water-induced renal dysfunction); sepsis-induced ARF(mimics the infection-induced renal failure); and radiocontrast-inducedARF (mimics renal failure in patients during use of radiocontrast mediaat the time of cardiac catheterization). For more information regardingthese models, see Singh et al., Pharmacol. Rep. 2012, 64 (1): 31-44.

Known tests of kidney function include ultrasound; CT scan; andmeasuring lactate dehydrogenase (LDH), blood urea nitrogen (BUN),creatinine, creatinine clearance, iothalamate clearance, glomerularfiltration rate, and inulin clearance.

Hepatic Protection. Exemplary animal models of liver injury include:ischemic reperfusion injury; chemically-induced liver fibrosis usinghepatotoxins (carbon tetrachloride, thioacetamide, dimethyl, or diethylnitrosamine); bile duct ligation; the Schistosomiasis model; theConcanavalin A hepatitis model; inducible HCV transgenic mice; variousgenetic models; the Enteral ethanol infusion model (Tsukamoto-Frenchmodel); and the methionine and choline deficiency model.

Further, a number of hepatotoxic compounds, including certaintherapeutics, induce cytotoxicity. Hepatotoxic compounds can produceliver cytotoxicity by direct chemical attack or by the production of atoxic metabolite. Cytotoxicity can be induced by direct chemical attackusing the following drugs: Anesthetics, such as, Enflurane, Fluroxene,Halothane, and Methoxyflurane; Neuropsychotropics, such as, Cocaine,Hydrazides, Methylphenidate, and Tricyclics; Anticonvulsants, such as,Phenyloin and Valproic acid; Analgesics, such as, Acetaminophen,Chlorzoxazone, Dantrolene, Diclofenac, Ibuprofen, Indomethacin,Salicylates, Tolmetin, and Zoxazolamine; Hormones, such as,Acetohexamide, Carbutamide, Glipizide, Metahexamide, Propylthiouracil,Tamoxifen, Diethylstilbestrol; Antimicrobials, such as, Amphotericin B,Clindamycin, Ketoconazole, Mebendazole, Metronidazole, Oxacillin,Paraaminosalicylic acid, Penicillin, Rifampicin, Sulfonamides,Tetracycline, and Zidovudine; Cardiovascular drugs, such as, Amiodarone,Dilitiazem, a-Methyldopa, Mexiletine, Hydrazaline, Nicotinic acid,Papaverine, Perhexiline, Procainamide, Quinidine, and Tocainamide; andImmunosuppressives and Antineoplastics, such as, Asparaginase,Cisplatin, Cyclophosphamide, Dacarbazine, Doxorubicin, Fluorouracil,Methotrexate, Mithramycin, 6-MP, Nitrosoureas, Tamoxifen, Thioguanine,and Vincristine; and Miscellaneous drugs, such as, Disulfiram, Iodideion, Oxyphenisatin, Vitamin A, and Paraaminobenzoic acid.

Hepatotoxic compounds inducing cholestasis, an arrest in the flow ofbile, may take several forms. Centribular cholestasis is accompanied byportal inflammatory changes. Bile duct changes have been reported withsome drugs such as erythromycin, while pure canalicular cholestasis ischaracteristic of other drugs such as the anabolic steroids. Chroniccholestasis has been linked to such drugs as methyltestosterone andestradiol. Cholestatic disease can be induced using hepatotoxiccompounds including the following: contraceptive steroids, androgenicsteroids, anabolic steroids, Acetylsalicylic acid, Azathioprine,Benzodiazepine, Chenodeoxycholic acid, Chlordiazepoxide, Erythromycinestolate, Fluphenazine, Furosemide, Griseofulvin, Haloperidol,Imipramine, 6-Mercaptopurine, Methimazole, Methotrexate, Methyldopa,Methylenediamine, Methyltestosterone, Naproxen, Nitrofurantoin,Penicillamine, Perphenazine, Prochlorperazine, Promazine, Thiobendazole,Thioridazine, Tolbutamide, Trimethoprimsulfamethoxazole, Arsenic,Copper, and Paraquat.

Some drugs, although primarily cholestatic, can also producehepatoxicity, and therefore the liver injury they cause is mixed. Drugscausing mixed liver injury include, for example, the following:Chlorpromazine, Phenylbutazone, Halothane, Chlordiazepoxide, Diazepam,Allopurinol, Phenobarbital, Naproxen, Propylthiouracil, Chloramphenicol,Trimethoprimsulfamethoxazxole, Aminone, Disopyramide, Azathioprine,Cimetidine, and Ranitidine.

Detection of one or more enzymes of the arginine/urea/NO cycle,sulfuration enzymes, and/or spectrin breakdown related products isdiagnostic of liver injury. Examples of these markers include:argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL),sulfuration (estrogen sulfotransferase (EST)), squalene synthase (SQS),liver glycogen phosphorylase (GP), carbamoyl-phosphate synthetase(CPS-1), α-enolase 1, glucose-regulated protein (GRP), and spectrinbreakdown products.

In other embodiments, the detection of biomarkers as a diagnostic ofliver injury, such as injury due to ischemia, can be correlated withexisting tests. These can include: alkaline phosphatase (AP);5′-nucleotidase (5′-ND); a-glutamyl transpeptidase (G-GT); leucineaminopeptidase (LAP); aspartate transaminase (AST); alanine transaminase(ALT); fructose-1,6-diphosphate aldolase (ALD); LDH; isocitratedehydrogenase (ICDH); ornithine-carbamoyltransferase (OCT); sorbitoldehydrogenase (SDH) arginase; guanase; creatine phosphokinase (CPK);cholinesterase (ChE); procollagen type III peptide levels (PIIIP);ammonia blood levels in hepatoencephalopathies; ligand in levels innecrosis and hepatoma; hyaluronate levels due to hepatic endothelialcell damage; α-1-fetoprotein (AFP) levels to detect hepatoma;carcinoembryonic antigen (CEA) levels to detect cancer metastasis to theliver; elevations of antibodies against a variety of cellularcomponents, such as, mitochondrial, and nuclear and specific livermembrane protein; and detection of proteins, such as, albumin, globin,amino acids, cholesterol, and other lipids. Also, biochemical analysisof a variety of minerals, metabolites, and enzymes obtained from liverbiopsies can be useful in identifying further biomarkers in inherited,acquired, and experimentally induced liver disorders.

In other embodiments, the amount of detected biomarkers can becorrelated to liver function tests to further assess liver injury. As isunderstood by one of skill in the art, liver function tests include thefollowing: assessment of hepatic clearance of organic anions, such as,bilirubin, indocyanine green (ICG), sulfobromophthalein (BSP) and bileacids; assessment of hepatic blood flow by measurements of galactose andICG clearance; and assessment of hepatic microsomal function, throughthe use of the aminopyrine breath test and caffeine clearance test. Forexample, serum bilirubin can be measured to confirm the presence andseverity of jaundice and to determine the extent of hyperbilirubinemia,as seen in parenchymal liver disease. Aminotransferase (transaminase)elevations reflect the severity of active hepatocellular damage, whilealkaline phosphatase elevations are found with cholestasis and hepaticinfiltrates (Isselbacher, K. and Podolsky, D. in Hartison's Principlesof Internal Medicine, 12th edition. Wilson et al. eds., 2: 1301-1308(1991)).

Additional scoring systems and parameters used to assess liver functioninclude the Child-Pugh scoring system as follows:

Child-Pugh scoring system Measure 1 point 2 points 3 points Bilirubin(total) <34 (<2) 34-50 (2-3) >50 (>3) μmol/l (mg/dl) Serum albuming/l >35 28-35 <28 INR <1.7 1.71-2.20 >2.20 Ascites None Mild SevereHepatic None Grade I-II (or  Grade III-IV (or encephalopathy suppressedwith refractory) medication)

The indocyanine plasma clearance test using a fingertip light sensor canbe used as well as a postoperative liver function scoring systemdeveloped by Schindl et al (Schindl M et al. 2005, Archives of Surgery140 (2):183-189). This system grades liver dysfunction according to thelevels of lactic acid, total bilirubin, INR, and encephalopathypostoperatively. Total scores of 0, 1-2, 3-4, or >4 are used to classifyliver dysfunction as absent, mild, moderate, or severe, respectively.Further, the bile salt to phospholipid ratio can be evaluated.

Cardiac Protection. Exemplary animal models of cardiac injury include:myocardial infarction (MI) models, post-MI remodeling models, genetherapy models, cell therapy models, transverse aortic constriction(TAC) models, acute ischemic stroke models, renal and limb ischemiamodels, the Langendorff perfusion model, and the doxorubicin-inducedcardiomyopathy model. See also, for example, cardiac injury animalmodels practiced by the Cardiovascular Research Laboratory, Baltimore,Md.

Various methods of detecting cardiac injury may be used, includingnon-invasive imaging, such as Magnetic Resonance Imaging (MRI),ultrasound, X-ray Computed Tomography (CT), single photon emissioncomputed tomography (SPECT) and/or positron emission tomography (PET).Additional measures can include echocardiography, electrocardiogram,Mikro-tip pressure catheter, telemetry, immunohistochemistry, andmolecular biological studies. U.S. Patent No. 2002/0115936 describes amethod and apparatus for assessment of cardiac function by monitoringmovement of the trachea.

Known tests of cardiac function include measuring PDH levels, plasmalactate levels, and/or cardiac carbohydrate oxidation. Markersassociated with non-ischemic heart injury include:Alpha-2-HS-glycoprotein precursor (e.g., SEQ ID NO:22); Asporin; ATPsynthase subunit delta (mitochondrial); Blood vessel epicardialsubstance (e.g., SEQ ID NO:23); C6ORF142; Carbonic anhydrase 1; Carbonicanhydrase 3; Ceruloplasmin; Coagulation factor IX; Collagen alpha-3(VI)chain; Dermatopontin; EGF-containing fibulin-like extracellular matrixprotein 1; Fibrinogen gamma chain; Fibulin-1; Fibulin-2; Heat shockprotein HSP 90-beta (e.g., SEQ ID NO:24); Hemoglobin subunit alpha;Hemoglobin subunit beta; Ig alpha-1 chain C region; Ig alpha-2 chain Cregion; Ig gamma-2 chain C region; Ig lambda chain C regions; Ig muchain C region; Latent-transforming growth factor β-binding protein 2;Microfibril-associated glycoprotein 4; Myosin-2; Serum amyloid Aprotein; Sorbin and SH3 domain-containing protein 2 (e.g., SEQ IDNO:25); and Sorbin and SH3 domain-containing protein 2 (e.g., SEQ IDNO:26).

Markers associated with ischemic heart injury include:Alpha-2-HS-glycoprotein precursor (e.g., SEQ ID NO:22);Alpha-2-macroglobulin; Carbonic anhydrase 1; Hemoglobin subunit alpha;Hemoglobin subunit beta; Ig alpha-1 chain C region; Ig alpha-2 chain Cregion; Ig mu chain C region; Leiomodin-1 (e.g., SEQ ID NO:27); Myosinregulatory light chain MRLC2 (e.g., SEQ ID NO:28); Nexilin (e.g., SEQ IDNO:29); Pyruvate dehydrogenase E1 component subunit a; serum amyloid Aprotein; and somatic form.

Pulmonary Protection. Animal models of lung injury, including acute lunginjury include injury inducement by intratracheal instillation ofendotoxin (LPS), mechanical ventilation, hypoxemia, live bacteria (E.coli), hyperoxia, bleomycin, oleic acid, cecal ligation and puncture,and acid aspiration. For more information regarding lung injury models,see Assay Depot, described as the World's Largest On-Line Marketplacefor Pharmaceutical Research Services.

Symptoms of lung injury include labored, rapid breathing, low bloodpressure, and shortness of breath. Any type of pulmonary functiontesting can be used. Pulmonary function testing generally can be dividedinto three main areas. The first type of pulmonary testing is generallyreferred to as spirometry which provides measurements in terms of volumeand breathing rates of different patient inspiratory and expiraroryefforts. In addition, various flow rates at various stages of a test arealso the type of data generated from spirometry testing. A second areaof pulmonary testing is a set of procedures designed to determine theuniformity of the distribution of inspired air throughout the lungs of apatient. By virtue of such tests, pulmonary insufficiency can bedetermined even though the alveolor ventilation of a patient is normal.A third type of pulmonary testing concerns the ability of the lungs todiffuse inspired air through alveolar membranes and such tests providean indication of the ability of the lung to arterialize venous blood byexchanging oxygen for carbon dioxide.

Breathing volume can be assessed using a volume flow-sensing deviceconnected to a subject's airway (e.g. by use of a spirometer ortachymeter) or by measuring the mechanical excursions of the chest andabdominal walls. Techniques that rely on recordings of chest andabdominal wall movements that are either strain gauge based (recordingof changes in body circumference length), or based on elastic inductiveelectrical conductor loops arranged around the chest and abdomen of thepatient can also be used. Recordings of the inductance of the loops canthen be used to estimate the magnitude of cross sectional areavariations of the chest and abdominal compartments. U.S. Pat. No.4,308,872 is an example of this self-inductance loop estimationtechnology. Such methods can be used for quantitative measurements ofrespiratory volumes after a calibration procedure.

In particular embodiments, tests of pulmonary function include measuringbreathing volume, arterial blood gases, and/or the A-a O₂ gradient.

Protection Against Sepsis. Sepsis, or Systemic Inflammatory ResponseSyndrome (SIRS), is characterized by a whole-body inflammatory statewith the presence of infection. Sepsis can lead to fever, rapidbreathing and low blood pressure and can injure all organs includingorgans of the cardiovascular system, the immunological system and theendocrine system.

Animal models of sepsis include cecal ligation and puncture(CLP)-induced sepsis alone or in combination with instillation ofbacteria (e.g., Pseudomonas aeruginosa or Streptococcus pneumoniae).Sepsis animal models also include intravenous or intraperitonealadministration of a toll-like receptor (TLR) agent such aslipopolysaccharide (LPS or endotoxin) or zymosan. Other sepsis modelsinclude ascending colon stent peritonitis and late-stageimmunostimulatory models. For more information regarding sepsis models,see Assay Depot, described as the World's Largest On-Line Marketplacefor Pharmaceutical Research Services.

Protection against sepsis can be confirmed by measuring blood pressure,blood gasses, cytokine measurements, and secondary organ function asdescribed elsewhere herein (e.g., lung, liver, heart, kidney function).

The Examples below are included to demonstrate particular embodiments ofthe disclosure. Those of ordinary skill in the art should recognize inlight of the present disclosure that many changes can be made to thespecific embodiments disclosed herein and still obtain a like or similarresult without departing from the spirit and scope of the disclosure.

Exemplary Embodiments

-   1. A kit for protecting a subject's organ(s) from injury, the kit    including a therapeutically effective amount of myoglobin, iron,    and/or vitamin B12 wherein administration of the therapeutically    effective amount of myoglobin, iron, and/or vitamin B12 to the    subject protects the subject's organ(s) from injury without causing    organ injury.-   2. A kit for protecting a subject's organ(s) from injury, the kit    including a therapeutically effective amount of a heme protein,    iron, and/or vitamin B12 wherein administration of the    therapeutically effective amount of heme protein, iron, and/or    vitamin B12 to the subject protects the subject's organ(s) from    injury without causing organ injury.-   3. A kit of embodiment 2 wherein the heme protein, iron, and/or    vitamin B12 is formulated within a composition.-   4. A kit of any one of embodiments 2 or 3 wherein the heme protein    is a heme protein variant, a heme protein d-substituted analog, a    heme protein modification, or combination thereof.-   5. A kit of any one of embodiments 2-4 wherein the heme protein is a    modified heme protein.-   6. A kit of embodiment 5 wherein the modified heme protein is a    nitrited heme protein or a PEGylated heme protein.-   7. A kit of any one of embodiments 2-6 wherein the heme protein is    myoglobin.-   8. A kit of any one of embodiments 2-7 wherein the heme protein is a    myoglobin variant and/or a myoglobin modification.-   9. A kit of embodiment 8 wherein the modified myoglobin is a    nitrited myoglobin or a PEGylated myoglobin.-   10. A kit of any one of embodiments 2-9 further including a heme    protein degradation inhibitor, optionally, a nitrited heme protein    degradation inhibitor.-   11. A kit of embodiment 10 wherein the heme protein degradation    inhibitor is formulated within a composition.-   12. A kit of any one of embodiments 10 or 11 wherein the heme    protein degradation inhibitor and the heme protein, iron, and/or    vitamin B12are formulated within the same composition.-   13. A kit of any one of embodiments 10-12 wherein the heme protein    degradation inhibitor is a heme oxygenase inhibitor.-   14. A kit of embodiment 13 wherein the heme oxygenase inhibitor is a    protoporphyrin, hemin, and/or hematin, optionally, a nitrited    protoporphyrin, hemin, and/or hematin.-   15. A kit of any one of embodiments 13 or 14 wherein the heme    oxygenase inhibitor is a metal protoporphyrin, optionally, a    nitrited metal protoporphyrin.-   16. A kit of embodiment 15 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   17. A kit of any one of embodiments 2-16 further including    administration instructions.-   18. A kit of any one of embodiments 2-17 wherein absence of organ    injury caused by the administration is confirmed by comparison to a    reference level.-   19. A kit of any one of embodiments 2-18 wherein protection is    evidenced by comparison to a reference level.-   20. A kit of any one of embodiments 18 or 19 wherein the reference    level is provided within the kit.-   21. A kit of any one of embodiments 2-20 wherein the organ is    protected from an injury based on an insult.-   22. A kit of embodiment 21 wherein the insult is scheduled.-   23. A kit of embodiment 22 wherein the administration occurs at    least 8 hours before the scheduled insult.-   24. A kit of any one of embodiments 22 or 23 wherein the scheduled    insult is surgery, induced cardiac/cerebral ischemic reperfusion,    cardiovascular surgery, balloon angioplasty, chemotherapy,    nephrotoxic drug administration, and/or radiocontrast toxicity.-   25. A kit of embodiment 24 wherein the surgery is an organ    transplant surgery.-   26. A kit of embodiment 21 wherein the insult is sepsis.-   27. A kit of any one of embodiments 2-26 wherein the organ is a    transplanted organ.-   28. A kit of any one of embodiments 2-27 wherein the organ is a    heart, kidney, liver, or lung.-   29. A kit of any one of embodiments 2-28 wherein the organ is a    heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   30. A kit of embodiment 29 wherein the cardiac enzyme is troponin.-   31. A kit of any one of embodiments 2-30 wherein the organ is a    kidney and protection is evidenced by prevention or reduction in    blood urea nitrogen (BUN) or serum creatinine increases.-   32. A kit of any one of embodiments 2-31 wherein the organ is a    liver and protection is evidenced by prevention or reduction in    liver enzyme increases.-   33. A kit of any one of embodiments 2-2 wherein the organ is a lung    and protection is evidenced by reduction in blood gas deterioration,    reduction in need for supplemental oxygen, and/or reduced ventilator    requirements.-   34. A kit for generating acquired cytoresistance in a subject's    organ(s), the kit including a therapeutically effective amount of a    heme protein, iron, and/or vitamin B12 wherein administration of the    therapeutically effective amount of heme protein, iron, and/or    vitamin B12 to the subject generates acquired cytoresistance in the    subject's organ(s) without causing organ injury.-   35. A kit of embodiment 34 wherein the heme protein, iron, and/or    vitamin B12 is formulated within a composition.-   36. A kit of any one of embodiments 34 or 35 wherein the heme    protein is a heme protein variant, a heme protein d-substituted    analog, a heme protein modification, or a combination thereof.-   37. A kit of any one of embodiments 34-36 wherein the heme protein    is a modified heme protein.-   38. A kit of embodiment 37 wherein the modified heme protein is a    nitrited heme protein or a PEGylated heme protein.-   39. A kit of any one of embodiments 34-38 wherein the heme protein    is myoglobin.-   40. A kit of embodiment 34-39 wherein the heme protein is a    myoglobin variant and/or a myoglobin modification.-   41. A kit of embodiment 40 wherein the modified myoglobin is a    nitrited myoglobin or a PEGylated myoglobin.-   42. A kit of any one of embodiments 34-41 further including a heme    protein degradation inhibitor, optionally a nitrited heme protein    degradation inhibitor.-   43. A kit of embodiment 42 wherein the heme protein degradation    inhibitor is formulated within a composition.-   44. A kit of any one of embodiments 42 or 43 wherein the heme    protein degradation inhibitor and the heme protein are formulated    within the same composition.-   45. A kit of any one of embodiments 42-44 wherein the heme protein    degradation inhibitor is a heme oxygenase inhibitor.-   46. A kit of embodiment 45 wherein the heme oxygenase inhibitor is a    protoporphyrin, hemin, and/or hematin, optionally a nitrited    protoporphyrin, hemin, and/or hematin.-   47. A kit of any one of embodiments 45 or 46 wherein the heme    oxygenase inhibitor is a metal protoporphyrin.-   48. A kit of embodiment 47 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   49. A kit of any one of embodiments 34-48 further including    administration instructions.-   50. A kit of any one of embodiments 34-49 wherein absence of organ    injury caused by the administration is confirmed by comparison to a    reference level.-   51. A kit of any one of embodiments 34-50 wherein the acquired    cytoresistance protects the organ from an injury.-   52. A kit of embodiment 51 wherein protection is evidenced by    comparison to a reference level.-   53. A kit of any one of embodiments 50 or 52 wherein the reference    level is provided within the kit.-   54. A kit of any one of embodiments 51-53 wherein the organ is    protected from an injury based on an insult.-   55. A kit of embodiment 54 wherein the insult is scheduled.-   56. A kit of embodiment 55 wherein the administration occurs at    least 8 hours before the scheduled insult.-   57. A kit of any one of embodiments 55 or 56 wherein the scheduled    insult is surgery, chemotherapy, or radiocontrast toxicity.-   58. A kit of embodiment 57 wherein the surgery is an organ    transplant surgery.-   59. A kit of embodiment 54 wherein the insult is sepsis.-   60. A kit of any one of embodiments 34-59 wherein the organ is a    transplanted organ.-   61. A kit of any one of embodiments 34-60 wherein the organ is a    heart, kidney, liver, or lung.-   62. A kit of any one of embodiments 51-61 wherein the organ is a    heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   63. A kit of embodiment 62 wherein the cardiac enzyme is troponin.-   64. A kit of any one of embodiments 51-63 wherein the organ is a    kidney and protection is evidenced by prevention or reduction in BUN    or serum creatinine increases.-   65. A kit of any one of embodiments 51-64 wherein the organ is a    liver and protection is evidenced by prevention or reduction in    liver enzyme increases.-   66. A kit of any one of embodiments 51-65 wherein the organ is a    lung and protection is evidenced by reduction in blood gas    deterioration, reduction in need for supplemental oxygen, and/or    reduced ventilator requirements.-   67. A kit for up-regulating expression of protective stress proteins    in a subject's organ(s), the kit including a therapeutically    effective amount of a heme protein, iron and/or vitamin B12 wherein    administration of the therapeutically effective amount of heme    protein, iron and/or vitamin B12 to the subject up-regulates    expression of protective stress proteins in the subject's organ(s)    without causing organ injury.-   68. A kit of embodiment 67 wherein the heme protein, iron and/or    vitamin B12 is formulated within a composition.-   69. A kit of any one of embodiments 67 or 68 wherein the heme    protein is a heme protein variant, a heme protein d-substituted    analog, a heme protein modification, or a combination thereof.-   70. A kit of any one of embodiments 67-69 wherein the heme protein a    modified heme protein.-   71. A kit of embodiment 70 wherein the modified heme protein is a    nitrited heme protein or a PEGylated heme protein.-   72. A kit of any one of embodiments 67-71 wherein the heme protein    is myoglobin.-   73. A kit of any one of embodiments 67-72 wherein the heme protein    is a myoglobin variant and/or a myoglobin modification.-   74. A kit of embodiment 73 wherein the modified myoglobin is a    nitrited myoglobin or a PEGylated myoglobin.-   75. A kit of any one of embodiments 67-74 wherein the protective    stress proteins are selected from heme oxygenase, haptoglobin,    hemopexin, hepcidin, alpha-1 antitrypsin, interleukin-10, heat-shock    proteins, neutrophil gelatinase-associated lipocalin, and HMG CoA    reductase.-   76. A kit of any one of embodiments 67-75 further including a heme    protein degradation inhibitor, optionally a nitrited heme protein    degradation inhibitor.-   77. A kit of embodiment 76 wherein the heme protein degradation    inhibitor is formulated within a composition.-   78. A kit of any one of embodiments 76 or 77 wherein the heme    protein degradation inhibitor and the heme protein are formulated    within the same composition.-   79. A kit of any one of embodiments 76-78 wherein the heme protein    degradation inhibitor is a heme oxygenase inhibitor.-   80. A kit of embodiment 79 wherein the heme oxygenase inhibitor is a    protoporphyrin, hemin, and/or hematin, optionally a nitrited    protoporphyrin, hemin and/or hematin.-   81. A kit of any one of embodiments 79 or 80 wherein the heme    oxygenase inhibitor is a metal protoporphyrin.-   82. A kit of embodiment 81 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   83. A kit of any one of embodiments 67-82 further including    administration instructions.-   84. A kit of any one of embodiments 67-83 wherein absence of organ    injury caused by the administration is confirmed by comparison to a    reference level.-   85. A kit of any one of embodiments 67-84 wherein the up-regulation    of protective stress proteins protects the organ from an injury.-   86. A kit of embodiment 85 wherein protection is evidenced by    comparison to a reference level.-   87. A kit of any one of embodiments 84 or 86 wherein the reference    level is provided within the kit.-   88. A kit of any one of embodiments 85-87 wherein the organ is    protected from an injury based on an insult.-   89. A kit of embodiment 88 wherein the insult is scheduled.-   90. A kit of embodiment 89 wherein the administration occurs at    least 8 hours before the scheduled insult.-   91. A kit of any one of embodiments 89 or 90 wherein the scheduled    insult is surgery, chemotherapy, or radiocontrast toxicity.-   92. A kit of embodiment 91 wherein the surgery is an organ    transplant surgery.-   93. A kit of embodiment 88 wherein the insult is sepsis.-   94. A kit of any one of embodiments 67-93 wherein the organ is a    transplanted organ.-   95. A kit of any one of embodiments 67-94 wherein the organ is a    heart, kidney, liver, or lung.-   96. A kit of any one of embodiments 85-95 wherein the organ is a    heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   97. A kit of embodiment 96 wherein the cardiac enzyme is troponin.-   98. A kit of any one of embodiments 85-97 wherein the organ is a    kidney and protection is evidenced by prevention or reduction in BUN    or serum creatinine increases.-   99. A kit of any one of embodiments 85-98 wherein the organ is a    liver and protection is evidenced by prevention or reduction in    liver enzyme increases.-   100. A kit of any one of embodiments 85-99 wherein the organ is a    lung and protection is evidenced by reduction in blood gas    deterioration, reduction in need for supplemental oxygen, and/or    reduced ventilator requirements.-   101. A composition including myoglobin, a myoglobin variant, a    myoglobin d-substituted analog, a myoglobin modification, or a    combination thereof, optionally iron and/or vitamin B12.-   102. A composition of embodiment 101 wherein the myoglobin is a    modified myoglobin.-   103. A composition of embodiment 102 wherein the modified myoglobin    is a nitrited myoglobin or a PEGylated myoglobin.-   104. A composition of any one of embodiments 101-103 wherein the    myoglobin is a myoglobin variant.-   105. A composition of any one of embodiments 101-104 further    including a heme protein degradation inhibitor, optionally a    nitrited heme protein degradation inhibitor.-   106. A composition of embodiment 105 wherein the heme protein    degradation inhibitor is a heme oxygenase inhibitor.-   107. A composition of embodiment 106 wherein the heme oxygenase    inhibitor is a protoporphyrin, hemin, and/or hematin, optionally a    nitrited protoporphyrin, hemin and/or hematin.-   108. A composition of any one of embodiments 106 or 107 wherein the    heme oxygenase inhibitor is a metal protoporphyrin.-   109. A composition of embodiment 108 wherein the metal    protoporphyrin is Sn-protoporphyrin.-   110. A composition including a heme protein and a heme protein    degradation inhibitor, optionally iron and/or vitamin B12.-   111. A composition of embodiment 110 wherein the heme protein is a    modified heme protein.-   112. A composition of embodiment 111 wherein the modified heme    protein is a nitrited heme protein or a PEGylated heme protein.-   113. A composition of any one of embodiments 110-112 wherein the    heme protein is myoglobin.-   114. A composition of any one of embodiments 110-113 wherein the    heme protein is a myoglobin variant and/or a myoglobin modification.-   115. A composition of embodiment 114 wherein the modified myoglobin    is a nitrited myoglobin or a PEGylated myoglobin.-   116. A composition of any one of embodiments 110-115 wherein the    heme protein degradation inhibitor is a heme oxygenase inhibitor.-   117. A composition of embodiment 116 wherein the heme oxygenase    inhibitor is a protoporphyrin, hemin, and/or hematin, optionally a    nitrited protoporphyrin, hemin and/or hematin.-   118. A composition of any one of embodiments 116 or 117 wherein the    heme oxygenase inhibitor is a metal protoporphyrin.-   119. A composition of embodiment 118 wherein the metal    protoporphyrin is Sn-protoporphyrin.-   120. A method of protecting a subject's organ(s) from injury    including administering to the subject a therapeutically effective    amount of a composition including a heme protein, iron and/or    vitamin B12 before the injury to the organ occurs, wherein the    administering protects the subject's organ(s) from the injury    without causing organ injury.-   121. A method of embodiment 120 wherein the composition includes a    modified heme protein.-   122. A method of embodiment 121 wherein the modified heme protein is    a nitrited heme protein or a PEGylated heme protein.-   123. A method of any one of embodiments 120-122 wherein the heme    protein is myoglobin.-   124. A method of any one of embodiments 120-123 wherein the heme    protein is a myoglobin variant and/or a myoglobin modification.-   125. A method of embodiment 124 wherein the modified myoglobin is a    nitrited myoglobin or a PEGylated myoglobin-   126. A method of any one of embodiments 120-125 wherein the    composition further includes a heme protein degradation inhibitor,    optionally a nitrited heme protein degradation inhibitor.-   127. A method of any one of embodiments 120-126 further including    administering to the subject a second composition including a heme    protein degradation inhibitor, optionally a nitrited heme protein    degradation inhibitor.-   128. A method of any one of embodiments 126 or 127 wherein the heme    protein degradation inhibitor is a heme oxygenase inhibitor.-   129. A method of embodiment 128 wherein the heme oxygenase inhibitor    is a protoporphyrin, hemin, and/or hematin, optionally a nitrited    protoporphyrin, hemin and/or hematin.-   130. A method of any one of embodiments 128 or 129 wherein the heme    oxygenase inhibitor is a metal protoporphyrin.-   131. A method of embodiment 130 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   132. A method of any one of embodiments 120-131 wherein absence of    organ injury caused by the administration is confirmed by comparison    to a reference level.-   133. A method of any one of embodiments 120-132 wherein protection    is evidenced by comparison to a reference level.-   134. A method of any one of embodiments 120-133 wherein the injury    is an injury based on an insult.-   135. A method of embodiment 134 wherein the insult is scheduled.-   136. A method of embodiment 135 wherein the administration occurs at    least 8 hours before the scheduled insult.-   137. A method of any one of embodiments 135 or 136 wherein the    scheduled insult is surgery, chemotherapy, or radiocontrast    toxicity.-   138. A method of embodiment 137 wherein the surgery is an organ    transplant surgery.-   139. A method of embodiment 134 wherein the insult is sepsis.-   140. A method of any one of embodiments 120-139 wherein the organ is    a transplanted organ.-   141. A method of any one of embodiments 120-140 wherein the organ is    a heart, kidney, liver, or lung.-   142. A method of any one of embodiments 120-141 wherein the organ is    a heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   143. A method of embodiment 142 wherein the cardiac enzyme is    troponin.-   144. A method of any one of embodiments 120-143 wherein the organ is    a kidney and protection is evidenced by prevention or reduction in    BUN or serum creatinine increases.-   145. A method of any one of embodiments 120-144 wherein the organ is    a liver and protection is evidenced by prevention or reduction in    liver enzyme increases.-   146. A method of any one of embodiments 120-145 wherein the organ is    a lung and protection is evidenced by reduction in blood gas    deterioration, reduction in need for supplemental oxygen, and/or    reduced ventilator requirements.-   147. A method of generating acquired cytoresistance in a subject's    organ(s) including administering to the subject a therapeutically    effective amount of a composition including a heme protein, iron,    and/or vitamin B12 wherein the administering generates acquired    cytoresistance without causing organ injury.-   148. A method of embodiment 147 wherein the composition includes a    modified heme protein.-   149. A method of embodiment 148 wherein the modified heme protein is    a nitrited heme protein or a PEGylated heme protein.-   150. A method of any one of embodiments 147-149 wherein the heme    protein is myoglobin.-   151. A method of any one of embodiments 147-150 wherein the heme    protein is a myoglobin variant and/or a myoglobin modification.-   152. A method of embodiment 151 wherein the modified myoglobin is a    nitrited myoglobin or a PEGylated myoglobin-   153. A method of any one of embodiments 147-152 wherein the    composition further includes a heme protein degradation inhibitor.-   154. A method of any one of embodiments 147-153 further including    administering to the subject a second composition including a heme    protein degradation inhibitor, optionally a nitrited heme protein    degradation inhibitor.-   155. A method of any one of embodiments 153 or 154 wherein the heme    protein degradation inhibitor is a heme oxygenase inhibitor.-   156. A method of embodiment 155 wherein the heme oxygenase inhibitor    is a protoporphyrin, hemin, and/or hematin, optionally nitrited    protoporphyrin, hemin and/or hematin.-   157. A method of any one of embodiments 155 or 156 wherein the heme    oxygenase inhibitor is a metal protoporphyrin.-   158. A method of embodiment 157 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   159. A method of any one of embodiments 147-158 wherein absence of    organ injury caused by the administration is confirmed by comparison    to a reference level.-   160. A method of any one of embodiments 147-159 wherein the acquired    cytoresistance protects an organ from injury.-   161. A method of embodiment 160 wherein the protection is evidenced    by comparison to a reference level.-   162. A method of any one of embodiments 160 or 161 wherein the    injury is injury based on an insult.-   163. A method of embodiment 162 wherein the insult is scheduled.-   164. A method of embodiment 163 wherein the administration occurs at    least 8 hours before the scheduled insult.-   165. A method of any one of embodiments 163 or 164 wherein the    scheduled insult is surgery, chemotherapy, or radiocontrast    toxicity.-   166. A method of embodiment 165 wherein the surgery is an organ    transplant surgery.-   167. A method of embodiment 162 wherein the insult is sepsis.-   168. A method of any one of embodiments 147-167 wherein the organ is    a transplanted organ.-   169. A method of any one of embodiments 147-168 wherein the organ is    a heart, kidney, liver, or lung.-   170. A method of any one of embodiments 160-169 wherein the organ is    a heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   171. A method of embodiment 170 wherein the cardiac enzyme is    troponin.-   172. A method of any one of embodiments 160-171 wherein the organ is    a kidney and protection is evidenced by prevention or reduction in    BUN or serum creatinine increases.-   173. A method of any one of embodiments 160-172 wherein the organ is    a liver and protection is evidenced by prevention or reduction in    liver enzyme increases.-   174. A method of any one of embodiments 160-173 wherein the organ is    a lung and protection is evidenced by reduction in blood gas    deterioration, reduction in need for supplemental oxygen, and/or    reduced ventilator requirements.-   175. A method of up-regulating expression of protective stress    proteins in a subject's organ(s) including administering to the    subject a therapeutically effective amount of a composition    including a heme protein, iron and/or vitamin B12 wherein the    administering up-regulates expression of protective stress proteins    in the subject's organs without causing organ injury.-   176. A method of embodiment 175 wherein the protective stress    proteins are selected from heme oxygenase, haptoglobin, hemopexin,    hepcidin, alpha-1 antitrypsin, interleukin-10, heat-shock proteins,    neutrophil gelatinase-associated lipocalin, and/or HMG CoA    reductase.-   177. A method of any one of embodiments 175 or 176 wherein the    composition includes a modified heme protein.-   178. A method of embodiment 177 wherein the modified heme protein is    a nitrited heme protein or a PEGylated heme protein.-   179. A method of any one of embodiments 175-178 wherein the heme    protein is myoglobin.-   180. A method of any one of embodiments 175-179 wherein the heme    protein is a myoglobin variant and/or a myoglobin modification.-   181. A method of any one of embodiments 180 wherein the modified    myoglobin is a nitrited myoglobin or a PEGylated myoglobin-   182. A method of any one of embodiments 175-181 wherein the    composition further includes a heme protein degradation inhibitor,    optionally a nitrited heme protein degradation inhibitor.-   183. A method of any one of embodiments 175-182 further including    administering to the subject a second composition including a heme    protein degradation inhibitor, optionally a nitrited heme protein    degradation inhibitor.-   184. A method of any one of embodiments 182 or 183 wherein the heme    protein degradation inhibitor is a heme oxygenase inhibitor.-   185. A method of embodiment 184 wherein the heme oxygenase inhibitor    is a protoporphyrin, hemin, and/or hematin, optionally a nitrited    protoporphyrin, hemin and/or hematin.-   186. A method of any one of embodiments 184 or 185 wherein the heme    oxygenase inhibitor is a metal protoporphyrin.-   187. A method of embodiment 186 wherein the metal protoporphyrin is    Sn-protoporphyrin.-   188. A method of any one of embodiments 175-187 wherein absence of    organ injury caused by the administration is confirmed by comparison    to a reference level.-   189. A method of any one of embodiments 175-188 wherein the    up-regulated expression of protective stress proteins protects an    organ from injury.-   190. A method of embodiment 189 wherein protection is evidenced by    comparison to a reference level.-   191. A method of any one of embodiments 189 or 190 wherein the    injury is an injury based on an insult.-   192. A method of embodiment 191 wherein the insult is scheduled.-   193. A method of embodiment 192 wherein the administration occurs at    least 8 hours before the scheduled insult.-   194. A method of any one of embodiments 192 or 193 wherein the    scheduled insult is surgery, chemotherapy, or radiocontrast    toxicity.-   195. A method of embodiment 194 wherein the surgery is an organ    transplant surgery.-   196. A method of embodiment 191 wherein the insult is sepsis.-   197. A method of any one of embodiments 175-196 wherein the organ is    a transplanted organ.-   198. A method of any one of embodiments 175-197 wherein the organ is    a heart, kidney, liver, or lung.-   199. A method of any one of embodiments 189-198 wherein the organ is    a heart and protection is evidenced by improvement of cardiac    function, and/or reduction in cardiac enzyme release.-   200. A method of embodiment 199 wherein the cardiac enzyme is    troponin.-   201. A method of embodiment any one of embodiments 189-200 wherein    the organ is a kidney and protection evidenced by prevention or    reduction in BUN or serum creatinine increases.-   202. A method of any one of embodiments 189-201 wherein the organ is    a liver and protection evidenced by prevention or reduction in liver    enzyme increases.-   203. A method of any one of embodiments 189-202 wherein the organ is    a lung and protection is evidenced by reduction in blood gas    deterioration, reduction in need for supplemental oxygen, and/or    reduced ventilator requirements.-   204. An embodiment of any one of embodiments 1-203 wherein the    composition is formulated for intravenous delivery, oral delivery,    subcutaneous delivery, or intramuscular delivery.-   205. An embodiment of any one of embodiments 1-204 wherein the    composition is formulated within a slow-release depot.-   206. A composition of matter comprising the structure

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; R₂ is OH or H; and R₃ isOH or H.

-   207. An embodiment of any one of embodiments 1-205, wherein the B12    has a structure

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; R₂ is OH or H; and R₃ isOH or H.

-   208. An embodiment of any of the proceeding embodiments wherein    rather than administration to an organ through administration to a    subject, administration is directly to an organ.-   209. A composition of matter comprising the structure

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; A is a phosphate group, Lis a linker, B is a saccharide-based structure, and M is a metalcomplexed with the saccharide-based structure.

-   210. A composition of matter of embodiment 209, wherein A is PO₄, L    is a hydrazone linker, B is a saccharide-based structure, and M is    Fe.-   211. A composition of matter of embodiment 209 or 210, wherein B has    10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen atoms.-   212. A composition of matter of embodiment 209, 210, or 211, wherein    B is derived from sucrose-   213. A composition of matter comprising the structure

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; R₃ is OH or H; L is alinker, B is a saccharide-based structure, and M is a metal complexedwith the saccharide-based structure.

-   214. A composition of matter of embodiment 213, wherein L is a    hydrazone linker and M is Fe.-   215. A composition of matter of embodiment 213, or 214, wherein B    includes 10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen    atoms.-   216. A composition of matter of embodiment 213, 214, or 215, whrein    B is derived from sucrose.-   217. A composition of matter comprising the structure:

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; R₃ is OH or H; L is alinker, B is a saccharide-based structure, and M is a metal complexedwith the saccharide-based structure.

-   218. A compositon of matter of embodiment 217, wherein L is a    hydrazone linker and M is Fe.-   219. A composition of matter of embodiment 217 or 218, wherein B    includes 10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen    atoms.-   220. A composition of matter of embodiment 217, 218, or 219, wherein    B is derived from sucrose.-   221. A composition of matter comprising the structure:

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; L is a linker, B is asaccharide-based structure, and M is a metal complexed with thesaccharide-based structure.

-   222. A composition of matter of embodiment 221, wherein L is a    hydrazone linker and M is Fe.-   223. A composition of matter of embodiment 221 or 222, wherein B has    10-16 carbon atoms, 9-15 oxygen atoms, and 16-28 hydrogen atoms.-   224. A composition of matter of embodiment 221, 222, or 223, wherein    B is derived from sucrose.-   225. A composition of matter comprising the structure:

where R₁ is 5′-deoxyadenosyl, CH₃, OH, or CN; L₁ is a first linker, L₂is a second linker, B₁ is a first saccharide-based structure, B₂ is asecond saccharide-based structure, M₁ is a first metal, and M₂ is asecond metal complexed with the saccharide-based structure.

-   226. A composition of matter of embodiment 225, wherein L₁ and L₂    are each independently a hydrazone linker and M1 and M2 are each    independently Fe.-   227. A composition of matter of embodiment 225 or 226, wherein B1    and B2 each independently include 10-16 carbon atoms, 9-15 oxygen    atoms, and 16-28 hydrogen atoms.-   228. A compositionof matter of embodiment 225, 226, or 227, wherein    B1 and B2 are each independently derived from sucrose.

Example 1

Renal Protection. The data described in FIGS. 1-4 and Tables 1-7 wascollected using the following protocols:

The Glycerol Model of AKI. This is a widely used model ofrhabdomyolysis-induced AKI that has been employed worldwide for 50years. The model was used to test whether prophylactic interventionsconfer protection against AKI. Basically, the protocol is as follows:Male CD-1 mice (35-45 grams), obtained from Charles River Laboratories,Wilmington, Mass. were studied. Mice were maintained under standardvivarium conditions and generally housed for 1-3 weeks prior to study.The mice were placed in a cylindrical restraining cage, and then weregiven a tail vein injection of the test substances (see below) or testsubstance vehicle. The mice were then returned to their cages. Eighteenhours (hrs) later, the mice were briefly anesthetized by isofluraneinhalation, and given an intramuscular injection of hypertonic (50%)glycerol in a dose of 9 ml/Kg body weight. The dose is divided in two,with half injected into the muscle of each of the hind limbs. The micewere then returned to their cages. Eighteen hrs later, the mice weredeeply anesthetized with pentobarbital (50-100 mg/Kg), the abdominalcavity was opened through a midline abdominal incision, a blood samplewas obtained from the abdominal vena cava and the kidneys were resected.A kidney cross section was obtained and fixed in formalin for subsequenthistologic analysis. The terminal blood samples were analyzed for BUNand creatinine, using commercially available assay kits. The remainingkidney tissue was subjected to cortical dissection, and the corticaltissues were then extracted for protein and RNA. The protein sampleswere saved for analysis of HO-1 levels, and the RNA samples weresubjected to RT-PCR to quantify HO-1 mRNA as well as levels of otherstress gene mRNAs (e.g. NGAL, haptoglobin, hemopexin, hepicidin).

Test preparation: Lyophilized horse skeletal muscle (myoglobin) (SigmaChemicals) was used as the test agent.

Myoglobin+SnPP: To 5 mg of dry myoglobin was added 0.9 ml of PBS+0.1 mlof a stock SnPP solution (50 umole/ml). The resulting finalconcentrations were 5 mg/ml myoglobin+5 umoles/ml of SnPP. The tail veinwas injected with 200 ul of this solution, which equals 1 mg myoglobin+1umole SnPP.

Nitrited Myoglobin: Na nitrite was added to myoglobin to achieve a 1-5mole/mole ratio to myoglobin (e.g. 1-5 umole of nitrite/1 umole ofmyoglobin). The resulting final concentrations were 5-10 mg/mlmyoglobin+0.04-0.4 mg/ml nitrite. The tail vein was injected with 200 ulof this solution.

Myoglobin+PEG: To a stock solution of 20 mg/ml Mgb in PBS was added 100mg/ml of PEG-6000; 0.250 ul. This was administered as a subcutaneousinjection in the dorsal neck (250 ul total injection). For combinedMgb/PEG+SnPP, SnPP was added to the above in a concentration of 3 mg/ml.

These are the test materials administered to mice to assess protectionagainst the glycerol AKI model, as noted above.

Independent effects of each test agent: To assess whether myoglobin+SnPPhad a greater effect than either myoglobin alone or SnPP alone, the samesolutions as noted above were created as follows: myoglobin+SnPP; SnPPalone, or myoglobin alone. These were used in the above noted glycerolmodel.

Four hr post myoglobin vs myoglobin+SnPP vs SnPP alone experiments. Toconfirm that the myoglobin+SnPP has a synergistic effect in inducingHO-1 mRNA and HO-1 protein levels, each of the above combinations havebeen administered alone via tail vein injection. Four hrs later, themice were sacrificed as noted above and the kidneys were harvested forassessment of HO-1 mRNA and protein levels. For additional informationregarding methods, see Zager et al., Am J Physiol Renal Physiol. 2014Jul. 30. Pii.

TABLE 1 SnPP quadruples the amount of HO-1 mRNA induction at 4 hrs postinjection vs. myoglobin alone (HO-1/GAPDH mRNA) 4 hr IV 4 hr IV 4 hr IV4 hr IV Myoglobin & Control Myoglobin SnPP SnPP 1.80 2.58 6.95 13.802.49 2.41 2.85 12.05 1.50 7.78 9.72 13.51 2.93 8.25 12.36 Average 1.933.93 6.94 12.93 Std Error 0.29 1.29 1.48 0.43 Unpaired p 0.25 0.0360.000006 (vs Control) Unpaired p 0.17 0.00057 (vs Ovnt Myoglobin)Unpaired p 0.0080 (vs Ovnt SnPP)

As shown in Table 2, at the 4 hr time point, there is a preferentialincrease in HO-1 protein expression (by ELISA). Given that it is just 4hrs post injection, the mRNA increases are greater than the proteinincreases as protein synthesis must follow the mRNA induction-requiringmore time.

TABLE 2 Preferential Increase in HO-1 Protein Expression (by ELISA) atthe 4 Hr Time Point (Cortex: ng HO-1/mg protein) 4 hr IV 4 Hr Carrier 4hr IV 4 hr IV 4 hr IV 1 mg IV (0.01N 1 mg 1 μmole Myoglobin & PBS NaOH)Myoglobin SnPP 1 μmole SnPP 12.6 20.2 64.7 53.6 68.8 12.9 22.8 36.0 32.241.7 15.6 40.7 31.5 88.6 13.1 40.2 20.5 86.4 Average 13.5 21.5 45.4 34.471.4 Std Error 0.7 1.3 6.5 6.9 10.8 Unpaired p 0.0037 0.0028 0.0240.0018 (vs Control) Unpaired p (vs 0.071 0.28 0.038 Carrier - 0.01NNaOH) Unpaired p 0.29 0.086 (vs IV myoglobin) Unpaired 0.028 p (vs IVSnPP)

Table 3 shows HO-1 mRNA induction roughly 18 hrs (overnight) postinjection vs. myoglobin alone (HO-1/GAPDH mRNA) vs. myoglobin incombination with SnPP.

TABLE 3 HO-1 mRNA induction overnight post injection with control (PBS),myoglobin alone (HO-1/GAPDH mRNA), and myoglobin in combination withSnPP. Ovnt IV Ovnt IV 1 mg Control Ovnt IV 1 mg Myoglobin + Subject(PBS) Myoglobin 1 μmole SnPP 1 0.28 0.51 0.75 2 0.47 0.71 2.26 3 0.620.53 6.76 Average 0.46 0.58 3.26 Std Error 0.10 0.06 1.81 unpaired p (vsNormal) 0.35 0.20 unpaired p (vs IV Myoglobin) 0.21

Table 4 shows HO-1 protein induction roughly 18 hrs (overnight) postcontrol injection vs. myoglobin alone (HO-1/GAPDH mRNA) vs. myoglobin incombination with SnPP.

TABLE 4 HO-1 protein induction overnight post control injection,myoglobin alone (HO-1/GAPDH mRNA), and myoglobin in combination withSnPP. Ovnt IV Ovnt IV 1 mg Control Ovnt IV 1 mg Myoglobin + Subject(PBS) Myoglobin 1 μmole SnPP 1 24.8 24.6 61.4 2 16.0 50.6 93.6 3 20.634.9 102.6 Average 20.5 36.7 85.9 Std Error 2.5 7.6 12.5 unpaired p (vsControl) 0.11 0.0068 unpaired p (vs Myoglobin) 0.028 Correlation proteinvs mRNA r = 0.80

FIGS. 1A and 1B show HO mRNA expression (FIG. 1A) and protein expression(FIG. 1B) following vehicle (control), myoglobin (Mgb), or myoglobin incombination with SnPP (Mgb+SnPP) administration 18 hours before glycerolinsult. The data indicate that there is a potentiation of myoglobininduced HO-1 induction with concomitant SnPP treatment.

Table 5 shows induction of haptoglobin protein expression followingexposure to myoglobin alone or myoglobin in combination with PEG ascompared to carrier control. The data demonstrate that myoglobin+PEGinduce far greater increases in cytoprotective haptoglobin expressionthan myoglobin alone.

TABLE 5 Haptoglobin Protein Expression 4 hour time point after SQinjection. Control Myoglobin Alone Myoglobin + PEG 9.5 ± −2.9 32.7 ± 6.3118.8 ± 20 ng/mg protein ng/mg protein ng/mg protein p < 001 vs control;p < 0.025 vs Myoglobin alone

Table 6 shows plasma LDH levels—a sensitive marker of liver, kidney,lung, and heart injury. Myoglobin+SnPP did not cause an LDH increase atthe 4 hr time point.

TABLE 6 Myoglobin + SnPP Does not cause an LDH increase at the 4 hr timepoint (Plasma: Absorbance U LDH/ml) 4 hr IV 4 hr IV 4 hr IV 4 hr IVMyoglobin & Subject Carrier Myoglobin SnPP SnPP 1 4.54 4.54 5.06 2 4.915.29 5.63 3 5.36 4.54 5.00 5.78 4 3.49 3.90 3.23 3.30 Average 4.43 4.474.51 4.94 Std Error 0.94 0.21 0.46 0.57 Unpaired p 0.95 0.93 0.64 (vsCarrier) Unpaired p 0.94 0.47 (vs Myoglobin) Unpaired p 0.58 (vs SnPP)

FIG. 2 left panels show cellular kidney damage following glycerol insultand the FIG. 2 right panels show the protective effect of pre-treatmentwith myoglobin in combination with SnPP.

FIG. 3 shows that N-Mgb+SnPP preferentially elevate the protectivestress protein, interleukin-10 (IL-10).

FIG. 4 shows that N-Mgb+SnPP elevates the protective stress protein,haptoglobin.

Example 2

Hepatic Protection. Hepatotoxic injury was assessed by plasma LDH levels24 hrs after insult. Liver insult included 9 ml/kg glycerol injection(this is the same model that is used to cause renal injury). Liverinjury raised plasma LDH from 3.5 to 114 units/ml. Wth myoglobin/SnPPpre-treatment, plasma LDH levels were reduced by 75%.

TABLE 7 Hepatotoxic injury assessed by plasma LDH levels 24 hrs afterinsult. Hepatic Hepatic Injury + Subject No. Control Injury Myoglobin +SnPP 1 3.7 4.4 2 2.1 130.1 10.4 3 3.9 69.5 20.9 4 4.1 87.5 60.2 5 128.338.9 6 155.4 61.3 Mean 3.5 114.2 32.7 Std Error 0.5 15.6 10.1 Unpaired ttest p < 0.0014 (injury +/− myoglobin + SnPP)

The data described in Examples 1 and 2 show that heme protein, modifiedheme protein, and heme protein in combination with a heme proteindegradation inhibitor protect the kidney and liver from injury due toglycerol insult. The protection is evidenced through markers of injury(LDH), organ function (BUN and creatinine) and induction of protectivestress proteins (HO-1 and haptoglobin).

Example 3

FIG. 5 shows assessment of the impact of equimolar nitrite binding tomyoglobin Fe on the expression of myoglobin toxicity. HK-2 cells (aproximal tubule cell line derived from normal human kidney) wereincubated in keratinocyte serum free medium either under normal(control) conditions or in the presence of 10 mg/mL horse skeletalmuscle myoglobin or nitrited myoglobin (produced by equimolar Na nitriteaddition to 10 mg/ml myoglobin). After 18 hr incubations, the severityof cell injury (% cell death) was assessed by MTT assay. Myoglobininduced 40% cell death (40% decrease in MTT cell uptake), compared tocontrol incubated cells. Nitrite binding to myoglobin reduced cell deathby 75%. Thus, nitrite binding is able to reduce myoglobin's cytotoxiceffects.

FIG. 6 shows the dose-response relationship between plasma hemeoxygenase 1 (HO-1) and administered N-myoglobin dose. Normal mice wereinjected IM with either 0, 1, 2, or 5 mg/Kg nitrited myoglobin+SnPP(constant dose of 1 μmole). Eighteeen hrs later, plasma HO-1 levels wereassessed by ELISA. A steep dose-response relationship between theadministered N-myoglobin dose and plasma HO-1 levels was observed. Thus,HO-1 assay has potential biomarker utility for N-Mgb/SnPP induced HO-1induction.

FIG. 7 shows maintenance of normal serum creatinine levels over a 25fold variation in N-myoglobin dose. Mice were subjected to a 2 hrsubcutaneous infusion of 1, 3, 6, 12, or 25 mg/Kg of nitrited myoglobin(holding SnPP at a constant dose of 1 μmole). Eighteen hrs later,potential renal injury was assessed by measuring serum creatinineconcentrations. No significant increase was observed at any of the N-Mgbdoses, indicating a lack of over toxicity (n, 2-4 mice/group).

Example 4

Introduction. Acute kidney injury (AKI) is a well-recognized risk factorfor morbidity, mortality, and the initiation of chronic kidney disease(CKD; Ishani et al. J Am Soc Nephrol 2009; 20:223-8; Xue et al. J Am SocNephrol 2006; 17:1135-42; Liangos et al. Clin J Am Soc Nephrol 2006;1:43-51; Wald et al. JAMA 2009; 302:1179-85; Goldberg et al. Kidney Int2009; 76:900-6). However, no proven ways to prevent AKI currently exist.It is well established that after an initial bout of ischemic or toxicinjury, the kidney develops marked resistance to subsequent damage(e.g., Honda et al. Kidney Int 1987; 31:1233-8; Zager et al. Kidney Int1984; 26:689-700; Zager et al. Lab Invest 1995; 72:592-600; Zager,Kidney Int 1995; 47:1336-45; Zager, Kidney Int 1995; 47:628-37). Thisphenomenon, which is mediated in part by an upregulation ofcytoprotective and anti-inflammatory “stress” proteins (e.g., hemeoxygenase 1 (HO-1), ferritin, haptoglobin, hemopexin, alpha 1antitrypsin, interleukin 10 (IL-10) has been referred to as “ischemicpreconditioning” or the “acquired cytoresistance” state. Zager et al. JAm Soc Nephrol 2014; 25:998-1012; Deng et al. Kidney Int 2001; 60:2118-28; Zarjou et al. J Clin Invest 2013; 123:4423-34; Nath et al. JClin Invest 1992; 90:267-70; Zager et al. Am J Physiol 2012;303:F1460-72; Fink, J Leukoc Biol 2009; 86:203-4 Arredouani et al.Immunology 2005; 114:263- 71; Blum et al. J Am Coll Cardiol 2007;49:82-7; Galicia et al. Eur J Immunol 2009; 39:3404- 12; Zager et al. AmJ Physiol 2012; 303:F139-48; Zager et al. PLoS One 2014; 9:e9838; Hunt &Tuder, Curr Mol Med 2012; 12:827-35; Janciauskiene et al. J Biol Chem2007; 282:8573-82.

Given the profound protective nature of acquired cytoresistance,investigators have sought ways to safely recapitulate it in humans.Notable in this regard is so-called “remote preconditioning,” wherebyrecurrent bouts of upper and lower limb ischemia are induced byrecurrently inflating and deflating blood pressure cuffs. Yang et al. AmJ Kidney Dis 2014; 64:574-83; Mohd et al. J Surg Res 2014; 186:207-16;Li et al. J Cardiothorac Surg 2013; 8:43. The goal is to release unknowntissue “conditioning factors” into the systemic circulation that willtrigger protective tissue responses (e.g., in brain, heart, liver, andkidney). Despite its appeal, this approach has had only questionablesuccess, likely because of the following reasons: (1) the “factors”released from postischemic limbs that might induce “preconditioning,”and how much factor release is required to induce this state, areunknown; (2) the cellular pathways by which such factors impact distantorgans to induce cytoresistance have not been defined; and (3) it isimpossible to judge whether the desired preconditioning actuallydevelops in any given individual.

An alternative approach for inducing acquired cytoresistance was sought.To this end, a pharmacologic regimen including low dose nitritedmyoglobin (N-Mgb)+tin protoporphyrin (SnPP), which markedly andsynergistically upregulate a host of renal tubular cell cytoprotectants(e.g., HO-1, haptoglobin, and IL-10) in the absence of obvious renal orextrarenal toxicities was developed. Within 18 hours of agentadministration, striking resistance to nephrotoxic AKI, adenosinetriphosphate (ATP) depletion-induced AKI, and post-AKI progression toCKD result. In addition, hepatic protection against postischemic andtoxic injury is expressed. Lastly, it was observed that the induction ofthis cytoresistant state can be gauged noninvasively by using plasmaHO-1 and haptoglobin levels as “biomarkers” of its induction.

Methods. General approach. Animals. All experiments were conducted usingmale CD-1 mice (35-45 g; Charles River Laboratories, Wilmington, Mass.).They were housed under standard vivarium conditions with free food andwater access throughout. The used protocols were approved by theInstitution's Institutional Animal Care and Utilization Committee(IACUC) according to the National Institutes of Health guidelines.

Cytoresistance-inducing reagents. Horse skeletal muscle (#Mb0360; Sigma)was used as the primary cytoresistance-inducing agent. However, becausemyoglobin (Mgb) has an inherent nephrotoxic potential (particularlyunder conditions of volume depletion and aciduria), two approaches wereused to mitigate Mgb's potential adverse effects. First, the Mgb wasconverted into a nitrited form by the addition of equimolar amount ofsodium (Na) nitrite. In this regard, nitrite is an ambidentate moleculethat directly binds 1:1 to myoglobin Fe either via its oxygen ornitrogen component. Cotton et al. Advanced inorganic chemistry.Hobocken, NJ: Wiley-Interscience, 1999:1355; Silaghi-Dumitrescu et al.Nitric Oxide 2014; 42C:32-9. Noteworthy is that Fe is the dominantmediator of Mgb's cytotoxic effect, (Zager et al. J Clin Invest 1992;89:989-95; Zager & Burkhart, Kidney Int 1997; 51:728-38) and thistoxicity is substantially reduced by prior nitrite binding. Rassaf etal. Circ Res 2014; 114:1601-10; Totzeck et al. Circulation 2012;126:325-34 [J Clin Invest 1992; 89: 989-95]; Totzeck et al. PLoS One2014; 22:e105951; Hendgen-Cotta et al. Proc Natl Acad Sci US A 2008;105:10256-61.

In addition to its ability to decrease Fe-mediated toxicity, nitrite hasbeen implicated as a mediator of “remote preconditioning,” possiblythrough nitric oxide (NO) generation. Rassaf, supra. In this regard,heme proteins directly reduce nitrite, with resultant NO production.Juncos et al. Am J Pathol 2006; 169:21-31; Kellerman, J Clin Invest1993; 92:1940-9; Zager et al. Am J Physiol 2008; 294:F187-97. Thus, bybinding nitrite directly to Mgb, Mgb injection with subsequent proximaltubule endocytic uptake, results in direct proximal tubule nitrite andNO targeting.

Second, for heme Fe to induce most of its cytotoxicity, it must first bereleased from its sequestration site within the porphyrin ring. This Ferelease is mediated via porphyrin ring cleavage via HO-1. Hence, toattenuate potential Mgb cytotoxicity, it was administered along with atransient HO-1 inhibitor, SnPP. In this regard, it has previously beenreported that SnPP addition to Mgb-exposed cultured proximal tubule(HK-2) cells or to in vivo heme loaded mouse proximal tubule segmentsreduces Mgb toxicity by as much as 85%. Zager & Burkhart, Kidney Int1997; 51:728-38. This cytoprotective action is further indicated byobservations that SnPP may mitigate postischemic acute renal failure(ARF). Juncos et al. Am J Pathol 2006; 169:21-31; Kaizu et al. KidneyInt 2003; 63:1393-403.

Impact of Mgb, SnPP, and Mgb 1 SnPP on renal cortical heme signaling. Itwas postulated that (1) N-Mgb would be a potent signaling molecule,leading to the upregulation of heme responsive element and redoxsensitive genes, which evoke cytoprotective activities (e.g., HO-1,haptoglobin, hemopexin, and IL-10); (2) SnPP can independentlyupregulate such genes; and (3) when administered together, N-Mgb+SnPPcoadministration can lead to additive or synergistic heme responsiveelement signaling. The following experiment tested these hypotheses.

Thirty-two mice were divided into 4 equal groups: (1) control mice; (2)mice treated with 1 mg of N-Mgb injection (as a bolus through the tailvein); (3) mice treated with 1 mmol of SnPP (via tail vein); and (4)mice treated with combined N-Mgb 1 SnPP. After either 4 hours (n=16) or18 hours (n=16), the mice were deeply anesthetized with pentobarbital(50 mg/kg), the abdomen was opened through a midline abdominal incision,and the kidneys were removed. To determine potential effects onextrarenal organs, a liver lobe and the heart were also removed. Thetissues were iced and then extracted for protein and RNA (RNeasy PlusMini; Qiagen, Valencia, Calif.) and subjected to enzyme linkedimmunosorbent assay (ELISA) and reverse transcriptase polymerase chainreaction (RT-PCR) for HO-1, haptoglobin, and IL-10 protein and messengerRNAs (mRNAs). Zager et al. J Am Soc Nephrol 2014; 25:998-1012; Zager etal. Am J Physiol 2012; 303:F139-48. As an assessment of renal function,control mice and the 18 hour after N-Mgb+SnPP—treated mice had bloodurea nitrogen (BUN) and plasma creatinine levels measured. Additionally,transverse 10% formalin fixed kidney sections (3 mM) were cut andstained with hematoxylin and eosin (H&E) and periodic acid Schiff (PAS)to further assess potential injury.

Assessments of cytoresistance. Glycerol model of rhabdomyolysis-inducedAKI. Twenty mice were divided into 4 equal groups (controls, micetreated with N-Mgb, SnPP, and mice treated with N-Mgb+SnPP tail veininjections) as described previously. 18 hours later, the mice werebriefly anesthetized with isoflurane and immediately injected with 9mL/kg of 50% glycerol, administered in equally divided doses into eachhind limb. At 18 hours after glycerol injection, the mice wereanesthetized with pentobarbital, the abdomen was opened, a blood samplefor BUN and creatinine assessments was obtained from the vena cava, andthe kidneys were resected. The control post-glycerol group and theN-Mgb+SnPP—pretreated glycerol group had kidney sections stained withH&E.

Maleate model of AKI. When injected into rodents, maleate undergoesselective proximal tubule uptake via organic anion transporters andinduces profound, proximal tubule-specific ATP depletion. Kellerman, JClin Invest 1993; 92:1940-9; Zager et al. Am J Physiol 2008;294:F187-97. This culminates in severe AKI. The following experimentassessed whether N-Mgb+SnPP pretreatment can protect against this formof renal damage. Twelve mice were divided into 2 equal groups, whichreceived either N-Mgb−SnPP or vehicle injection. Eighteen hours later,they all received an intraperitoneal (IP) injection of Na maleate (600mg/kg). Zager et al. Am J Physiol 2008; 294:F187-97. 18 hours later, themice were anesthetized, and terminal blood samples were obtained fromthe inferior vena cava for BUN and creatinine measurements.

Postischemic AKI progression to CKD. After 30 minutes of unilateralrenal ischemia, the damaged kidney undergoes a transition to CKD,manifested by progressive tubular dropout, interstitial inflammation,and fibrosis, culminating in a 40% loss of renal mass (kidney weight).Zager et al. Am J Physiol 2011; 301:F1334-45; Zager et al. Kidney Int2013; 84:703-12. To ascertain whether N-Mgb−SnPP treatment couldmitigate postischemic disease progression, 6 mice were pretreated withthese agents and 18 hours later they were anesthetized withpentobarbital and subjected to 30 minutes of left renal pedicleocclusion performed through a midline abdominal incision at a bodytemperature of 37° C.

The right kidney was left untouched. After the period of renal ischemia,the vascular clamp was removed and complete reperfusion was confirmed byloss of renal cyanosis. The mice were then sutured and allowed torecover from anesthesia. Six mice, subjected to the same surgicalprotocol, but without N-Mgb−SnPP pretreatment, served as controls. Twoweeks later, the abdominal incision was reopened and the kidneys wereresected. Relative degree of renal injury between the 2 groups wasassessed by loss of left renal mass (as determined by renal wet weight)vs weight of left kidneys from 6 normal mice. Renal cortical neutrophilgelatinase associated lipocalin (NGAL) mRNA and protein levels were alsoassessed as additional markers of renal damage.

Dose-response relationships after IP N-Mgb−SnPP injections. To assesswhether a slower delivery rate of N-Mgb−SnPP (vs via intravenous [IV]bolus injection) also induces an upregulation of cytoprotective proteinsand renal cytoresistance, mice were injected with 0, 1, 2.5, or 5 mg ofN-Mgb 1 the standard SnPP dose (1 mmol) (3 mice each; 1 mL salinevehicle). Eighteen hours later, the mice were anesthetized withpentobarbital, a blood sample was obtained, and the kidneys wereresected to determine HO-1 and haptoglobin mRNA and protein levels. Totest whether plasma HO-1 and haptoglobin levels rose and reflecteddegrees of renal HO-1 and haptoglobin upregulation, plasma HO-1 andhaptoglobin levels were also determined.

To assess whether the previously determined plasma and kidney HO-1 andhaptoglobin levels correlated with degrees of cytoresistance, additionalmice were injected with 0, 2.5, or 5 mg of N-Mgb 1 1 mmol of SnPP (n=3mice per group). Eighteen hours later, all mice were subjected to theglycerol AKI model as described previously. Severities of AKI weredetermined 18 hours after glycerol injection by BUN and plasmacreatinine analyses.

Hepatic ischemia experiments. Fourteen mice were subjected to thepreviously published partial hepatic ischemia model, which is conductedby occluding blood flow (at the portal triad) to 3 of 5 hepatic lobesfor 25 minutes. Zager et al. Am J Physiol Renal Physiol 2014;307:F856-68. Half of the mice were pretreated 18 hours earlier with 1 mgN-Mgb+1 mmol SnPP as described previously. Reperfusion after theischemic period was assessed by restoration of normal hepatic color inthe 3 involved liver lobes. Eighteen hours later, the mice werereanesthetized, the abdominal cavity was reopened, and a terminal bloodsample was obtained for plasma alanine aminotransferase (ALT) andlactate dehydrogenase (LDH) levels as markers of postischemic liverdamage.

Hepatotoxic injury. To assess whether N-Mgb−SnPP can protect against atoxic form of liver injury, 12 anesthetized mice received injections of50% glycerol. The glycerol (8 mg/kg) was given via an IP injection tofavor hepatocellular uptake via the portal circulation. Half of the micehad been pretreated 18 hours earlier with N-Mgb−SnPP (1 mg Mgb/1 mmolSnPP) as described previously. Four hours after IP glycerol injection,when the mice were still anesthetized, they were sacrificed viatransection of the abdominal vena cava. The extent of acute hepaticinjury was gauged by plasma ALT concentrations.

Calculations and statistics. All values are given as the mean 6 standarderror of the mean. Statistical comparisons were made by unpairedStudent's t test. If multiple comparisons were made, the Bonferronicorrection was applied. The severity of renal histologic injury in theglycerol AKI model was graded on a 11 to 41 scale (least to most severetubular necrosis and cast formation observed). The histologic resultswere compared by Wlcoxon rank sum test. Statistical significance wastaken as a P value of <0.05.

Results. Renal function and histology after IV N-Mgb+SnPP injection.Neither BUN nor plasma creatinine increases were observed at 18 hoursafter IV injection of 1 mg N-Mgb+SnPP (BUN, 22±3 vs 25±3 mg/dL;creatinine, 0.32±0.03 vs 0.30±0.04 mg dL; controls vs Mgb/SnPPtreatment, respectively). Furthermore, there was no evidence of renalmorphologic injury as evidenced by either PAS or H&E staining. Inparticular, no evidence of tubular necrosis or heme cast formation wasapparent in the treatment group (see FIG. 8) The proximal tubular brushborder as depicted by PAS staining, remained entirely intact (upper 2panels). In this regard, brush border blebbing and swelling intoproximal tubule lumina are judged to be highly sensitive lightmicroscopic markers of tubular damage. Venkatachalam et al. Kidney Int1978; 14:31-49; Donohoe et al. Kidney Int 1978; 13:208-22.Thus, thesedata indicated that the IV N-Mgb−SnPP treatment was well tolerated bythe kidney.

Impact of IV N-Mgb and SnPP, alone and in combination on HO-1, IL-10,and haptoglobin expressions. Renal HO-1 assessments. As shown in FIG. 9,left panel, N-Mgb alone and SnPP alone caused only modest increases in 4hour HO-1 mRNA levels. In contrast, a 20-fold increase in HO-1 mRNA wasobserved at 4 hours after combined N-Mgb+SnPP injection. By 18 hourspost-treatment, these mRNA increases translated into marked HO-1 proteinincreases, being 7-fold higher than control values. In contrast, onlyrelatively small HO-1 protein increases were observed with N-Mgb aloneor SnPP alone at the 18-hour time point. To sum up, these 4 hour mRNAand 18 hour HO-1 protein increases indicate a synergistic effect ofN-Mgb+SnPP on renal cortical HO-1 gene expression. (Additional HO-1 mRNA[18 hours] and protein data [4 hours] are presented in Table 8).

TABLE 8 Kidney mRNA and protein values 4 h (a) and 18 h (b) after Rxtreatment Measured substance Control N-Mgb SnPP SnPP 1 N-Mgb (a) 4 hafter Rx treatment Kidney mRNA HO-1 0.61 ± 0 1  3.38 ± 0.38 4.38 ± 0.2810.5 ± 1.23 (<0.0001) Haptoglobin  0.20 ± 0.06  1.94 ± 0.31 0.19 ± 0.015.45 ± 1.16 (<0.005) IL-10  0.56 ± 0.20 1.45 ± 0.6 0.39 ± 0.15 5.18 ±1.23 (<0.005) HO-1 protein 13.3 ± 1.3 36.1 ± 2.9 22.9 ± 2.6  55.5 ± 3.7(<0.001) Haptoglobin  7.9 ± 1.9 17.6 ± 1  13.1 ± 1.3  18.9 ± 2.7(<0.001) IL-10 304 ± 29 265 ± 54 550 ± 86  838 ± 63 (<0.001) (b) 18 hafter Rx treatment Kidney mRNA cortex HO-1 0.61 ± 0 1  0.58 ± 0.18 0.63± 0.06 1.45 ± 0.61 (NS) Haptoglobin  0.20 ± 0.06  0.24 ± 0.04 0.23 ±0.08 0.4 ± 0.19 (NS) IL-10  0.56 ± 0.20  0.43 ± 0.10 0.18 ± 0.09 0.57 ±0.13 (NS) Kidney protein HO-1 13.3 ± 1.3 30 ± 6 18 ± 2  71 ± 10 (<0.001)Haptoglobin 10.3 ± 2.7 183.8 ± 20.4 53.5 ± 17.2 203 ± 8 (<0.0001) IL-10304 ± 29 292 ± 54 454 ± 51  840 ± 60 (<0.001) Abbreviations: HO-1, hemeoxygenase 1; IL-10, interleukin 10; mRNA, messenger RNA; N- Mgb,nitrited myoglobin; NS, not significant; Rx, treatment; SnPP, tinprotoporphyrin. Individual renal cortical mRNA and protein levelsinduced by the test agents administered alone or in combination at 4 h(a) and 18 h (b) after injection.

Renal IL-10 assessments. As shown in FIG. 10, left panel, N-Mgb aloneand SnPP alone had either minimal or no impact on IL-10 mRNA levels atthe 4-hour time point. In contrast, combined N-Mgb+SnPP caused a 10-foldIL-10 mRNA increase at 4 hours after injection. Corresponding to theseresults was the absence of IL-10 protein increases at 18 hours afterN-Mgb alone or SnPP injection alone. Conversely, a >2-fold increase inIL-10 protein was seen at 18 hours after combined N-Mgb−SnPP injection.(Additional IL-10 mRNA [18 hours] and protein data [4 hours] arepresented in Table 8).

Renal cortical haptoglobin assessments. As with HO-1 and IL-10, thecombination of N-Mgb+SnPP induced the greatest haptoglobin mRNAincreases at 4 hours after agent injection (FIG. 11). At 18 hours afterinjections, a massive (20-fold) increase in renal cortical haptoglobinprotein levels was observed in response to N-Mgb−SnPP injection.However, the haptoglobin protein levels were comparably increased withN-Mgb alone at the 18-hour time point. This implies that it was theN-Mgb component of the combined therapy that drove the 18-hourhaptoglobin protein increases. (Given this massive increase, it isconceivable that no added increase could be induced by the combinationtherapy). Additional haptoglobin mRNA (18 hours) and protein data (4hours) are presented in Table 8.

Impact of IV N-Mgb alone, SnPP alone, and N-Mgb+SnPP on the severity ofthe glycerol AKI model. As shown in FIG. 12, pretreatment with SnPPalone had virtually no effect on the severity of glycerol-induced AKI.N-Mgb alone induced modest protection as judged by BUN/creatininelevels. However, when N-Mgb+SnPP were used together, complete functionalprotection was observed (BUN/creatinine levels remained at normalvalues). Coinciding histologic protection was also observed (3.5±0.25 vs1.25±0.25 histologic scores for the glycerol vs the N-Mgb+SnPP-treatedgroup; P<0.05). In this regard, the untreated glycerol group manifestedwidespread tubular necrosis and cast formation as previously depicted.Zager et al. Am J Physiol Renal Physiol 2014; 307:F856-68. These changeswere virtually absent in the N-Mgb+SnPP pretreatment group.

Maleate AKI model. As depicted in FIG. 13, maleate injection causedsevere renal injury as denoted by marked BUN/creatinine increases.Pretreatment with N-Mgb+SnPP conferred almost complete protectionagainst this injury as denoted by near normal BUN/ creatinine levels.

FIG. 14 shows maleate-induced cardiotoxicity is reduced by pretreatmentwith N-Mgb+SnPP. Mice were treated with 1 mg/Kg N-myoglobin+1 μmole SnPPor IV vehicle injection). Eighteen hrs later, 800 mg/Kg maleate wasadministered IP. The extent of myocardial injury was determined 18 hrspost maleate injection by measuring plasma troponin I concentrations (byELISA). Maleate injection caused a 10 fold increase in plasma troponinlevels. Pre-treatment with N-Mgb+SnPP reduced the maleate inducedtroponin increase by 75%.

Postischemic AKI model. By 2 weeks postischemia, a 38% reduction inpostischemic left renal mass was observed in the control unilateralischemia mice (FIG. 15). In contrast, only a 12% reduction was seen inthe mice that had received prophylactic N-Mgb+SnPP treatment (P<0.005).This reduction in renal injury was also denoted by marked reductions inNGAL mRNA and protein levels in the N-Mgb−SnPP pretreatment group (FIG.15).

Dose-response relationships between renal cortical and plasmaHO-1/haptoglobin levels and degrees of protection againstglycerol-induced AKI. As shown in FIG. 16, progressive increases in IPN-Mgb dosages into normal mice produced progressive increases in renalcortical and plasma HO-1 and haptoglobin levels. Significantcorrelations between plasma and renal cortical HO-1 and haptoglobinlevels were observed (e.g., r=0.82 between renal cortical and plasmahaptoglobin levels). Furthermore, these increasing N-Mgb doses wereassociated with progressive (50%; 100%) protection against the glycerolAKI model (FIG. 17). Thus, these data imply that the degree of plasmaHO-1 or haptoglobin increases can serve as biomarkers ofN-Mgb−SnPP-induced renal gene induction and the degrees of resistance tosubsequent ARF. Despite administering 5 mg of N-Mgb (+standard SnPPdose), no evidence of renal injury (normal BUN, creatinine; see FIG. 17,right panel) was observed.

Liver assessments. Hepatic HO-1, IL-10, and haptoglobin expressions inliver in response to N-Mgb/SnPP injections. The fold increases overcontrol values for HO-1, IL-10, and haptoglobin mRNAs (4 hours) and forprotein levels (18 hours) are depicted in FIG. 18, top panels. Markedincreases in each were observed. Individual values for each agent aloneor in combination are given in Table 9.

TABLE 9 Liver mRNA and protein levels 4 h (a) and 18 h (b) after Rxtreatment Measured substance Control N-Mgb SnPP SnPP 1 N-Mgb (a) 4 hafter Rx treatment Liver mRNA HO-1  1.1 ± 0.12  1.83 ± 0.33 3.15 ± 0.255.66 ± 0.29 (<0.001) Haptoglobin  0.5 ± 0.1 0.98 ± 0.1 0.32 ± 0.02 1.01± 0.12 (<0.01) IL-10   0.06 ± 0.0.02  0.67 ± 0.46 0.14 ± 0.1  1.12 ±0.64 (<0.001) Liver protein HO-1 protein 10.2 ± 1.2 17 ± 2 7.4 ± 0.715.1 ± 1.4 (<0.025) Haptoglobin 115.3 ± 9.6  359.5 ± 39.6 130.0 ± 8.9 351.0 ± 40.7 (<0.001) IL-10 314 ± 36 286 ± 32 485 ± 47  412 ± 34 (=0.1)(b) 18 h after Rx treatment Liver mRNA HO-1  1.1 ± 0.12  0.82 ± 0.072.56 ± 0.21 2.86 ± 0.4 (<0.001) Haptoglobin  0.5 ± 0.1  0.91 ± 0.07 0.65± 0.17 1.19 ± 0.4 (<0.05) IL-10  0.06 ± 0.02  0.06 ± 0.02 0.05 ± 0.010.06 ± 0.02 (NS) Liver protein HO-1 protein 10.2 ± 1.2 14.9 ± 0.3  18 ±2.5 22.9 ± 1.2 (<0.0001) Haptoglobin 115.3 ± 9.6  358.8 ± 32.8 212.0 ±63.6  410 ± 64.3 (<0.001) IL-10 314 ± 36 5988 ± 549 8198 ± 725  8015 ±225 (<0.001) Abbreviations: HO-1, heme oxygenase 1; IL-10, interleukin10; mRNA, messenger RNA; N-Mgb, nitrited myoglobin; NS, not significant;Rx, treatment; SnPP, tin protoporphyrin. Individual liver mRNA andprotein levels induced by the test agents administered alone or incombination at 4 h (a) and 18 h (b) after injection.

At 4 hours after injection, hepatic HO-1, IL-10, and haptoglobin mRNAlevels were significantly higher with combined N-Mgb+SnPP injection vseither agent alone (Table 9). This translated into greater hepatic HO-1,IL-10, and haptoglobin protein increases as assessed at the 18-hour timepoint (P<0.001 for each protein vs control tissues).

Hepatic ischemic model. Hepatic ischemia induced marked increases inplasma ALT and LDH concentrations (see FIG. 19). The LDH and ALTincreases were reduced by 75% and 50%, respectively, with N-Mgb+SnPPpretreatment (corresponding to the hepatic HO-1, haptoglobin, and IL-10protein increases; Table 9). As shown in FIG. 20 (top), widespreadnecrosis was observed in gross sections of postischemic liver.Pretreatment with N-Mgb+SnPP led to a much more normal gross hepaticappearance (FIG. 20 (bottom)).

Hepatotoxic injury. As shown in the right panel of FIG. 19, N-Mgb+SnPPtreatment also reduced the extent of IP glycerol-induced liver injury asassessed by plasma ALT levels.

Cardiac HO-1, IL-10, and haptoglobin mRNA and protein levels. As shownat the bottom of FIG. 18, combined N-Mgb+SnPP induced 3-to 4-foldincreases in HO-1, haptoglobin, and IL-10 mRNAs at 4 hours, and up to3-to 15-fold increases in their protein levels at the 18-hour timepoint. Individual values are given in Table 10.

TABLE 10 Cardiac mRNA and protein levels 4 h (a) and 18 h (b) after Rxtreatment Measured substance Control N-Mgb SnPP SnPP + N-Mgb (a) 4 hafter Rx treatment Cardiac mRNA HO-1 0.07 ± 0.01 0.09 ± 0.01 0.14 ± 0.010.3 ± 0.01 (<0.001) Haptoglobin 0.31 ± 0.07 0.75 ± 0.10 0.52 ± 0.21 1.32± 0.22 (<0.002) IL-10 0.36 ± 0.10 0.86 ± 0.11 0.58 ± 0.16 0.96 ± 0.22(<0.04) Cardiac Protein HO-1 1.50 ± 08  1.64 ± 0.19 1.310.13 1.54 ± 0.09(NS) Haptoglobin 15.6 ± 5.0  40.4 ± 8.6  19.1 ± 2.1  29.4 ± 4.1 (<0.1)IL-10 8.1 ± 5  21 ± 12 15.8 ± 10  41 ± 14 (<0.035) (b) 18 h after Rxtreatment Cardiac mRNA HO-1 0.07 ± 0.01 0.08 ± 0.01 0.09 ± 0.03 0.24 ±0.07 (<0.005) Haptoglobin 0.31 ± 0.07 0.53 ± 0.21 0.59 ± 0.17 1.28 ± 0.2(<0.002) IL-10 0.36 ± 0.10 0.67 ± 0.10 0.53 ± 0.10 0.64 ± 0.14 (=0.1)Cardiac protein HO-1  1.5 ± 0.08 1.9.7 ± 0.37  2.67 ± 0.4  4.2 ± 0.98(<0.01) Haptoglobin 15.6 ± 5.0  249.6 ± 15.0  96.1 ± 36.2 250.7 ± 37.8(<0.001) L-10 8 ± 5 14.5 ± 10  23.4 ± 14  51.4 ± 19 (<0.035)Abbreviations: HO-1, heme oxygenase 1; IL-10, interleukin 10; mRNA,messenger RNA; N-Mgb, nitrited myoglobin; NS, not significant; Rx,treatment; SnPP, tin protoporphyrin. Individual cardiac mRNA and proteinlevels induced by the test agents administered alone or in combinationat 4 h (a) and 18 h (b) after injection.In general, far greater mRNA and protein increases were observed withcombined agent administration vs either agent alone.

Discussion. In 1992, Nath et al. (J Clin Invest 90:267-70) demonstratedthat hemoglobin administration in the rat can induce marked protectionagainst subsequent (24 hours later) glycerol-mediatedrhabdomyolysis-induced ARF. This protective response was ascribed toheme-mediated HO-1 upregulation, based on 2 pivotal observations: (1)heme pretreatment markedly increased renal HO-1 mRNA and protein levels,as well as HO-1 enzyme activity, and (2) the glycerol model was markedlyworsened by administering the potent HO-1 inhibitor, SnPP, at the timeof (and after) glycerol injection. From the time of these seminalobservations, the role of HO-1 as a potent antioxidant andanti-inflammatory molecule has been well established in multiple modelsof AKI (e.g., cisplatin, renal ischemia, endotoxemia; reviewed in Nath,Curr Opin Nephrol Hypertens 2014; 23:17-24). Furthermore, its protectiveeffects have been extensively described in diverse forms of extrarenaltissue damage (e.g., brain, liver, heart, organ transplantation). Kusmicet al. J Transl Med 2014; 12:89; Czibik et al. Basic Res Cardiol 2014;109:450; Sharp et al. Transl Stroke Res 2013; 6:685-92; Le et al. CNSNeurosci Ther 2013; 12:963-8; Huang et al. World J Gastroenterol 2013;21:2937-48; Liu et al. Crit Care Med 2014; 42:e762-71; Wszola et al.Prog Transplant 2014; 1: 19-26. However, less certain than the existenceof HO's protective actions is the exact mechanism by which thatprotection is effected. Because HO-1 cleavage of the porphyrin ringreleases highly toxic catalytic Fe (which exerts direct adverse effects;Zager & Burkhart, Kidney Int 1997; 51:728-38) it is now believed thatsecondary consequences of increased HO-1 activity are involved. Theseinclude the generation of the antioxidants biliverdin and bilirubin,cytoprotective carbon monoxide production, and increased tissue (H)ferritin levels, with its great capacity for catalytic Fe binding.Zarjou et al. J Clin Invest 2013; 123:4423-34; Nath, Curr Opin NephrolHypertens 2014; 23:17-24. Additional complexities in interpreting HO-1involvement in cytoprotection stem from the fact that HO-1 inducers(e.g., heme) also upregulate a number of other cytoprotective pathways,for example, haptoglobin (Zager et al. Am J Physiol 2012; 303:F139-48),hemopexin (Zager et al. Am J Physiol 2012; 303:F1460-72) alpha 1antitrypsin (Zager et al. PLoS One 2014; 9:e9838) and IL-10 (as shown inthe present disclosure). This complicates interpretation of HO-1 effectson tissue injury given the presence of multiple upregulated tissueprotective proteins.

The interplay of SnPP and HO-1 is also complex. First, as a competitiveinhibitor of HO-1, SnPP administration can secondarily increase HO-1mRNA and protein levels either by enzyme “feedback inhibition” or by theinduction of a mild pro-oxidant state with counter-balancing HO-1production (e.g., Kaizu et al. Kidney Int 2003; 63:1393-403). Second,the Sn moiety of SnPP may independently upregulate HO-1 via directpro-oxidant effects. Barrera-Oviedo et al. Ren Fail 2013; 35:132-7.Third, whenever considering the effects of SnPP, it is important torecognize that secondary HO-1 induction could potentially be offset bySNPP-induced HO-1 inhibition. However, it is noteworthy that SnPP has arelatively short half-life (2-4 hours; Berglund et al. Hepatology 1988;8:625-31). Thus, delayed HO-1 increases (e.g., 18 hours after glyceroladministration or N-Mgb−SnPP treatment) should be free to exert itsbiological effects because of prior SnPP elimination. This concept issupported by observations that at 24 hours after SnPP administration,upregulated HO-1 was able to exert a cytoprotective effect (e.g.,against ischemic ARF; Juncos et al. Am J Pathol 2006; 169:21-31; Kaizuet al. Kidney Int 2003; 63:1393-403).

In light of the previously mentioned considerations, it was hypothesizedthat a combination of N-Mgb+SnPP might induce either additive orsynergistic increases in HO-1 and in other redox sensitivecytoprotective proteins (e.g., haptoglobin and IL-10). This hypothesiswas tested by measuring HO-1, haptoglobin, and IL-10 mRNA and proteinlevels at 4 and 18 hours after N-Mgb, SnPP, or N-Mgb+SnPP injection. Asshown in FIGS. 7-9, combined therapy generally induced synergistic oradditive responses. For example, at 4 hours after injection, a 20-foldincrease in HO-1 mRNA was observed, more than doubling the increasesseen with either N-Mgb or SnPP alone. At 18 hours, this early mRNAincrease translated into 7-fold HO-1 protein increases. Qualitativelysimilar results were observed with IL-10 . Particularly noteworthy was amassive (20-fold) increase in haptoglobin protein at 18 hours afterN-Mgb−SnPP administration. However, in this case, it appeared that itwas N-Mgb rather than an N-Mgb−SnPP interaction, which was largelyresponsible, given that N-Mgb alone vs N-Mgb+SnPP induced comparablerenal haptoglobin increases. Clearly, additional cytoprotective redoxsensitive proteins, other than HO-1, IL-10, and haptoglobin, may alsohave been induced by the N-Mgb−SnPP protocol (e.g., a1 antitrypsin,hemopexin, hepcidin). Thus, it seems logical that multiplecytoprotective proteins could act in concert to mitigate cell injuryresponses.

Having observed dramatic renal cortical increases in cytoprotectiveproteins after N-Mgb−SnPP administration, the latter's effectiveness inprotecting against 3 forms of AKI was tested. FIG. 12 depicts theresults in the glycerol model. As shown, SnPP administration aloneinduced no significant reductions in BUN or creatinine levels. WhenN-Mgb alone was administered, a modest protective effect was observed.However, when administered together, N-Mgb+SnPP pretreatment evokedessentially complete functional protection as indicated by normal BUNand plasma creatinine concentrations at 18 hours after glycerolinjection. Furthermore, near normal renal histology was observed. Thus,these findings underscore the principle that synergistic increases incytoprotective proteins can translate into synergistic protectionagainst ARF.

To further explore the scope of N-Mgb−SnPP-mediated protection, themaleate model of proximal tubular ATP depletion-mediated ARF was used.Again, dramatic or near complete protection was observed (FIG. 13).Because it is now well recognized that AKI can initiate the onset ofprogressive chronic renal disease, whether N-Mgb−SnPP pretreatment couldabrogate this process in a previously published unilateral postischemicrenal injury model (Zager et al. Kidney Int 2013; 84:703-12; Zager etal. Am J Physiol Renal Physiol 2014; 307:F856-68) in which a 40% loss ofrenal mass normally results in 2 weeks was assessed. As shown in FIG.15, postischemic injury was markedly attenuated with N-Mgb−SnPPpretreatment as evidenced by a reduction in renal mass loss from 38% to12%, and marked reductions in NGAL mRNA and protein levels. Thus, ineach of 3 heterogeneous AKI models, dramatic protection was observed.Although the kidney has the largest exposure to the 2 test agents (e.g.,via rapid filtration, Mgb endocytosis), virtually all cells aretransiently exposed to them after their IV injection. Furthermore,protoporphyrins can bind to and be taken up by a variety of cells.Anderson et al. J Pharmacol Exp Ther 1984; 228:327-33. Thus, it wasquestioned whether the disclosed N-Mgb−SnPP regimen might alsoupregulate protective responses in extrarenal organs. Indeed, this wasthe case, given that both hepatic and cardiac tissues manifested HO-1,IL-10, and haptoglobin mRNA and protein increases at both 4 and 18 hoursafter N-Mgb−SnPP injection (as presented in Tables 9 and 10). That N-Mgbalone could induce a response in extrarenal tissues was surprising,given that megalin-cubilin-mediated endocytosis is thought to be a renalspecific pathway. This either suggests potential extrarenal uptake,possibly via scavenger receptors, (Canton et al. Nat Rev 2013;13:621-34) or that when present in the microcirculation, N-Mgb and SnPPare able to activate intracellular cytoprotective genes. To test whetherextrarenal protection might result, the impact of N-Mgb+SnPPpretreatment on the extent of postischemic hepatic injury was assessed.As presented in FIG. 18, marked reductions in both LDH and ALT plasmaconcentrations were observed. Furthermore, obvious protection wasindicated by the gross appearance of postischemic hepatic tissues (FIG.19). To further test hepatic resistance to injury, mice were subjectedto an IP injection of glycerol, which on reaching the liver through theportal circulation induces modest hepatic damage. Within 4 hours of IPglycerol injection, increases in plasma ALT resulted, which were largelyabrogated by prior N-Mgb−SnPP injection.

It has previously been demonstrated that plasma levels of eitherhaptoglobin or HO-1 can serve as biomarkers of renal corticalhaptoglobin and HO-1 increments in the setting of ARF. Z Zager et al. AmJ Physiol 2012; 303:F139-48; Zager et al. J Am Soc Nephrol 2012;23:1048-2057. Thus, it was questioned whether plasma haptoglobin andHO-1 might also serve as biomarkers for induction of these proteins inkidney after N-Mgb−SnPP administration and for the emergence of thecytoresistant state. This indeed was the case. As shown in FIG. 16,increasing doses of N-Mgb−SnPP induced dose-dependent increases inplasma haptoglobin and HO-1 levels, and these increases directlycorrelated with renal cortical haptoglobin and HO-1 content.Furthermore, striking inverse relationships between N-Mgb−SnPP-inducedplasma HO-1 and plasma haptoglobin increases and postglycerol BUNconcentrations were observed (r, −0.79/r, −0.71 for BUN vs plasma HO-1and haptoglobin levels, respectively). Thus, plasma HO-1/haptoglobinincrements would likely confirm biological activity of N-Mgb−SnPP inclinical trials, and the degrees of HO-1 and haptoglobin plasma increasemight also be predictive of degrees of resistance to subsequent AKI.

An obvious concern by applying this prophylactic strategy to patients ispotential renal and/or extrarenal toxicities. However, in this regard,it is noteworthy that SnPP has already been shown to be well toleratedin humans (e.g., Berglund et al. Hepatology 1988; 8:625-31; Kappas etal. Pediatrics 1988; 81:485-97; Reddy et al. J Perinatol 2003; 23:507-12). Furthermore, it was previously documented in a cell culturesystem that nitrite addition markedly reduces myoglobin's cytotoxiceffects by 75% (unpublished data, 2014). To assess the potential in vivomargin of safety for N-Mgb+SnPP (see Supplemental FIGs.), the maximalamount of N-Mgb that could be given to mice before nephrotoxicity wasobserved was tested. Up to 25 times the employed N-Mgb dose (with aconstant SnPP dose) could be administered (over 2 hours) withoutinduction of nephrotoxicity (normal BUN and creatinine, 18 hours later).Finally, neither the standard N-Mgb−SnPP dosage (1 mg N-Mgb/1 mmol SnPP)nor 5 mg IP N-Mgb (FIG. 17) induced overt renal injury (18 hourBUN/creatinine, or histology), nor did it raise hepatic ALT or cardiactroponin levels. In concert, these data indicate usefulness in clinicalapplication.

Conclusions. Administration of N-Mgb, along with an inhibitor of itsdegradation (SnPP), leads to dramatic increases in a number ofcytoprotective proteins in kidney. The potency of this response isindicated by observations that the documented renal HO-1 proteinincreases were 15 times greater than that which has been achieved withbardoxolone methyl, a well recognized Nrf-2-mediated HO-1 inducer. Wu etal. Am J Physiol 2011; 300: F1180-92. Within 18 hours of itsadministration, N-Mgb+SnPP evoked dramatic protection against 3 diversemodels of AKI: glycerol-induced rhabdomyolysis, maleate-induced proximaltubule ATP depletion, and postischemic AKI progression to CKD.Surprisingly, N-Mgb+SnPP administration also induced synergisticincreases in cytoprotective proteins in liver, leading to dramaticprotection against hepatic ischemic-reperfusion injury andhepatotoxicity. Finally, N-Mgb+SnPP can upregulate cytoprotectiveproteins in heart, suggesting cardiac protection, and thus, broadranging cytoprotective effects. Of note, each of these responses wasinduced in the absence of discernable renal, hepatic, or cardiactoxicity. Thus, these data suggest that N-Mgb+SnPP coadministration canprovivde a clinical prophylactic strategy for protecting against bothrenal and extrarenal injuries, such as may result during cardiopulmonarybypass, aortic aneurysm repair, or other complex, high-risk surgeries.Thus, this strategy could potentially meet a number of significant unmetclinical needs.

Example 5

Two mongrel dogs, one male, one female, had baseline blood drawn formeasurement of plasma heme oxygenase 1 (HO-1; canine ELISA,) BUN, plasmacreatinine, and lactate dehydrogenase (LDH) levels. A baseline spoturine sample was also obtained for HO-1 assay. Dog 1 then received a 50m1/50 min infusion of normal saline/40mM NaHCO₃ containing 5 mg/Kg ofnitrited canine myoglobin+3.75 mg/Kg of SnPP. Dog 2 received 2.5 mg/Kgcanine N-myoglobin+7.5 mg/Kg SnPP. Four and 26 hrs later, repeat bloodsamples were obtained. A second urine sample was collected at 26 hrspost infusion. As shown in Table 11, the infusion evoked massiveincreases in plasma and urinary HO-1 concentrations in the absence ofrenal injury (based on pre and BUN and plasma creatinine levels). LDHvalues remained unchanged, implying an absence of obviousrenal/extrarenal tissue injury.

TABLE 11 HO-1 Induction in Dogs Dog 1 (male) Dog 2 (female) Baseline BUN(mg/dl) 20 →   28 →   26 hr BUN 28     23     Baseline Creatinine(mg/dl) 0.5 → 0.7 → 26 hr Creatinine 0.5   0.6   Baseline LDH (units/dl)0.4 →  0.31 → 26 hr LDH 0.2   0.31   Baseline Plasma HO-1 1.3 → 4.0 →(mg/ml) 4 hr Plasma HO-1 34 →   44.7 →  26 hr Plasma HO-1 155     90.6    Baseline Urine HO-1 (mg/mg 2 →   0.8 → cr) 26 hr Urine HO-118.8    11.1   

Example 6

Effects of Fe sucrose and cyanocobalamin (Vitamin B₁₂) on heme oxygenase1 induction in kidney. Heme oxygenase-1 (HO-1) upregulation is acritical mediator of N-myoglobin/SnPP's cytoprotective activity inkidney and extra-renal organs. Hence, additional agents were sought thatcan induce HO-1 up-regulation, and thus, contribute to the emergence oftissue protection against toxic and ischemic forms of injury. Because Feis the critical mediator of N-Mgb's activity, the impact of anFe-carbohydrate polymer (Fe sucrose; molecular weight ranging from 34-61kDa) on HO-1 levels was assessed.

As an alternative and/or complementary strategy, the impact ofcyanocobalamin (vitamin B12) on HO-1 induction in kidney was studied.The rationale for B12 testing is that both cobalt and cyanide canindependently induce HO-1. Thus, B12 could represent a safe method toadminister both cyanide and cobalt, and as a single agent, since bothare integral parts of the B12 molecule.

Methods. Male CD-1 mice (25-40 grams) Charles River, Wilmington, Mass.)were used for all experiments. They were housed under standard vivariumconditions with free food and water access. All experiments wereapproved by the Fred Hutchinson Cancer Research Center IACUC inaccordance with NIH guidelines.

Effects of Fe sucrose (FeS)/tin protoporphyrin (SnPP) on AKI severity.Maleate model of AKI. When injected into rodents, maleate undergoesrelatively selective proximal tubule cell uptake via organic aniontransporters. Once intracellular accumulation occurs, maleate is apreferred substrate for succinyl-CoA:3-oxoacid CoA transferase. Thisresults in the formation of maleyl-coenzyme A. With subsequentconversion of maleyl CoA into a stable thioether, severe coenzyme A(CoA) depletion results. Ample levels of CoA are essential for fattyacid “activation”, allowing for their subsequent metabolism through theKrebs cycle, yielding ATP. In the absence of this process, proximaltubule ATP depletion and cell injury result. Additionally, maleateconjugates the sulfhydryl group of glutathione (GSH), culminating in GSHdepletion and potential oxidant tubular stress.

The following experiment tested whether FeS, SnPP or combined FeS+SnPPcan mitigate this form of acute kidney injury (AKI). Twenty seven micewere subjected to 200 μL IV tail injections of one of the following: 1)vehicle (phosphate buffered saline, PBS; n, 10); 2) 1 mg FeS (AmericanRegent (Shirley, N.Y.; n, 3); 3) 1μmole SnPP (Frontier Scientific,Logan, Utah.; n 7), or FeS+SnPP, n, 7). Eighteen hrs later, all micereceived an IP injection of Na maleate (800 mg/Kg; in 500 ul of PBS).Eighteen hrs later, the mice were deeply anesthetized with pentobarbital(50 mg/Kg IP), the abdominal cavities were opened, and blood sampleswere obtained from the abdominal vena cava. The severity of kidneyinjury was assessed by determining plasma blood urea nitrogen (BUN) andplasma creatinine (PCr) concentrations.

Renal ischemic-reperfusion injury (IRI) model of AKI. The followingexperiment assessed whether combination FeS+SnPP can mitigate the renalartery occlusion model of AKI. Mice received 200 μtail vein injectionsof either PBS (n, 9) or FeS+SnPP (n, 8), as noted above. Eighteen hrslater, the mice were deeply anesthetized with pentobarbital (40-50 mg/KgIP), the abdominal cavities were opened, the renal pedicles wereidentified and both were occluded with microvascular clamps. Bodytemperature was maintained at 36-37°C. throughout. Following 22 minutesof bilateral renal ischemia, the clamps were removed, uniformreperfusion was visually confirmed by the reappearance of a normal renalcolor (loss of tissue cyanosis), and then the abdominal cavities wereclosed in two layers with silk suture. Eighteen hrs later, the mice werere-anesthetized, the abdominal cavities were re-opened, and terminalblood samples were obtained from the vena cava. The severity of renalinjury was determined by BUN and PCr concentrations.

FeS/B12 effects on the severity of AKI. Glycerol model of AKI. Micereceived tail vein injections of either PBS vehicle (n 6), orcombination FeS+1 μmole B12 (n, 6; B12 from Alfa Aesar, Ward Hill,Mass.). Eighteen hrs later, the mice were lightly anesthetized withisoflurane, and then the glycerol model of rhabdomyolysis AKI wasinduced (9 ml/Kg 50% glycerol, administered in two equally divided IMinjections into the upper hind limbs). Eighteen hrs post glycerolinjection, the mice were deeply anesthetized with pentobarbital andterminal vena cava blood samples were obtained. Renal injury severitywas gauged by terminal BUN and PCr concentrations.

Maleate model of AKI. Mice received tail vein injections of eithercombination of FeS+B12 or vehicle (n, 6 per group). Eighteen hrs laterthey received IP maleate injections, as noted above. The severity of AKIwas determined 18 hrs post maleate injection by terminal BUN and PCrassessments.

Effects of FeS, SnPP, and B12 on renal cortical induction of hemeoxygenase 1 (HO-1). The following experiments assessed the effects ofFeS, SnPP, and B12 on the possible induction of the cytoprotectiveprotein HO-1. To this end, mice were injected with each of these agents,as noted above. Either 4 or 18 hrs later, they were anesthetized and thekidneys were removed through a midline abdominal incision. The renalcortices were dissected on ice and then extracted for protein and mRNA.The samples were then assayed for HO-1 protein by ELISA, and HO-1 mRNAby RT-PCR, factored by GAPDH levels. Five normal mice provided controlvalues.

Results. Effects of FeS/SnPP on the severity of AKI. Maleate-inducedAKI: As shown in FIG. 22, maleate injection caused severe AKI as denotedby marked BUN and PCr increases over maleate injected controls (C).Neither SnPP alone nor FeS alone significantly altered the severity ofrenal injury. However, combined FeS+SnPP conferred marked protection, asdenoted by 75% reductions in BUN/PCr concentrations (the horizontallines represent the means of BUN/PCr levels in normal mice).

Renal ischemia-reperfusion (IRI) induced AKI: Within 18 hrs of inducingIRI, 4 fold elevations in BUN and PCr concentrations resulted (FIG. 23).Pre-treatment with FeS+SNPP conferred significant protection, loweringthe BUN and PCr levels by 50%. The horizontal lines represent meanBUN/PCr levels in normal mice.

Effects of FeS/B12 on AKI severity. Maleate induced AKI: Again, maleateinjection induced severe AKI (FIG. 24). Pre-treatment with FeS+B12markedly mitigated this injury, as denoted by BUN/ PCr reductions. Thehorizontal lines represent mean BUN/PCr levels in normal mice.

Glycerol model of AKI: Severe renal failure resulted within 18 hrs ofglycerol injection (FIG. 25). Pre-with FeS+B12 conferred substantialfunctional protection, as denoted by marked reductions in both 18 hr BUNand PCr concentrations. The horizontal lines represent mean BUN/PCrlevels for normal mice.

Renal cortical HO-1 mRNA and protein levels. As shown in FIG. 26, eachof the agents induced marked and significant increases in HO-1 mRNA, asassessed 4 hr post injection. By 18 hrs, HO-1mRNA levels returned tonormal values. As shown in FIG. 27, a correlate of the 4 hr mRNAincreases was a significant increase in HO-1 protein levels. Theselevels remained elevated at the 18 hr time point, particularly in thecase of FeS administration.

Prophetic Examples Prophetic Example 1

Whether a depot formulation confers equal or greater cytoprotection withless potential toxicity than intravenous (IV) myoglobin/SnPP treatmentand/or Fe—S and/or B12 will be assessed. Different doses of myoglobinwith SnPP and/or Fe—S and/or B12 will be added as a suspension to 100mg/ml PEG (PEG 5000). There are two rationales for conducting thisexperiment. First, by injecting either intramuscularly (IM) orsubcutaneously (SQ) the myoglobin and SnPP and/or Fe—S and/or B12 willbe absorbed relatively slowly (vs. instantaneous systemic myoglobin/SnPPand/or Fe—S and/or B12 exposure following IV injection). By slowing themyoglobin and/or Fe—S and/or B12 absorption with a depot PEG injection,a slower, more sustained renal exposure to myoglobin and/or Fe—S and/orB12 will result. This will favor increased myoglobin and/or Fe—S and/orB12 uptake, and at the same time, decrease the potential fornephrotoxicity, as can occur due to rapid renal myoglobin and/or Fe—Sand/or B12 loading (which results in obstructive cast formation withintubular lumina). Second, PEG is an osmotic agent and will undergo renalexcretion. Because an acute increase in urinary osmolality can inducecytoprotective proteins on its own, and also confer protection bycausing increased urinary flow rates, an additive or synergisticbeneficial effect may be observed.

Prophetic Example 2

Hematin will inhibit HO, and like SnPP, it can also induce an increasein HO production (via enzyme feedback inhibition). Thus, hematin shouldrecapitulate the beneficial effects of SnPP treatment. Importantly,hematin has been approved by the FDA for the treatment of the clinicaldisease, porphyria. Thus, if hematin is as effective as SnPP, hematinmay be selected for further study and clinical development.

Prophetic Example 3

It is well documented that HO protects against experimental sepsis andendotoxemia. HO-1 will be up-regulated according to the compositions,kits, and methods disclosed herein and then 18 hrs later, the mice willbe challenged with endotoxin. At 2 and 24 hrs later, the severity ofsepsis is gauged by inflammatory cytokine (TNF, MCP-1) levels in plasmaand in kidney. Also, because endotoxemia causes kidney injury, theseverity of kidney dysfunction by BUN and creatinine levels will betested. The results will be compared to naäve mice subjected toFendotoxin injection. When successful, this will greatly expand theutility of the disclosed protective strategies to patients at high riskof sepsis (e.g. ICU patients).

Prophetic Example 4

On-going studies will demonstrate the effectiveness of iron and/orvitamin B12 in protecting various organ systems from insult.

The compositions, kits, and methods disclosed herein are distinguishedfrom “remote preconditioning” whereby one causes ischemia in the legs(e.g., by inflating blood pressure cuffs) to precondition other organs,which has met only very limited success. In particular embodiments, thecompositions, kits and methods disclosed herein can be referred to as“remote pharmacologic preconditioning” (RPR).

As will be understood by one of ordinary skill in the art, eachembodiment disclosed herein can comprise, consist essentially of, orconsist of its particular stated element, step, ingredient or component.Thus, the terms “include” or “including” should be interpreted torecite: “comprise, consist of, or consist essentially of.” Thetransition term “comprise” or “comprises” means includes, but is notlimited to, and allows for the inclusion of unspecified elements, steps,ingredients, or components, even in major amounts. The transitionalphrase “consisting of” excludes any element, step, ingredient orcomponent not specified. The transition phrase “consisting essentiallyof” limits the scope of the embodiment to the specified elements, steps,ingredients or components and to those that do not materially affect theembodiment. A material effect would cause a statistically-significantreduction in the ability of a disclosed composition, kit or method toprotect an organ from a scheduled insult.

Unless otherwise indicated, all numbers expressing quantities ofingredients, properties such as molecular weight, reaction conditions,and so forth used in the specification and claims are to be understoodas being modified in all instances by the term “about.” Accordingly,unless indicated to the contrary, the numerical parameters set forth inthe specification and attached claims are approximations that can varydepending upon the desired properties sought to be obtained by thepresent invention. At the very least, and not as an attempt to limit theapplication of the doctrine of equivalents to the scope of the claims,each numerical parameter should at least be construed in light of thenumber of reported significant digits and by applying ordinary roundingtechniques. When further clarity is required, the term “about” has themeaning reasonably ascribed to it by a person skilled in the art whenused in conjunction with a stated numerical value or range, i.e.denoting somewhat more or somewhat less than the stated value or range,to within a range of ±20% of the stated value; ±19% of the stated value;±18% of the stated value; ±17% of the stated value; ±16% of the statedvalue; ±15% of the stated value; ±14% of the stated value; ±13% of thestated value; ±12% of the stated value; ±11% of the stated value; ±10%of the stated value; ±9% of the stated value; ±8% of the stated value;±7% of the stated value; ±6% of the stated value; ±5% of the statedvalue; ±4% of the stated value; ±3% of the stated value; ±2% of thestated value; or ±1% of the stated value.

Notwithstanding that the numerical ranges and parameters setting forththe broad scope of the invention are approximations, the numericalvalues set forth in the specific examples are reported as precisely aspossible. Any numerical value, however, inherently contains certainerrors necessarily resulting from the standard deviation found in theirrespective testing measurements.

The terms “a,” “an,” “the”, and similar referents used in the context ofdescribing the invention (especially in the context of the followingclaims) are to be construed to cover both the singular and the plural,unless otherwise indicated herein or clearly contradicted by context.Recitation of ranges of values herein is merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range. Unless otherwise indicated herein, eachindividual value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in any suitable order unless otherwise indicated herein orotherwise clearly contradicted by context. The use of any and allexamples, or exemplary language (e.g., “such as”) provided herein isintended merely to better illuminate the invention and does not pose alimitation on the scope of the invention otherwise claimed. No languagein the specification should be construed as indicating any non-claimedelement essential to the practice of the invention.

Groupings of alternative elements or embodiments of the inventiondisclosed herein are not to be construed as limitations. Each groupmember can be referred to and claimed individually or in any combinationwith other members of the group or other elements found herein. It isanticipated that one or more members of a group can be included in, ordeleted from, a group for reasons of convenience and/or patentability.When any such inclusion or deletion occurs, the specification is deemedto contain the group as modified thus fulfilling the written descriptionof all Markush groups used in the appended claims.

Certain embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention. Ofcourse, variations on these described embodiments will become apparentto those of ordinary skill in the art upon reading the foregoingdescription. The inventor expects skilled artisans to employ suchvariations as appropriate, and the inventors intend for the invention tobe practiced otherwise than specifically described herein. Accordingly,this invention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.

Furthermore, numerous references have been made to patents, printedpublications, journal articles and other written text throughout thisspecification (referenced materials herein). Each of the referencedmaterials are individually incorporated herein by reference in theirentirety for their referenced teaching.

The particulars shown herein are by way of example and for purposes ofillustrative discussion of the preferred embodiments of the presentinvention only and are presented in the cause of providing what isbelieved to be the most useful and readily understood description of theprinciples and conceptual aspects of various embodiments of theinvention. In this regard, no attempt is made to show structural detailsof the invention in more detail than is necessary for the fundamentalunderstanding of the invention, the description taken with the drawingsand/or examples making apparent to those skilled in the art how theseveral forms of the invention can be embodied in practice.

Definitions and explanations used in the present disclosure are meantand intended to be controlling in any future construction unless clearlyand unambiguously modified in the following examples or when applicationof the meaning renders any construction meaningless or essentiallymeaningless. In cases where the construction of the term would render itmeaningless or essentially meaningless, the definition should be takenfrom Webster's Dictionary, 3^(rd)Edition or a dictionary known to thoseof ordinary skill in the art, such as the Oxford Dictionary ofBiochemistry and Molecular Biology (Ed. Anthony Smith, Oxford UniversityPress, Oxford, 2004).

In closing, it is to be understood that the embodiments of the inventiondisclosed herein are illustrative of the principles of the presentinvention. Other modifications that can be employed are within the scopeof the invention. Thus, by way of example, but not of limitation,alternative configurations of the present invention can be utilized inaccordance with the teachings herein. Accordingly, the present inventionis not limited to that precisely as shown and described.

What is claimed is:
 1. A method of protecting an organ from injury basedon a scheduled insult comprising administering to the organ atherapeutically effective amount of a composition comprising vitaminB12, iron, or a combination thereof, before the scheduled insult to theorgan occurs, wherein the administering protects the organ from theinjury without causing injury to the organ.
 2. A method of claim 1,wherein the composition comprises vitamin B12.
 3. A method of claim 1,wherein the composition comprises iron.
 4. A method of claim 1, whereinthe composition comprises the combination of iron and vitamin B12.
 5. Amethod of claim 1, wherein the scheduled insult is surgery,chemotherapy, or radiocontrast toxicity.
 6. A method of claim 1, whereinthe organ is a heart, kidney, liver, or lung.
 7. A method of claim 2,wherein the composition further comprises a heme protein degradationinhibitor.
 8. A method of claim 7, wherein the heme protein degradationinhibitor is a nitrited heme protein degradation inhibitor.
 9. A methodof claim 2, further comprising administering to the organ a secondcomposition comprising a heme protein degradation inhibitor.
 10. Amethod of claim 7, wherein the heme protein degradation inhibitor is aheme oxygenase inhibitor.
 11. A method of claim 10, wherein the hemeoxygenase inhibitor is a protoporphyrin, hemin, or hematin.
 12. A methodof claim 10, wherein the heme oxygenase inhibitor is a metalprotoporphyrin.
 13. A method of claim 12, wherein the metalprotoporphyrin is Sn-protoporphyrin.
 14. A method of up-regulatingexpression of protective stress proteins in an organ before a scheduledinsult comprising administering to the organ a therapeutically effectiveamount of a composition comprising a heme protein, vitamin B12, iron, ora combination thereof, wherein the administering up-regulates expressionof protective stress proteins in the organ without causing injury to theorgan and protects the organ from injury based on the scheduled insult.15. A method of claim 14, wherein the composition comprises vitamin B12.16. A method of claim 14, wherein the composition comprises iron.
 17. Amethod of claim 14, wherein the composition comprises the combination ofthe vitamin B12 and the iron.
 18. A method of claim 14, wherein theadministration occurs at least 8 hours before the scheduled insult. 19.A method of claim 14, wherein the scheduled insult is surgery,chemotherapy, or radiocontrast toxicity.
 20. A method of claim 14,wherein the organ is a heart, kidney, liver, or lung.
 21. A method ofclaim 14, wherein the protective stress proteins are selected from hemeoxygenase, haptoglobin, hemopexin, hepcidin, alpha-1 antitrypsin,interleukin-10, heat-shock proteins, neutrophil gelatinase-associatedlipocalin, or HMG CoA reductase.
 22. A method of claim 14, wherein thecomposition further comprises a heme protein degradation inhibitor. 23.A method of claim 22, wherein the heme protein degradation inhibitor isa nitrited heme protein degradation inhibitor.
 24. A method of claim 14,further comprising administering to the organ a second compositioncomprising a heme protein degradation inhibitor.
 25. A method of claim22, wherein the heme protein degradation inhibitor is a heme oxygenaseinhibitor.
 26. A method of claim 25, wherein the heme oxygenaseinhibitor is a protoporphyrin, hemin, or hematin.
 27. A method of claim25, wherein the heme oxygenase inhibitor is a metal protoporphyrin. 28.A method of claim 27, wherein the metal protoporphyrin isSn-protoporphyrin.